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Trauma deaths are a result of hemorrhage in 37% of civilians and 47% military 
personnel and are the primary cause of death for individuals under 44 years of age.  
Current techniques used to treat hemorrhage are inadequate for severe bleeding.  
Preliminary research indicates that fibrin sealants (FS) alone or in combination with a 
dressing may be more effective; however, it has not been economically feasible for 
widespread use because of prohibitive costs related to procuring the proteins.  To meet 
future demands for hemostatic therapies, FS will likely include recombinant human 
fibrinogen (rFI) and recombinant human Factor XIII (rFXIII).  The underlying 
hypothesis of the research presented in this dissertation is that a liquid fibrin sealant 
(LFS) composed of recombinant FI, FXIII and FIIa in optimized proportions can assist 
hemostasis in the presence and absence of a bioresorbable bandage while using 
considerably fewer biologics than commercial products currently available.  This 
dissertation characterized rFI produced in the milk of transgenic cows, plasma-derived 
thrombin (pdFIIa) activated by sodium citrate and rFXIIIa expressed in genetically 
engineered Pichia pastoris with respect to their capacity to serve as components in a 
LFS.  The ratios of these factors were optimized to yield a LFS with a rapid clot 
formation rate and high viscoelastic strength.  This optimized LFS was preliminarily 
tested ex vivo and in vivo.  The clotting kinetics and viscoelastic strength of our 
optimized LFS was equivalent to those of a commercially available LFS; however, it 
uses approximately 75% less fibrinogen and thrombin.  Our optimal LFS successfully 
achieved hemostasis in a significant number of the wounds that included extensive 
tissue and vascular damage.  LFS applied without the assistance of a dressing was able 
 to stop bleeding of oozing wounds or those with small vessels; however, a scaffold was 
needed when wounds contained large vasculature.   
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Introduction 
  
2 
Hemostasis 
Hemostasis is a delicate balance between pro- and anticoagulant forces which 
require numerous proteins in the proper concentrations to activate, function and inactivate 
correctly to stop bleeding after tissue injury and avert inappropriate clotting events.
1, 2
  
Hemostasis has three phases: the primary and secondary phases occur quickly to stop 
bleeding while the final stage breaks down the clot once the blood vessel is repaired.  
Primary hemostasis is instigated by tissue injury which exposes collagen fibers from the 
injured vascular endothelium to blood.  When exposed to the collagen, platelets are 
activated initiating the release of numerous signaling molecules and coagulation factors 
which results in their adherence to each other and the vessel wall.  Once activated, 
negatively charged phospholipids are transported to the external membrane of platelets to 
serve as a catalytic surface for binding of coagulation factors.
1
  During this initial phase, 
the platelet plug minimizes blood loss
1, 3
 but only a miniscule amount of prothrombin (1 
to 5 nM) is activated to thrombin (FIIa) by activated Factor X (FXa) attached to the 
phospholipid membrane.
4, 5
  While the enzyme FXa can convert prothrombin, it has 
insufficient catalytic efficiency to activate the necessary proteins to stop bleeding.
6
   
Secondary hemostasis is initiated by the exposure of tissue factor (TF) to blood 
resulting in a cascade of activation of numerous serine proteases and several 
nonenzymatic cofactors (Figure 1.1).   
 
3 
 
Figure 1.1.  Schematic of the cascade of protein activation reactions that occur to create a fibrin 
clot.  Red arrows indicate steps within the procoagulation pathway.  Blue arrows are steps initiated 
within the intrinsic pathway.  Black arrows indicate inactivation of FVIIIa and FVa by APC (one of the 
components of the anticoagulant pathway) resulting in the down-regulation of thrombin. 
 
TF activates Factor VII (FVII) which activates Factor IX (FIX).  FIX can also be 
activated without tissue injury by activated Factor XI (FXIa) through the intrinsic 
coagulation pathway.  In both pathways, activated Factor IX (FIXa) binds with activated 
Factor VIII (FVIIIa), a nonenzymatic cofactor, and the negatively charged phospholipid 
surface of platelets to form the tenase complex which activates Factor X (FX) to FXa.  
FXa and thrombin proteolyze Factor V (FV) to activated Factor V (FVa), another 
nonenzymatic cofactor that serves as a catalyst for FXa’s generation of thrombin.  
Finally, thrombin cleaves fibrinogen into soluble fibrin fibers which polymerize into a 
fibrin clot
1, 3
 which is subsequently cross-linked and made insoluble by thrombin 
activated Factor XIII (FXIIIa).
3, 7, 8
  This fibrin clot is critical in the cessation of bleeding.   
 
4 
Fibrinogen 
Fibrinogen (FI) is the penultimate protein in hemostasis.  In addition to assisting 
in the initial platelet aggregation following vascular injury,
9, 10
 during the last step of the 
clotting cascade FI is activated to fibrin which aggregates and is crosslinked to form the 
fibrin clot.  In clot form, the fibrin stops bleeding and provides a scaffold for cellular 
migration and proliferation required for tissue regeneration.
11-14
   
FI, a 340,000 Da (450 Å) protein, is synthesized by hepatocytes and circulates in 
plasma at 2-4 mg/ml (6-12 µM).
5, 15
  FI consists of two Aα (66 kDa), two Bβ (52 kDa) 
and two γ-chains (46.5 kDa)16 held together by 29 disulfide bonds.5, 15  Each chain is 
synthesized by hepatocytes and each undergoes posttranslational modifications:  Aα-
chain phosphorylation
17
 (Ser3 and Ser345),
18
 Bβ- and γ-chain N-glycosylation19 and γ’-
chain tyrosine sulfation.
20
  Following modification, hexameric FI is assembled in the 
endoplasmic reticulum (ER)
21
 creating a trinodal structure
22
 with a central “E” nodule, 
containing the N-terminals of the six chains, and two “D” nodules linked by α-helical, 
coiled-coil segments (Figure 1.2A).
22
   
FI is activated into fibrin monomer by thrombin which binds to the E nodule and 
cleaves the 16 residue N-terminal peptide of the Aα chain (fibrinopeptide A, FpA) at 
Arg16-Gly17 and then the 14 residue N-terminal peptide of the Bβ chain (fibrinopeptide 
B, FpB) at Arg14-Gly15 (Figure 1.2B).  The release of FpA exposes the new N-terminal 
sequence of the α-chain (“A” site) which is involved in noncovalent interactions with the 
C-terminal γ-chain in the D nodule (“a” pocket, blue triangles in Figure 1.2) of an 
adjacent FI molecule resulting in protofibril formation.
5, 23
  Subsequent release of FpB 
yields a similar interaction between the newly formed N-terminal of the β-chain (“B” 
5 
site) with the D nodule β chain (“b” pocket, pink triangles in Figure 1.2) of another 
molecule.
5, 24
  Activated fibrin molecules combine to make double-stranded protofibrils 
(Figure 1.2C).  These  double-stranded protofibrils subsequently aggregate laterally 
producing a soluble fibrin clot composed of thick fibers (Figure 1.3).
25
   
 
Figure 1.2.  Schematic of the fibrinogen and fibrin molecules and protofibril formation.
22, 25, 26
  
Fibrinogen consists of an E nodule (blue circles) and two D nodules (green and red ovals) connected by 
coiled-coils.  The αC-domains (orange ovals) extend out from the D nodule and curl around and bind to the 
E nodule in fibrinogen (A).  When activated by thrombin, fibrin monomer is formed when fibrinopeptide A 
and B are released resulting in the freeing of the αC-domains (B).  These activated fibrin monomers 
aggregate into protofibrils (C).   
 
A 
B 
C 
fibrinogen 
fibrin monomer 
fibrin protofibril 
FPA 
FPB 
FIIa 
6 
 
Figure 1.3.  Schematic of aggregation and γ-γ crosslinking of fibrin.27-29  The αC-domains of the fibrin 
protofibrils interact resulting in lateral association creating thicker fibrin polymers.  FXIIIa creates a stiffer 
clot by γ-γ crosslinking (represented by gray bars).  Longitudinal (end-to-end) crosslinking occurs between 
“D:D” sites located at the outside of the D nodule.27, 28   Transverse crosslinking occurs between γXL sites 
located on γA and γ’ chains protruding out from the D nodule.
27, 28
  γ chains can also be linked laterally.30   
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Factor XIII (FXIII) and its activated form (FXIIIa) crosslinks FI
31
 and fibrin 
protofibrils by a calcium-dependent reaction
32, 33
 transforming the soluble clot to a 
stiffer
26, 34
 insoluble clot
35
  with resistance to fibrinolysis.
34
  Once activated, FXIIIa binds 
to residues 241 to 476 in the αC-domain of fibrin36 which brings fibrin protofibrils into 
close proximity.  Aggregation of fibrin monomers aligns the proteins easing the 
crosslinking process.
37, 38
  Crosslinks are constructed by FXIII’s catalytic triad (Cys314, 
His373 and Asp396)
39
 which creates an intermolecular γ-glutamyl-ε-lysine bridge 
between the side-chains of two aligned fibrin molecules (Figure 1.4).
40-45
   
 
 
Figure 1.4.  Biochemistry of ε-(γ-glutamyl)lysine crosslinking of fibrin molecules by FXIIIa.32, 42, 45, 46    
FXIIIa, a transglutaminase, forms a thioester bond to a specific glutamine residue of the bound molecule, 
releasing ammonia.
47
  This thioester reacts with the primary amine of a lysine residue of another molecule 
near the catalytic site creating an amide bond.
43, 48
   
 
FXIIIa crosslinks antiparallel
49
 fibrin α- and γ-chains with the γ-γ formation proceeding 
at a much faster rate than the α-α crosslinking.46, 50, 51  Gln398 or 399 on one fibrin γ-
chain crosslinks to Lys406 on an adjacent fibrin γ-chain within 10 minutes.52, 53  In 
addition to contributing to viscoelastic strength,
54, 55
 γ-γ crosslinking holds the fibrin 
aggregates in the proper orientation allowing α-α crosslinking to occur.8  α-chain 
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crosslinking can take up to 24 hours to form
56
 but is important in resisting 
plasminolysis
57-60
 because it yields high viscoelastic strength
46, 50
 and insolubility.
50
  α- 
and γ-chains can also be crosslinked; however, this does not greatly affect clot strength.55   
 
Hemorrhage treatment 
Hemorrhage occurs when primary and secondary hemostasis fails to stop blood 
loss.  Trauma deaths are a result of hemorrhage in 37% of civilians
61
 and 47% military
62
 
and is the primary cause of death for individuals under 44 years of age.
63
  For the past 
2000 years, the same techniques have been used to stop hemorrhage:  packing with 
gauze, direct pressure and tourniquet.
64
  This method is inadequate for treating severe 
hemorrhage.  The Department of Defense Combat Casualty Care Research Program is 
focused on developing more effective options for treating hemorrhage.
65
   
Several hemostatic products are currently used or under development.  
Cyanoacrylates are utilized as hemostatic aides in oral surgery but can cause 
inflammation and necrosis.
66
  Gelatin-resorcinol-formaldehyde (GRF) glue is frequently 
used as a sealant and yields excellent tensile strength but has less clotting ability, 
inferior clots to other sealants and results in fibroblast infiltration.
67
  QuikClot speeds 
clot formation by creating an exothermic reaction when absorbing water; however, it is 
not biodegradable requiring its removal post-treatment.
68, 69
  Compared to other 
treatment options, fibrin sealants (FS), also known as fibrin glues, are viewed as the 
best sealant
70
 because they are biocompatible,
66, 71, 72
 biodegradable
66
 and safe
71
 and are 
not linked to excessive inflammation, immune responses or necrosis.
66, 72
   
 
9 
Fibrin sealants 
Fibrin sealants (FS) which are composed of fibrinogen (FI), thrombin (FIIa), 
calcium chloride and occasionally Factor XIII (FXIII) are designed to mimic the final 
stage of the coagulation cascade by forming a fibrin clot.  When applied to a wound, 
these exogenous components can assist the same endogenous proteins in achieving 
hemostasis.  Because they mimic natural clotting mechanisms, FS are biocompatible,
66, 
71, 72
 biodegradable
66
 and safe
71
 and are not linked to excessive inflammation, immune 
responses or necrosis
66, 72
 and provide similar functions as endogenous plasma 
components.
73
   
FS is used as a hemostatic agent,
74
 matrix for wound healing,
72, 74
 adherence for 
tissues
74
 and drug delivery
74
 in a variety of procedures.  With respect to hemostasis, FS 
can be used alone or in combination with a dressing to stop blood oozing from holes, 
incisions and raw surfaces which cannot be stopped by suturing.
67
  The use of FS has 
been shown to reduce blood loss,
74, 75
 fluid loss,
74
 transfusion occurrence,
76
 operative 
time,
75
 mortality,
75
 hospital stay
77
 and treatment costs.
74
   
Despite its usefulness, FS have drawbacks.  Current FS are relatively expensive 
making it economically infeasible for use as a dressing coating or for widespread uses 
in the field.  In addition, commercial sealants contain plasma-derived proteins which are 
purified from limited blood sources and have associated risks of pathogen 
contamination
77
 that can withstand current treatments.
66, 74
  Some FS use bovine 
proteins which can initiate immune responses.
74, 77
  Consequently, a safer, more 
abundant source of materials for FS is needed.   
 
10 
Recombinant alternatives for fibrin sealants 
A hallmark of  hypocoagulopathic states (disseminated intravascular coagulation 
(DIC),
78-81
 liver disease,
81, 82
 surgery,
79, 83, 84
 acute haemorrhagic injury
79, 85
 and 
haemodilution due to fluid resuscitation,
79, 81, 83, 86
) is depletion of FI which plays a 
primary role in the formation of blood clots.  Consequently, FI may be helpful as topical 
and systemic therapies for treatment of severe haemorrhagic injury.
81, 87
  Because of its 
utility, fibrin(ogen) is the key and prominent protein in fibrin sealants (FS) which are 
used for hemostasis in various surgical procedures and treatments for wound healing.  
Both topical
88, 89
 and systemic administrations of FI may require gram dosings as 
normal plasma concentrations range from 2 to 5 grams per liter.
5, 32, 46, 71, 83
  As a result, 
the therapeutic use of fibrin(ogen) will continue to increase, requiring a source to 
provide an abundant amount of medical-grade material.   
Current products contain plasma-derived fibrinogen (pdFI) which is purified 
from limited blood sources and has associated risks of pathogen contamination.  These 
risks and limitations could be minimized by producing a recombinant version of human 
fibrinogen (rFI).  Recombinant versions of the α-, β- and γ-chains have been 
individually expressed in Escherichia coli;
90-92
 however, they were not biologically 
functional.
20
  Active recombinant human fibrinogen has been expressed by baby 
hamster kidney (BHK),
20
 monkey kidney COS-1 cells
93
 and Chinese hamster ovary 
(CHO) cells which closely mimics its plasma-derived counterpart.
94
  Unfortunately, 
these systems produce less than 4 µg/ml and are therefore unable to meet therapeutic 
demands.
95
    
11 
Another option for producing an ample amount of rFI is production in transgenic 
animals.  Functional human fibrinogen has been expressed and assembled in the milk of 
transgenic mice at expression levels up to 2 mg/ml.
95
  This proved the feasibility of 
producing ample amounts of fibrinogen in transgenic animals.  The work in this 
dissertation uses a rFI expressed in the milk of transgenic cows.  Cows were chosen 
because they can produce amounts necessary to meet therapeutic demands.  Each 
transgenic cow can produce 25 liters of milk per day for 300 days per year allowing the 
production of significant amounts of protein per transgenic animal.   
Fibrinogen is a complex protein requiring multiple post-translational 
modifications; therefore, to produce a functional protein, it must be produced by 
mammalian cells.  Unlike fibrinogen, an active A-chain of FXIII can be produced in 
abundance by yeast.
96-98
  
 
Hemophilia A 
Hemophilia A is an X-linked, inherited disorder of blood coagulation primarily 
caused by deficiency or dysfunction of factor VIII (FVIII) that affects approximately one 
in every 5,000-10,000 males.
99-101
 Currently, hemophilic patients are treated with 
intravenous infusion of highly purified FVIII concentrates derived from donor human 
plasma or a variety of recombinantly-derived FVIII (rFVIII) produced by animal cells in 
large scale bioreactors.
102-104
  Despite the clear benefits of prophylactic therapy in this 
population, 80% of the world hemophilia population does not receive adequate access to 
replacement therapy.  Many factors contribute to this, but a lack of abundance and 
associated costs of current production of plasma-derived FVIII and rFVIII concentrates 
12 
preclude the application of universal prophylactic treatment of hemophilia A in even the 
most economically developed countries and routine access in developing countries.
99, 102, 
103
  Thus, another system must be developed that can economically produce an abundant 
quantity of therapeutic-grade FVIII.  FVIII is complex and requires numerous post-
translational modifications necessitating the production by mammalian cells.  While cell 
culture has thus far not been economically viable for unlimited production, expressing 
therapeutic proteins in the milk of transgenic animals has yielded ample amounts more 
economically.
105
   
 
Dissertation objectives 
The underlying hypothesis of the research presented in this dissertation is that a 
LFS composed of recombinant FI, FXIII and FIIa in optimized proportions can assist 
hemostasis in the presence and absence of a bioresorbable bandage while using 
considerably less biologics than commercial products currently available.  To test this 
hypothesis, each of the components of the LFS need to be evaluated.  This dissertation 
has multiple specific aims: 
1. Identify the mechanism of activation of pdFII by sodium citrate:  Recombinant 
thrombin was not available for initial LFS experiments; therefore, plasma-derived 
thrombin (pdFIIa) was used.  pdFIIa for these experiments was activated from 
plasma-derived prothrombin (pdFII) by 35% sodium citrate.  The research 
presented in this chapter was designed to identify the intermediates produced 
when activating plasma-derived prothrombin (pdFII) with 35% sodium citrate.  
13 
The time course of intermediate formations was evaluated and a mechanism of 
activation suggested.   
2. Characterize rFXIII:  Recombinant Factor XIII (rFXIII) produced in Pichia 
pastoris was evaluated with respect to the hypothesis that recombinant FXIII A-
chain expressed in Pichia pastoris has the same structure, function and activity as 
its plasma-derived counterpart.  It was evaluated as a future component of an 
LFS.   
3. Optimize LFS components:  Research was designed to test the hypotheses that (1) 
the addition of rFXIIIa will increase clot strength thereby reducing the amount of 
FI need in FS; and (2) our LFS containing optimized ratios of rFI, rFXIIIa and 
FIIa will yield equivalent clot kinetics and strengths as plasma-derived LFS.   
4. Test optimal LFS ex vivo:  Interactions of normal human blood, platelet rich 
plasma and platelet poor plasma with each LFS component alone or in 
combination with others were evaluated to anticipate in vivo success.   
5. Evaluate efficacy of LFS in multiple surgical models:  FS function is based on 
complicated interactions between other pro- and anticoagulant proteins, blood 
cells and vessel surface under flow and viscosity conditions;
67
  therefore, the 
optimized LFS was tested in vivo in liver and femoral artery models. 
6. Characterize partially B-domain deleted rFVIII:  rFVIII (226/N6-tg) was 
produced in the milk of transgenic mice with both von Willebrand Factor (vWF) 
and α1-antitrypsin (A1AT).  The milk was evaluated for the presence of all three 
recombinant proteins and was tested by several techniques to determine whether 
the mammary gland could produce a functional FVIII molecule in abundance.    
14 
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Chapter 2 
Sequence of Activation of Prothrombin by Sodium Citrate 
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Abstract 
Thrombin is the key serine protease in hemostasis because it is responsible for 
activating both procoagulant proteins critical for creating fibrin clots and anticoagulant 
proteins needed to return the system to balance.  Prothrombin is converted to thrombin in 
primary hemostasis by activated Factor X (FXa) attached to the phospholipid membrane 
and secondary hemostasis by the prothrombinase complex which consists of FXa, 
activated Factor V (FVa), calcium ions complexed on the phospholipid surface of 
activated platelets.  In the laboratory, prothrombin can be activated to thrombin in 
solutions containing high sodium citrate concentrations; however, the mechanism is not 
well understood.  The work presented in this chapter focuses on identifying intermediates 
and fragments derived from prothrombin activation by sodium citrate using SDS-PAGE 
and N-terminal sequencing analyses.  The activity of the citrate activated thrombin was 
analyzed by chromogenic assay and functionality evaluated by ability to cleave FXIIIa 
and activate fibrinogen.  This research found that prothrombin could be activated in the 
absence of added activators.  This activation was not due to autocatalytic degradation but 
is due to contaminating FX which alone or activated to FXa proteolyzed prothrombin.  
Incubating prothrombin in 25% or 35% sodium citrate also resulted in activation of 
prothrombin.  Activation by citrate may be autocatalytic or a result of FX; however, FXa 
and thrombin did not play a role in citrate activation.  Analysis of activation fragments 
indicates that the sequence of activation does not follow the primary or secondary 
hemostasis pathways; rather, it follows an alternative pathway with a prethrombin-1 
intermediate that is subsequently proteolyzed into prethrombin-2, prethrombin-2a, 
thrombin, α-thrombin and β-thrombin.  The activity of citrate activated thrombin was 368 
22 
± 173 U/mg (mean ± standard deviation) which is significantly lower than previous 
reports probably due to the presence of less active thrombin forms.  Thrombin formed by 
35% sodium citrate appeared to release all of fibrinopeptide B but only a portion of 
fibrinopeptide A; however, it was able to cleave FXIIIa in the same manner as 
recombinant thrombin.  When evaluated by thromboelastography, citrate activated 
thrombin created a fibrin clot at equivalent kinetics as the highly purified recombinant 
thrombin.  Although activation of prothrombin by sodium citrate is different than 
physiological mechanisms, the thrombin produced is functional.   
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Introduction 
Thrombin (FIIa) is the key serine protease in hemostasis because it is responsible 
for activating both procoagulant proteins critical for creating fibrin clots and 
anticoagulant proteins needed to return the system to balance.
1
  With regard to 
procoagulation, FIIa activates many of the proteins in the clotting cascade including 
fibrinogen (FI), factor V (FV), factor VIII (FVIII), factor XI (FXI), factor XIII (FXIII), 
and can convert additional prothrombin to FIIa.
1, 2
 FIIa also activates platelets and 
vascular endothelial cells
3
 and is integral in initiating cellular responses including 
production and secretion of cytokines, growth factors and cellular adhesion molecules.
1, 2
  
With regard to its anticoagulant function, FIIa activates anti-fibrinolytic components such 
as protein C and FIIa-activated fibrinolysis inhibitor (TAFI).
4
   
Thrombin’s precursor, prepro-prothrombin (Figure 2.1), is synthesized in 
hepatocytes where it undergoes posttranslational modifications.  After entering the 
endoplasmic reticulum (ER), the signal peptide is removed and 10 glutamate residues 
adjacent to the propeptide are converted to γ-carboxyglutamate (Gla) residues.5-7  This 
Gla domain interacts with calcium ions and is critical for creating the conformation 
required to bind to negatively-charged phospholipid surfaces of injured vascular tissue 
and activated platelets
1
 which concentrates this key enzyme at the injury site.  Following 
alteration of the Gla residues, the propeptide is removed followed by the attachment of 
three N-linked oligosaccharide chains, two in the first kringle domain and the last in the 
B-domain.  Thrombin’s zymogen, prothrombin (70 kDa), is then secreted into blood at a 
concentration of 1.2 μM.1   
24 
Prothrombin is converted to FIIa during primary and secondary hemostasis by 
slightly different mechanisms (Figure 2.2).  During primary hemostasis (the formation of 
a platelet plug) a miniscule amount of prothrombin (1 to 5 nM) is activated by activated 
Factor X (FXa) attached to the phospholipid membrane (Figure 2.2, left side).
8
  FXa 
activates prothrombin by cleaving Arg273-Thr274 creating the intermediate prethrombin-
2 consisting of combined A- and B-chains and releasing fragment 1.2.
9
  This intermediate 
is subsequently converted to FIIa by cleavage at Arg322-Ile323 to separate the A- and B-
chains
9
 which remain attached by a disulfide bridge.
10
  While the enzyme FXa can 
convert prothrombin, it has insufficient catalytic efficiency to activate the necessary 
proteins to stop bleeding.
11
  Formation by FXa alone is significantly slower than 
conversion during secondary hemostasis.
8, 9, 12
  During secondary hemostasis, exposed 
tissue factor (TF) initiates a cascade of activation of numerous serine proteases and 
several nonenzymatic cofactors.  Once the coagulation cascade is activated, prothrombin 
is converted to FIIa by the prothrombinase complex which consists of FXa, activated 
Factor V (FVa), and calcium ions complexed on the phospholipid surface of activated 
platelets.
9, 13, 14
  This complex converts prothrombin to meizothrombin by cleaving 
Arg322-Ile323
9, 15
 resulting in the B-chain held to the rest of the molecule by a disulfide 
bridge (Figure 2.2, right side).  Subsequent cleavage at Arg273-Thr274 results in FIIa and 
the release of fragment 1.2.
9, 12
  During this second, critical phase, the prothrombinase 
complex activates prothrombin to FIIa five-fold faster than FXa alone
15
 propagating the 
formation of FIIa (700 to 900 nM)
10
 by FXa and its cofactor FVa in close proximity.
16
  
FXa
17
 or FIIa
9
 can then cleave Arg155-Ser156 to separate the kringle domains into 
25 
Fragments 1 and 2 from fragment 1.2.  FIIa can also cleave Arg286-Thr287 creating 
prothrombin-2a from prethrombin-2 and α-thrombin from meizothrombin or FIIa.9   
 
 
Figure 2.1.  Schematic of the amino acid sequence of prepro-prothrombin.  Prepro-
prothrombin contains a signal peptide, propeptide, Gla domain, two Kringle domains and a light 
(A-chain) and heavy (B-chain) chain.
1
  The N-terminal sequence of prothrombin is indicated by 
an orange arrow.  Gla residues are in the sequence as γ and the three ◊ indicated N-linked 
carbohydrates.  FXa cuts that occur during activation are marked with red arrows and blue 
arrows indicate sites cleaved by FIIa.  The serine protease catalytic triad (His, Asp and Ser) are 
circled in red.  This figure minus a few additions is adapted from Davie and Kulman.
1
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Figure 2.2.  Activation of prothrombin.  Prothrombin is activated by two mechanisms in vivo during 
primary and secondary hemostasis.  This figure modifies the prothrombin schematic published by Davie 
and Kulman.
1
  Note:  Prethrombin-2a is equivalent to prethrombin-2 minus the 13 amino acid N-terminal of 
the A-chain.   
Prothrombin (72 kDa) 
Meizothrombin (72 kDa) 
Fragment 1.2 (30 kDa) 
Thrombin (42 kDa) 
α-thrombin (40 kDa) 
Prethrombin-2 (42 kDa) 
Prothrombinase Complex: 
FVa,  FXa, PL, Ca
2+
 
FIIa 
FXa 
Secondary Hemostasis 
Primary 
Hemostasis 
FXa 
Fragment 1.2 (30 kDa) 
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The serine protease, FIIa, consists of the 49 residue A-chain linked to the 259 
residue B-chain by a disulfide bond (Figure 2.2).  α-thrombin is formed when FIIa is 
cleaved after Arg284 releasing a 13 residue peptide (Figure 2.3).  Both FIIa and α-
thrombin (α-FIIa) are active serine proteases; however, which species acts at the injury 
site in vivo is unknown.
1
  FIIa is homologous to and has the same catalytic triad as other 
serine proteases.  The catalytic triad consists of His43, Asp99 and Ser205 which is 
located in a cleft within the B-domain
18, 19
 and brought into close proximity by salt 
bridges following activation.
19
  The active site is surrounded by three surface loops
19-21
 
and two charged surface areas (exosites)
11
 that create specificity for certain substrates.   
FIIa is removed quickly from the blood stream in vivo; however, in vitro, FIIa can 
be degraded into less active products:   β- and γ-thrombin (Figure 2.3).1  These degraded 
species result from proteolysis of the B-chain by plasmin, trypsin,
22
 FXa
23
 or FIIa itself.
22
  
β-thrombin is formed when FIIa cleaves the B-chain after Arg380 and Arg391 
(prothrombin numbering, Arg62 and Arg73 in FIIa numbering) releasing a small 11 
residue peptide important for recognizing fibrinogen thereby creating the B1 and B2 
fragments.
22
  γ-thrombin is subsequently formed with the cleavage after Arg442 and 
Lys472 (prothrombin numbering, Arg123 and Arg154 in FIIa numbering) resulting in the 
creation of the B3 and B4 fragments.
1, 22
  The B-chain in β- and γ-thrombin are held 
together by noncovalent interactions
22
 and because they still contain the catalytic triad 
they retain some activity.
23
   
In the laboratory, prothrombin is frequently activated to FIIa by venom.  Ecarin, 
the venom from Indian saw-scale vipers (Echis carinatus), activates prothrombin to FIIa 
with the meizothrombin intermediate.
24, 25
  Other venoms, like that from the Taipan snake 
28 
(Oxyuranus scutellatus), activates prothrombin with both meizothrombin and 
prethrombin-1 intermediates.
26
  Prothrombin can also be activated to FIIa in solutions 
containing high sodium citrate concentrations;
27-31
 however, the mechanism is not well 
understood.
32
  Prothrombin was initially thought to auto-activate under high citrate 
conditions;
29, 30
 however, other researchers assert that impurities, such as FX, play key 
roles in the activation.
28, 32
  While low concentrations of sodium citrate yield minimal 
activation of prothrombin, concentrations of 25% (weight/volume) is much more 
effective.
30
   
Like Lanchantin, Friedmann and Hart (1965),
28
 this work focuses on identifying 
species derived from prothrombin activation and evaluating the functionality of the 
resulting FIIa with respect to fibrinogen and Factor XIII (FXIII) activation and fibrin clot 
formation.  To our knowledge, this work is the first detailed analysis of the time course of 
activation of prothrombin by sodium citrate and first attempt at identifying the 
intermediates and fragments created during the process.  This information was used to 
suggest a sequence of activation.     
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Figure 2.3.  Autolytic inactivation of thrombin.  α-thrombin can be autolytically 
degraded to β- and γ-thrombin.22  This figure modifies the prothrombin schematic 
published by Davie and Kulman.
1
 
 
 
Materials and Methods 
Materials 
Purified, plasma-derived prothrombin was bought from Enzyme Research 
Laboratories (South Bend, IN) with a specific activity of 11.11 U/mg.  Recombinant 
thrombin (Recothrom
®
) (rFIIa) was purchased from Zymogenetics.  Purified recombinant 
fibrinogen, expressed in the milk of transgenic cows, was obtained from Pharming Group 
α-thrombin 
β-thrombin 
γ-thrombin 
B1 (9 kDa) 
B2 (21 kDa) 
B1 (9 kDa) 
B3 (6 kDa) 
B4 (12 kDa) 
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NV (Leiden, Netherlands).  Phe-Pro-Arg-chloromethylketone (PPACK) and Glu-Gly-
Arg-chloromethylketone (GGACK), specific and irreversible inhibitors of FIIa
33, 34
 and 
FXa,
33, 35
 respectively, were purchased from Haematologic Technologies (Essex Junction, 
VT).  Materials for the thromboelastograph were purchased from Haemoscope (Niles, 
IL).  Ecarin, sodium citrate and all other reagents were purchased from Sigma (St. Louis, 
MO) unless otherwise specified.   
Vector construction, expression and purification of FXIIIA in Pichia pastoris 
The human Ultimate ORF clone containing the human coagulation factor 
FXIIIA1 cDNA in the pENTR
TM
221 vector was purchased from Invitrogen (Carlsbad 
CA). The following primers were used to obtain FXIIIa gene to subclone in pPICZA 
intracellular Pichia expression vector. (Forward, 5'-
CCAATTGATGCATCATCATCATCATCATTCAGAAACTTCCAGGACCGC-3'; 
Reverse, 5'-GCGGCCGCTCACATGGAAGGTCGTCTTTGAATC-3').  The forward 
primer introduced a methionine and 6 histidine amino acids at the N-terminus of mature 
FXIIIa peptide. The PCR product was digested with MfeI and NotI and subcloned into 
pPICZA which was digested with the same enzymes.  The DNA sequence of the FXIIIA 
was confirmed by sequencing the insert fragment. One of the confirming plasmid 
pPICZAFXIIIa was linearized with PmeI and transformed into P. pastoris X-33 host 
strain and copy number of the clones was determined as described.
36
 Varying copy 
number clones were screened in shake flask culture to confirm intracellular production of 
FXIIIa protein. The highest producing clone was scaled up to 5 L bench scale. A fed-
batch fermentation protocol was followed to optimize FXIIIa production as described by 
31 
Zhang et al., (2007).
37
  At the end of fermentation process the cells were separated by 
centrifugation (6,000g)  and pellet was stored at -80
o
C.   
Frozen cell paste was processed in 300 gram batches.  Cells were lysed in three 
sets of 100 gram batches.  100 grams of cell paste was resuspended in 100 ml of cold 
lysis buffer (50 mM Tris-HCL, 10 mM MgSO4, 1 mM EDTA, 10 mM potassium acetate, 
1 mM DTT (DL-Dithiothreitol), 2 mM PMSF (phenylmethanesulphonylfluoride) in 
methanol, pH 9.5).  100 ml (250 g) of 0.5 mm glass beads (Biospec, Bartlesville, OK) 
were added to the cells.  Surrounded by an ice bath, cells were lysed using a BeadBeater 
Blender (Biospec, Bartlesville, OK) with twenty 20 second on/off cycles.  The cell lysate 
mixture was then centrifuged to remove cellular debris.  The lysate from 300 grams of 
cell paste was combined and purified using the HisBind Purification Kit (EMD 
Chemicals, Inc., San Diego, CA) with 40 ml of resin slurry.  Following purification, 
rFXIII was dialyzed in 10 mM Tris-HCl, 0.1 mM EDTA, 60 µM polysorbate-20, pH 8.0 
in snake-like dialysis membranes and the protein samples were filter-sterilized and 
concentrated using the Amicon tubes (Millipore, Billerica, MA).  The purity of the 
sample was tested by SDS-PAGE (NuPAGE 12% Bis-Tris) (Invitrogen, Carlsbad, CA) 
and immunoblot.  The concentration of rFXIII was determined by standard Bicinconic 
Acid (BCA) methods.   
Prothrombin activation by ecarin, rFIIa, FXa and sodium citrate 
Plasma-derived human prothrombin (Enzyme Research Laboratories, South Bend, 
IN) was treated with PPACK (final concentration: 60 µM) and GGACK (final 
concentration: 60 µM) (Haemotologic Technologies, Essex Junction, VT) to eliminate 
FIIa and FXa activity, respectively.  Following a 24 hour incubation period at 37
o
C on a 
32 
rotating mixer, the PPACK and GGACK was removed by ultracentrifugation with 
Amicon tubes with a 10,000 Da molecular weight cut-off membrane (Millipore, Billerica, 
MA).  Prothrombin was subsequently activated by several methods:  rFIIa, FXa, ecarin 
and sodium citrate in the presence and absence of 60 µM GGACK.   
Prothrombin (final concentration: 1 mg/ml) was incubated at 37
o
C with 0.2% 
rFIIa (0.002 mg/ml, 4.65 U/ml) (Zymogenetics, Seattle, WA) or 2% FXa (0.02 mg/ml) 
(Enzyme Research Laboratories, South Bend, IN), 20 U/ml of ecarin (Echis carinatus) 
(Sigma, St. Louis, MO), or 25% or 35% (weight/volume) sodium citrate (0.25 or 0.35 
grams of sodium citrate per milliliter of solution).  Ecarin samples were incubated for 0, 
5, 15, 30, 60, 120, 180, 240, 360 and 480 minutes.  Sodium citrate treated samples were 
incubated for 0, 6, 12, 18, 24, 36 and 48 hours while samples activated by FIIa and/or 
FXa were incubated for 0, 24, 48 and 72 hours.  Control samples were also run:  
prothrombin in the presence and absence of PPACK and GGACK were incubated for 0, 
24, 48 and 72 hours under the same conditions as the activated samples.  At the proper 
time periods, 10 µl of unactivated samples and those activated by ecarin, rFIIa and FXa 
were removed and the reaction stopped by adding it to 8.75 µl NuPage
®
 LDS sample 
buffer (Invitrogen, Carlsbad, CA) and storing it at -20
o
C.  Sodium citrate samples were 
removed and stored at -80
o
C.  Sodium citrate was removed with PD-10 desalting columns 
(GE Healthcare, Giles, United Kingdom).   
For identifying the role FIIa plays during citrate activation and to determine the 
efficacy of the FXa inhibitor under harsh conditions created by 35% sodium citrate, 
prothrombin (final concentration: 1 mg/ml) was incubated at 37
o
C with 35% sodium 
citrate (0.35 grams of sodium citrate per milliliter of solution) alone or with 0.2% rFIIa 
33 
(0.0002 mg/ml) or 0.2% FXa (0.0002 mg/ml) (Enzyme Research Laboratories, South 
Bend, IN) in the presence of 60 µM GGACK.  Samples were incubated for 6, 24 and 72 
hours horizontally on a shaker maintained at 37
o
C.  Sodium citrate samples were 
removed and stored at -80
o
C.  Sodium citrate was removed with PD-10 desalting columns 
(GE Healthcare, Giles, United Kingdom).   
Activation of prothrombin was evaluated by SDS-PAGE on 12% NuPage
®
 Bis-
Tris gels (Invitrogen, Carlsbad, CA) under nonreducing conditions with 2-(N-
morpholino)ethanesulfonic acid (MES) running buffer and NuPage
®
 LDS sample buffer 
which were purchased from Invitrogen (Carlsbad, CA).  Samples were incubated at 74
o
C 
for 10 minutes before loading on the gels which were run at 200 volts for one hour.  Gels 
were stained with Colloidal Blue (Invitrogen). 
N-terminal sequencing of activated samples 
Fragments produced by rFIIa, FXa, ecarin and 35% sodium citrate activation of 
prothrombin (see above) were evaluated by N-terminal sequencing.  Bands were 
separated by sodium dodecylsulfate-polyacrylamide (SDS-PAGE) gel electrophoresis on 
4-12% NuPage
®
 Bis-Tris gels with 2-(N-morpholino)ethanesulfonic acid (MES) running 
buffer, NuPage
®
 LDS sample buffer (Invitrogen, Carlsbad, CA).  Samples were 
incubated at 74
o
C for 10 minutes before loading on the gels and then electroblotted onto 
polyvinylidene fluoride (PVDF) membrane (Millipore, Billerica, MA) by applying 30 
volts for one hour.  The blot was stained with Colloidal Blue (Invitrogen, Carlsbad, CA).  
Each band was excised and the first ten amino acids in the N-terminal were sequenced by 
Edman degradation with an Applied Biosystems 494 Procise automated sequencer.  N-
34 
terminal N-terminal sequencing was performed by the University of Nebraska Medical 
Center’s Protein Structure Core Facility. 
Thrombin activity by chromogenic assay 
The specific activity of the FIIa produced by FXa and 35% sodium citrate 
activation was determined by a chromogenic assay.  50 µl of standard and samples were 
added in triplicate to wells of a 96-well plate.  Recothrom
®
 was used to create an eight-
interval standard curve ranging from 1.8 mU to 293.6 mU.  Based on BCA concentration 
results, rFIIa was diluted so that wells would contain 1, 20 and 80 ng.  The plate was 
incubated at 37
o
C for two minutes.  50 µl Tris-buffered saline (TBS) were added to each 
well followed by three minute incubation at 37
o
C.  50 µl Chromogenix S-2238 
(DiaPharma Group, West Chester, OH) were added to each well followed by two minute 
incubation at 37
o
C.  50 µl 20% acetic acid was added to stop the reaction.  The 
absorbance was then read on a Beckman Coulter AD340 Microplate Reader (Brea, CA) 
at 405 and 495 nm wavelengths.  Data was imported into Microsoft Excel and the 495 nm 
absorbance was subtracted from that at 405 nm.  The standard curve was established and 
the sample activity calculated.   
Thrombin activity by SDS-PAGE 
The ability of the activated prothrombin samples were evaluated by monitoring 
the activation of fibrinogen to fibrin and FXIII to FXIIIa by SDS-PAGE.  rFI or rFXIII 
(final concentrations: 0.4 mg/ml) were incubated with FIIa (0.10 mg/ml) in Ringers 
solution (155 mM  NaCl, 5 mM KCl, 2 mM CaCl2, 1 mM MgCl2) for 60 minutes at 37
o
C.  
The activation reactions were halted by the addition of NuPage
®
 LDS sample buffer and 
35 
NuPage
®
 Sample Reducing buffer (β-mercaptoethanol) (Invitrogen, Carlsbad, CA).  
Samples were evaluated by sodium dodecylsulfate-polyacrylamide (SDS-PAGE) gel 
electrophoresis on 4-12% NuPage
®
 Bis-Tris gels with 2-(N-morpholino)ethanesulfonic 
acid (MES) running buffer.  Samples were incubated at 74
o
C for 10 minutes before 
loading on the gels which were run at 200 volts for one hour and were stained with 
Colloidal Blue (Invitrogen, Carlsbad, CA).   
Thrombin activity by thromboelastography 
The kinetics of the FIIa initiation of a fibrin clot was determined by 
thromboelastography (TEG) which was performed on solutions containing purified rFI 
and rFXIII with a Thromboelastograph
®
 (TEG
®
) Hemostasis System 5000 series 
(Haemoscope Corp., Niles, IL).  rFI (final concentration: 8.56 mg/ml) was transferred to 
a single-use TEG cup maintained at 37
o
C by the instrument.  rFXIII (final concentration: 
0.35 mg/ml) was added.  CaCl2 (final concentration: 11 mM) and Ringers solution (155 
mM  NaCl, 5 mM KCl, 2 mM CaCl2, 1 mM MgCl2, was added to standardize the 
volumes in the cups) was added followed quickly by FIIa (final concentration: 52.8 U/ml) 
to initiate clot formation.  Data was collected every five seconds for 30 minutes by the 
TEG interfaced with a computer.  The TEG Analytical Software (version 4.2.2, 
Haemoscope, Niles, IL) collected the time to clot initiation (R), the time to achieve a clot 
firmness of 20mm (K) and the maximal clot strength (MA).  The instrument was 
calibrated each day of use.  Each sample was run in triplicate so means and standard 
deviations could be calculated.  The data was exported and analyzed in Microsoft
®
 Excel.   
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Results 
rFXIIIa characterization 
SDS-PAGE and N-terminal sequencing indicated that the purified protein from 
the yeast was rFXIIIa rather than rFXIII.  These and immunoblots indicated rFXIIIa had 
a purity of greater than 98% (data not shown).  The Pefakit
®
 Factor XIII Incorporation 
Assay (Pentapharm, CT) yielded a specific activity of almost 7,000 U/mg for rFXIII 
compared to the theoretical specific activity of approximately 100 U/mg of plasma-
derived FXIII.   
Prothrombin activation by ecarin, rFIIa, FXa and sodium citrate 
Plasma-derived prothrombin was incubated at 37
o
C in the presence and absence 
of FXa (GGACK) and FIIa (PPACK) inhibitors (Figure 2.4).  Over a 72 hour incubation 
period, there was a gradual decrease in the main 72 kDa band which corresponded to a 
gradual increase in bands at approximately 50 and 22 kDa.  When GGACK and PPACK 
were added, prothrombin consists of a main band at approximately 72 kDa and a minor 
band at 50 kDa at all time periods (Figure 2.4B).  If incubated for a month at 37
o
C, 
prothrombin was gradually activated even in the presence of FXa and FIIa inhibitors 
(Figure 2.5).  The starting material for this experiment started with a major band at 
approximately 72 kDa and minor bands at 50 and 30 kDa (Figure 2.5, lane 2).  The bands 
were not significantly changed at 26 hours of incubation; however, over the next month, 
the 72 and 50 kDa bands gradually decreased while the band at approximately 42 
increases.   
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Figure 2.4.  Evaluation of the activation of prothrombin without added 
activators in the presence and absence of FIIa and FXa inhibitors by nonreduced 
SDS-PAGE.  Prothrombin was incubated at 37
o
C in the absence (A) and presence of 
60 µM FIIa and 60 µM FXa inhibitors, PPACK and GGACK respectively (B).  Lane 
1: molecular weight marker.  Lane 2: starting prothrombin.  Lanes 3 through 6: 
prothrombin incubated for 0, 24, 48 and 72 hours.  Lane 7 of each contains rFIIa.   
 
 
 
Figure 2.5.  Evaluation of prothrombin activation over 28 days after being 
treated with FIIa and FXa inhibitors by nonreduced SDS-PAGE.  Prothrombin 
was incubated at 37
o
C in the presence of 60 µM FIIa and 60 µM FXa inhibitors for 28 
days.  Lane 1: molecular weight marker.  Lane 2: starting prothrombin.  Lanes 3 
through 7: prothrombin incubated for 1.1, 7, 14, 21 and 28 days.   
 
Prothrombin was activated by several methods in order to compare and 
characterize the mechanism employed by sodium citrate.  Activation was evaluated by 
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nonreduced SDS-PAGE.  When treated with 0.2% rFIIa, prothrombin (~72 kDa) was 
gradually activated resulting in the appearance of bands at approximately 50 kDa, 38 kDa 
(doublet), 25 kDa and 13 kDa (Figure 2.6A).  As the 72 kDa band faded, the bands at 50 
kDa, 38 kDa and 28 kDa darken.  After 72 hours incubation, most of the prothrombin 
was degraded; however, there is still a significant band at 50 kDa.  If added FIIa was 
increased or the reaction was allowed to incubate longer, all of the prothrombin was 
degraded into FIIa and other fragments.  If incubated too long, FIIa was degraded (data 
not shown).  If GGACK was added prior to rFIIa addition, the band at ~72 kDa is 
maintained over the 72 hour incubation period (Figure 2.6B).   
 
 
Figure 2.6.  Evaluation of the activation of prothrombin by rFIIa in the presence 
and absence of FXa inhibitor by nonreduced SDS-PAGE.  Prothrombin was 
activated by 0.2% rFIIa in the absence (A) and presence of 60 µM GGACK (B). Lane 
1: molecular weight marker.  Lane 2: starting prothrombin.  Lanes 3 through 6: 
prothrombin with rFIIa incubated for 0, 24, 48 and 72 hours.  Lane 7: rFIIa.   
 
Activation by FX resulted in gradual proteolysis of the band at approximately 72 
kDa (Figure 2.7A).  At the initial time point, prothrombin remained at 72 kDa.  At 24 
hours, there were minor bands at 72 and 46 kDa with heavier bands at approximately 36, 
22 and 10 kDa (Figure 2.7A, lane 4).  At 48 and 72 hours, the same bands were present; 
however, the 72 kDa band density decreased with increases in low molecular weight 
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degradation bands.  When incubated with 2% FXa, prothrombin (~72 kDa) immediately 
started degrading.  Just after addition, FXa had formed a light band at approximately 40 
kDa (Figure 2.7B, lane 3).  Within 24 hours, the 72 kDa band was gone leaving bands at 
approximately 40, 26, and 13 kDa (Figure 2.7B, lane 4).  Incubation for an additional 24 
or 48 hours did not result in further activation or degradation (Figure 2.7B, lanes 5 and 6, 
respectively).   
 
 
Figure 2.7.  Evaluation of the activation of prothrombin by FX and FXa by 
nonreduced SDS-PAGE.  pdFII was activated by 10% FX (A) and 2% FXa (B).  
Lane 1: molecular weight marker.  Lane 2: starting prothrombin.  Lanes 3 through 6: 
prothrombin with rFIIa incubated for 0, 24, 48 and 72 hours.  Lane 7 of the FX and 
FXa activation gels contains FX and FXa, respectively.  Lane 8: rFIIa.   
 
Prothrombin was also activated by ecarin (Figure 2.8).  Within 5 minutes, the 
addition of ecarin resulted in the reduction of the prothrombin band (~72 kDa) and the 
formation of bands at approximately 50 and 26 kDa (Figure 2.8A, lane 4).  After 15 
minutes, most of the 72 kDa band had disappeared resulting in the darkening of the 50 
kDa band and the appearance of a doublet band at approximately 40 kDa (Figure 2.8A, 
lane 5).  After 30 minutes, most of the 50 kDa band had disappeared resulting in the 
darkening of the 40 kDa band and the appearance of a band at approximately 13 kDa 
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(Figure 2.8A, lane 6).  Incubation for 60 minutes, yielded only three bands at 
approximately 40, 26 and 13 kDa (Figure 2.8A, lane 7).  Incubation for 240 or 480 
minutes did not result in further activation or degradation (Figure 2.8A, lanes 8 and 9, 
respectively).  If GGACK is added prior to the addition of ecarin, the band at ~72 kDa 
gradually disappeared with the appearance and darkening of bands at approximately 50 
and 26 kDa.  By 30 minutes, the entirety of the 72 kDa band was gone replaced by 
primarily the band at 50 kDa and 26 kDa with a doublet at ~40 kDa.  The following 60 
minutes of incubation did not significantly alter the band ratio (Figure 2.8B).   
 
Figure 2.8.  Evaluation of the activation of prothrombin by ecarin by nonreduced SDS-PAGE.  pdFII 
was activated by 20 U/ml ecarin in the absence (A) and presence of 60 µM GGACK (B).  Lane 1: 
molecular weight marker.  Lane 2: starting prothrombin.  For the gel in the absence of GGACK (A), lanes 3 
through 9: prothrombin incubated with ecarin for 0, 5, 15, 30, 60, 240 and 480 minutes.  For the gel in the 
presence of GGACK (B), lanes 3 through 9: prothrombin incubated with ecarin for 0, 5, 10, 15, 30, 45 and 
60 minutes.  Lane 10 of each gel contains rFIIa.   
 
Activation by 25% sodium citrate resulted in a slow lightening of the 72 kDa band 
and gradual appearance of bands at approximately 50 and 26 kDa starting after 
incubation for 24 hours (Figure 2.9A).  If the reaction was allowed to incubate longer, all 
of the prothrombin was degraded into FIIa and other fragments.  If incubated too long, 
FIIa was degraded (data not shown).  Increasing sodium citrate to 35% resulted in the 
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appearance of the 50 and 26 kDa bands within 12 hours (Figure 2.9B, lane 5).  At 36 
hours, the 72 kDa band was almost gone; however, the 50 kDa band has not darkened.  
Bands have appeared at approximately 40, 26, 24, 13 and 10 kDa (Figure 2.9B, lane 7).  
After 72 hours incubation, only a light band was visible at 40 kDa (Figure 2.9B, lane 9).  
35% sodium citrate activation follows the same activation time course and sequence in 
the presence or absence of 60 µM GGACK (Figure 2.10).    
 
 
Figure 2.9.  Evaluation of the activation of prothrombin by 25% and 35% sodium citrate 
by nonreduced SDS-PAGE.  Prothrombin was activated by 25% (A) and 35% (B) sodium 
citrate.  Lane 1: molecular weight marker.  Lane 2: starting prothrombin.  Lanes 3 through 9: 
samples incubated for 0, 6, 12, 24, 36, 48 and 72 hours.  Lane 10 contains rFIIa.   
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Figure 2.10.  Evaluation of the activation of prothrombin by 35% 
sodium citrate in the presence and absence of FXa inhibitor by 
nonreduced SDS-PAGE.  Prothrombin was activated by 35% sodium 
citrate in the absence (A) and presence (B) of 60 µM GGACK.  Lane 1: 
molecular weight marker.  Lane 2: starting prothrombin.  Lanes 3 through 
5: samples incubated for 24, 48 and 72 hours.  Lane 6: rFIIa.   
 
 
Prothrombin was incubated with 35% sodium citrate alone, with FXa or with FIIa 
in the presence of FXa inhibitor (Figure 2.11).  All three samples showed equivalent 
activation rates and fragments.  
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Figure 2.11.  Evaluation of the activation of prothrombin by 35% sodium citrate in combination with 
FXa or FIIa in the presence of FXa inhibitor by nonreduced SDS-PAGE.  Prothrombin was activated 
by 35% sodium citrate alone or in combination with rFIIa or FXa.  Samples were incubated for 8 (A), 24 
(B) and 72 (C) hours.  Lane 1: molecular weight marker.  Lane 2: starting prothrombin.  Lanes 3:  
prothrombin incubated with 35% citrate alone.  Lane 4: prothrombin incubated with 35% citrate and 0.02% 
FXa.    Lane 5: prothrombin incubated with 35% citrate and 0.02% rFIIa.    Lane 6:  rFIIa.  Lane 7: FXa.   
 
 
Prothrombin was also activated by a combination of 0.2% FIIa and 35% sodium 
citrate (Figure 2.12).  At 0 and 1 minutes, the major band is at approximately 72 kDa.  
Over the following hour, the band at 72 kDa decreased with an increase in the bands at 
50, 42, 28 and 14 kDa.   
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Figure 2.12.  Evaluation of the activation of prothrombin by FIIa and sodium 
citrate by nonreduced SDS-PAGE.  Prothrombin was activated by 0.2% plasma-
derived FIIa and 35% sodium citrate.  Lane 1: molecular weight marker.  Lane 2: 
starting prothrombin.  Lane 3: plasma-derived FIIa used for activation.  Lanes 4 
through 9: samples incubated for 0, 1, 5, 15, 30 and 60 minutes.   
 
N-terminal sequencing of activated samples 
The first five to ten amino acids of the N-terminal were determined for each of the 
main fragments resulting from activation by 2% FXa and 35% sodium citrate (Table 2.1).  
Activation by FXa resulted in fragments with molecular weights of ~45 kDa (FXa), ~40 
kDa (IVESGEADIG), ~22 kDa (ANTFLEAVVK) and ~13 kDa (SEGNXVA).  Several 
prothrombin fragments activated by 35% sodium citrate alone or with 0.2% FIIa were 
analyzed by N-terminal sequencing.  These fragments included bands at ~50 kDa (N-
terminal sequence:  ANTFLXLVVX), ~42 kDa (N-terminal sequence:  TATSEYQTFF), 
~40 kDa (N-terminal sequence:  TFGSGEADIG), ~26 kDa (N-terminal sequence:  
ANTFLXXVXK), ~25 kDa (N-terminal sequence:  TFGSGEADIG), ~22 kDa (N-
terminal sequence:  IVEGSDAEIG), ~13 kDa (N-terminal sequence:  TFXXX) and 
various degradation bands with lower molecular weights.  Based on these sequences, 
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molecular weights and presence or absence of other bands at certain time points, each 
sequenced band was identified as a particular prothrombin/thrombin species (Table 2.1, 
Figure 2.13).   
 
Table 2.1.  N-terminal amino acid sequences of prothrombin and its fragments following activation 
by FXa (2%) and sodium citrate (35%).   
Activation Enzyme 
Approximate 
Molecular Weight 
(kDa) 
Amino Acid Sequence Identity 
None (starting material) 72 ANTFLXLVVX Prothrombin 
    
 40 IVESGEADIG B-chain 
    
 22 ANTFLEAVVK Fragment 1 
    
 13 SEGNXVA Fragment 2 
    
 50 SEGSSVNLSP Prethrombin-1 
    
 42 TATSEYQTFF Prethrombina-2 or FIIa 
    
 
40 TFGSGEADIG 
Prethrombina-2a or 
αFIIa 
    
 26 ANTFLXXVXK Fragment 1 
    
 25 TFGSGEADIG βFIIa 
    
 22 IVEGSDAEIG B-chain from βFIIa 
    
 13 TFXXX Fragment 2 
Notations:  Prethrombin-1 (PreFIIa-1), Prethrombin-2 (PreFIIa-2), Prethrombin-2a (PreFIIa-2a), Thrombin 
(FIIa), α-thrombin (αFIIa), β-thrombin (βFIIa), γ-thrombin (γFIIa). 
 
 
Activated Factor X (FXa) 
35% Sodium Citrate 
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Figure 2.13.  Identification of the fragments of prothrombin activated by 35% 
sodium citrate suggested by N-terminal sequencing.  Results from several N-
terminal sequencing analyses of multiple prothrombin samples activated by 35% 
sodium citrate with or without thrombin were compiled and shown overlaying an 
equivalent time course activation by citrate.  Lane 1: molecular weight marker.  Lane 
2: starting prothrombin.  Lanes 3 through 9: samples incubated for 0, 6, 12, 24, 36, 48 
and 72 hours.  Lane 10: rFIIa. 
 
Thrombin activity by chromogenic assay 
The activity of plasma-derived thrombin (pdFIIa) prepared by FXa and citrate 
activation were determined by chromogenic assay.  Positive and negative controls yielded 
specific activities similar to those reported by the manufacturer (Table 2.2).  The specific 
activity of the FXa activated prothrombin sample was 293 U/mg.  The mean specific 
activity of citrate activated prothrombin was 368 ± 173 U/mg (mean and standard 
deviation of four samples activated by 35% sodium citrate).   
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Table 2.2.  Specific activity of activated prothrombin by chromogenic assay. 
 
Estimated 
Specific Activity 
(U/mg) 
Specific Activity, 
as per 
manufacturer 
(U/mg) 
Prothrombin (Enzyme Research) 0 11 
   
Prothrombin (Enzyme Research) 2,805 3,230 
   
rFIIa (Zymogenetics) 2,618 2,370 
   
Prothrombin activated by 2% FXa 293  
   
Prothrombin activated by 35% sodium citrate 368 ± 173  
Note:  Each sample was measured in triplicate at three dilutions.  Intra-sample standard 
deviations were 0 for prothrombin, 874 for plasma-derived FIIa (Enzyme Research), 625 for 
rFIIa (Zymogenetics), 1 for FXa activated and between 12 and 38 for citrate activated 
samples.  Four samples from different 35% sodium citrate activations were measured in three 
assays to yield a mean ± standard deviation.   
Thrombin activity by SDS-PAGE 
The functions of the samples activated by 0.2% rFIIa (72 hours), 2% FXa (72 
hours), 20 U/ml ecarin (480 minutes), 35% sodium citrate (48 hours) were evaluated by a 
60 minute incubation with rFI (Figure 2.14A) and rFXIII (Figure 2.14B).  rFI incubated 
with a commercial recombinant thrombin (rFIIa) is activated into fibrin with the release 
of fibrinopeptide A (FpA) and fibrinopeptide B (FpB) as seen by the decrease in 
molecular weight of the 66 and 52 kDa bands (Figure 2.14A, lane 3).  Prothrombin 
samples activated to pdFIIa by 2% FXa (Figure 2.14A, lane 5) and 20 U/ml ecarin 
(Figure 2.14A, lane 6) resulted in identical shifts.  Prothrombin samples activated to 
pdFIIa by 0.2% rFIIa resulted in a shift of the 52 kDa band but not the 66 kDa band 
(Figure 2.14A, lane 4).  The sample activated by 35% sodium citrate resulted in a partial 
shift in the 66 kDa band and full shift in the 52 kDa band (Figure 2.14A, lane 7).   
When incubated with a commercial thrombin (rFIIa), the molecular weight of 
rFXIIIa shifted down slightly from ~84 kDa to ~80 kDa (Figure 2.14B, lane 3).  The 
molecular weight shift of rFXIIIa was fully achieved by pdFIIa activated by 2% FXa 
48 
(Figure 2.14B, lane 5) and 20 U/ml ecarin (Figure 2.14B, lane 6).  pdFIIa activated by 
0.2% rFIIa and 35% sodium citrate shifted most of the rFXIIIa; however, a minor band at 
the original molecular weight was visible (Figure 2.14B, lanes 4 and 7, respectively).  
The proper thrombin-mediated FXIIIa inactivation fragments (~25 and ~54 kDa) were 
also seen for rFIIa, FXa and ecarin activated pdFIIa.   
 
 
Figure 2.14.  Fibrinopeptide release and Factor XIIIa molecular weight shift by prothrombin 
samples activated by rFIIa, FXa, ecarin and 35% sodium citrate.  Prothrombin (0.10 mg/ml) activated 
by rFIIa, FXa, ecarin and 35% sodium citrate were evaluated by incubation with 0.4 mg/ml rFI (A) or 0.4 
mg/ml rFXIII (B).  Lane 1: molecular weight marker.  Lane 2: rFI (A) or rFXIII (B) alone.  The remaining 
lanes contain rFI (A) or rFXIII (B) incubated for 60 minutes rFIIa (lane 3) or with prothrombin activated by 
0.2% rFIIa (lane 4), 2% FXa (lane 5), 20 U/ml ecarin (lane 6) or 35% sodium citrate (lane 7).   
 
Thrombin activity by thromboelastography 
The kinetics and strength of clots formed by 8.56 mg/ml rFI, 0.35 mg/ml rFXIII 
and 52.8 U/ml rFIIa or prothrombin activated by 35% sodium citrate (pdFIIa) were 
evaluated by thromboelastography (TEG) (Figure 2.15).  The time to clot initiation (R) 
and clotting kinetics (K) catalyzed by pdFIIa (11.86 ± 2.89 and 50.0 ± 0 seconds, 
respectively) were equivalent to that catalyzed by rFIIa (10.00 ± 0 and 50.0 ± 0 seconds, 
respectively).  Maximal clot strengths for the pdFIIa catalyzed reaction (10,585.97 ± 
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1,670.88 dynes/sec) were comparable to that created by rFIIa (12,865.60 ± 1,688.44 
dynes/sec).   
 
Figure 2.15:  Comparison of clotting activity of rFIIa and citrate activated pdFIIa clotting 
analysis by thromboelastography.  TEG monitored the initiation of clot formation, clotting kinetics 
and change in clot strength over time of rFI (8.56 mg/ml) and rFXIII (0.35 mg/ml) activated by pdFIIa 
(red) or rFIIa (blue) (52.8 U/ml).  
 
 
Discussion 
Detailed analysis of the activation of prothrombin by sodium citrate has not 
previously been accomplished and only limited evaluations have been completed on the 
fragments produced.  The mechanism of activation by citrate is unknown.  The research 
presented in this chapter focused on identifying the sequence of activation of prothrombin 
by sodium citrate.  This was accomplished by analyzing molecular weight changes by 
SDS-PAGE, N-terminal sequencing and comparison to activations with known 
sequences.  The activity of the subsequently activated thrombin samples was also 
determined.   
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Research has been complicated by the presence of trace amounts of other plasma 
proteins in purified prothrombin samples which can activate it into thrombin.
32
  These 
results support that assertion.  When purified prothrombin with a >95% purity is 
incubated over 72 hours, a portion of prothrombin is activated into prethrombin-1 (Figure 
2.4A).  If the same prothrombin sample is pre-treated with FXa and FIIa inhibitors which 
are subsequently removed, prothrombin is not activated over a 72 hour incubation period 
(Figure 2.4B).  These results indicate that trace amounts of FXa and/or FIIa are 
responsible for activating prothrombin.  Even if pretreated, prothrombin is slowly 
activated when incubated at 37
o
C for 28 days (Figure 2.5).  If incubated for over five and 
a half months, most of the prothrombin is proteolyzed into small molecular weight pieces 
(data not shown).  The activation of prothrombin after pre-treatment with FIIa and FXa 
inhibitors indicates that some component in the sample is activating the zymogen.  Some 
researchers believe prothrombin can autoactivate
27
 while others assert that FX is 
responsible for activating prothrombin.
32
   
Research presented in this chapter indicates that trace amounts of FIIa in the 
prothrombin sample are not responsible for activation of prothrombin.  When thrombin 
was added to prothrombin pretreated with FXa and FIIa inhibitors, prothrombin was 
activated within 24 hours (Figure 2.6A); however, when FXa inhibitor was added with 
the FIIa, prothrombin was not activated (Figure 2.6B).  Thus, rather than activating 
prothrombin, FIIa is activating the trace amount of FX into FXa which is subsequently 
activating prothrombin.   
When FX is added to prothrombin, FX (~59 kDa) is activated into FXa (~46 kDa) 
and prothrombin is activated into thrombin and other fragments within 24 hours (Figure 
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2.7A).  Activating with FXa similarly transformed all of the prothrombin to thrombin 
within 24 hours (Figure 2.7B).  This activation of FX occurs in the absence of thrombin; 
therefore, this research supports assertions that FX can be autocatalytically activated or 
activated by prothrombin.
32
  It is still unclear whether FX can activate prothrombin or 
whether prothrombin is activated once FXa is created.   
Research has been mixed with regard to the success of citrate activation.  Early 
research indicated that prothrombin could auto-activate to thrombin in the presence of 
25% sodium citrate;
29, 30
  however, Teng and Seegers (1981) found that prothrombin, 
prethrombin-1 nor prethrombin-2 were activated by 25% sodium citrate with or without 
activated thrombin.
32
  Teng and Seegers asserted that contaminating traces of other 
plasma proteins are necessary to activate prothrombin to thrombin.
32
  They stated that 
citrate activation of prothrombin was a result of “reciprocal proenzyme activation” where 
FX and prothrombin activate each other; however, while FX can auto-activate, 
prothrombin requires the presence of FX.
32
   
While we know our prothrombin sample is contaminated with other plasma 
proteins, pretreatment with FXa and FIIa inhibitors cease activation over 72 hours; 
however, the addition of sodium citrate initiates prothrombin activation and as seen 
previously
27
 activation proceeded at a faster rate at the higher citrate level.  We have 
shown that FIIa is not responsible for this activation.  It is unclear whether trace amounts 
of FX are responsible but FXa is not.  Incubation with 35% citrate alone or with added 
FXa inhibitor yielded equivalent activation profiles (Figure 2.10); therefore, FXa does 
not appear to play a role in this activation.  When FXa was added to prothrombin in 
combination with FXa inhibitor and 35% sodium citrate, activation rates and fragments 
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were equivalent indicating that the FXa inhibitor is still functional in the harsh sodium 
citrate environment.  Activation by sodium citrate could be due to FX, autocatalytic or 
non-enzymatic activation.  Autolytic degradation of thrombin has been reported in the 
literature.  α-thrombin in the presence of 0.4 M NaCl will autolytically degrade into β- 
and γ-thrombin.22  Future research needs to include studies designed answer this question.   
Whatever the activator, previous research found that in the presence of 25% 
citrate, thrombin was formed within five hours as measured by thrombin activity.
27, 28, 32
  
In our studies, it typically took more than 72 hours and between 24 and 36 hours for 
prothrombin to be activated to FIIa by 25% and 35% sodium citrate, respectively (Figure 
2.9); however, activation times were occasionally more than 72 hours (Figure 2.10).  Our 
erratic activation times in the presence of citrate have been previously observed in 
prothrombin samples that are not highly pure; however, the causes for these 
inconsistencies are unknown.
27
   
In 1950, Seegers, McClaughry and Fahey, using electrophoretic mobility and 
activity assays, tentatively asserted that a minimum of three different molecular weight 
species were derived following activation by 25% sodium citrate.
27
  Lanchantin, 
Friedmann and Hart (1965), using sedimentation velocity techniques, identified a 
molecular weight decrease from approximately 70 kDa to 35 kDa with subsequent 
fragments with approximate weights of 25 and 10 kDa after incubation with 25% sodium 
citrate.
28
  This work identifies several more intermediates and fragments produced by 
citrate activation of prothrombin.  Both 25% and 35% sodium citrate followed identical 
pathways with 25% citrate activating at a slower rate (Figure 2.9 and other data not 
shown).   
53 
Initially, prothrombin is activated into two species at approximately 50 and 26 
kDa (Figure 2.9B, lane 5 and 6).  N-terminal sequencing indicates that the band at ~26 
kDa has the same amino terminal as prothrombin; therefore, the band is either fragment 1 
or fragment 1.2.  The molecular weight is more consistent with fragment 1.2 which 
should be approximately 30 kDa which would indicate a meizothrombin intermediate.  
However, if it were fragment 1.2, a band should also exist at approximately 42 kDa for 
FIIa which is the other fragment formed with meizothrombin.  Since there is no 
corresponding band at 42 kDa but only bands at 72 and 50, then the 26 kDa band must be 
fragment 1.  This conclusion is supported by the N-terminal sequencing of the 50 kDa 
band which indicates it is prethrombin-1 indicating that the 26 kDa band is the released 
of fragment 1.   
After further incubation, prothrombin and prethrombin-1 are activated into a band 
at approximately 42 and 40 kDa (Figure 2.9B, lane 7).  N-terminal sequencing indicates 
that the 42 kDa band corresponds to thrombin and/or prethrombin-2 and the 40 kDa band 
is α-thrombin and/or prethrombin-2a.  A proteolyzed thrombin, β-thrombin (~25 kDa), is 
also formed.  This proteolysis results in fragments at 13 kDa which is α-thrombin or 
prethrombin-2a degraded on the C-terminal and multiple lower molecular weight 
degradation bands.  It is possible that prethrombin-2a is directly activated from 
prethrombin-1; however, after all of the prothrombin and most of the prethrombin-1 has 
been proteolyzed, the band at 42 kDa is no longer present replaced by only the 40 kDa 
band corresponding to prethrombin-2a and/or α-thrombin.  Therefore, it appears that 
prethrombin-2 is converted to prethrombin-2a.  Under reducing conditions, the 40 kDa 
band splits into a doublet of bands at approximately 40 and 36 kDa exist which N-
54 
terminal sequencing indicates as prethrombin-2a and the B-chain, respectively.  These 
results indicate that under nonreducing conditions, the band at 40 kDa includes both α-
thrombin and prethrombin-2a.   
This sequence of activation by sodium citrate does not follow the primary or 
secondary hemostasis pathways (Figure 2.1); rather, it follows an alternative pathway 
similar to that of primary hemostasis (Figure 2.16).  Activation with prethrombin-1 as an 
intermediate has been reported for bovine and human prothrombin when treated with 
thrombin.
38
  It is interesting to note that activation by ecarin resulted in a similar 
sequence of activation with a prethrombin-1 intermediate although it should have yielded 
a fragment 1.2 intermediate instead.   
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Figure 2.16.  Suggested primary pathway of activation of prothrombin by sodium citrate.  When 
activated by sodium citrate, prothrombin is proteolyzed into prethrombin-1 then to prethrombin-2, FIIa, 
prethrombin-2a or αFIIa.  The order of activation after formation of prethrombin-1 is uncertain.  This figure 
modifies the prothrombin schematic published by Davie and Kulman.
1
 
 
Fragment 2 
(~13 or 15 kDa) 
Prethrombin-2 
(42 kDa) 
Prothrombin (72 kDa) 
Prethrombin-1 (55 kDa) 
Fragment 1  
(~26 kDa) 
Thrombin (42 kDa) Prethrombin-2a 
(40 kDa) 
α-thrombin (40 kDa) 
56 
The activity of four thrombin solutions, activated by 35% sodium citrate and 0.2% 
FIIa, containing primarily prethrombin-2a and α-thrombin but also β-thrombin (Figure 
2.12, lane 3) was determined by chromogenic assay.  The activity was 368 ± 173 U/mg 
(mean ± standard deviation) which is significantly lower than earlier specific activity 
reports of 1,400
27
 to 4,000 U/mg.
28
  Our activities are probably lower than other reports 
and purchased thrombin references because it contains thrombin, α-thrombin, and the less 
active β-thrombin rather than a pure thrombin as is in Recothrom.   
The activity of citrate activated thrombin was also measured by SDS-PAGE and 
thromboelastography.  Activity was evaluated with regard to the ability of the citrate 
activated thrombin sample to activate fibrinogen to fibrin and factor XIIIa to its lower 
molecular weight form.  Thrombin formed by 35% sodium citrate appeared to release all 
of fibrinopeptide B but only a portion of fibrinopeptide A (Figure 2.14A).  However, it 
was able to cleave FXIIIa in the same manner as recombinant thrombin (Figure 2.14B).  
The lower efficiency of citrate activated thrombin in releasing fibrinopeptide A compared 
to recombinant thrombin may be due to high number of degradation bands.  When 
evaluated by thromboelastography, citrate activated thrombin created a fibrin clot at 
equivalent kinetics as the highly purified recombinant thrombin (Figure 2.15).  For the 
SDS-PAGE analysis, thrombin was added by mass; therefore, the recombinant thrombin 
reactions contained approximately 7-fold more units per ml than the citrate activated 
thrombin reactions.  When dosed at equivalent activity levels as rFIIa in the 
thromboelastographic analysis, pdFIIa activated by sodium citrate yielded equivalent 
clotting kinetics and clot strength.   
57 
This research examined the activation of prothrombin in the presence and absence 
of sodium citrate.  Thrombin is not responsible for activation of prothrombin in the 
absence of high salts; rather, thrombin activates trace amount of FX to FXa which 
subsequently activates prothrombin.  FX did result in prothrombin proteolysis; however, 
it is unclear whether FX directly proteolyzed prothrombin or autocatalytically produced 
FXa which subsequently activated prothrombin.  Despite remaining questions regarding 
the activation of prothrombin in the absence of sodium citrate, prothrombin activation in 
the presence of citrate does not appear to be related to FXa.  The sequence of activation 
of prothrombin by sodium citrate did not follow the primary or secondary hemostasis 
pathways; rather, it followed an alternative pathway with prethrombin-1 as an 
intermediate.  Although activation of prothrombin by sodium citrate is different than 
physiological mechanisms, the thrombin produced is functional.  Further research with a 
recombinant prothrombin will eliminate contamination of other plasma proteins and 
thereby allow further elucidation of activation sequences and intermediates.    
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Chapter 3 
Characterization of Recombinant Factor XIII Expressed in Pichia pastoris 
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Abstract 
Factor XIII A-chain (FXIII), also known as fibrin-stabilizing factor, is important 
in establishing hemostasis because it crosslinks fibrin during clot formation imparting 
viscoelastic strength and resistance to lysis.  Consequently, FXIII deficiency results in a 
hemophilia characterized by recurrent bleeding.  Its importance in producing a resilient 
clot indicates that it would be a valuable component in liquid fibrin sealants; therefore, 
FXIII was produced in Pichia pastoris.  Rather than producing FXIII, N-terminal 
sequencing indicated that the yeast expressed FXIIIa which is the active form of the 
enzyme.  This recombinant protein was produced at approximately 0.24 mg per gram of 
cell mass and purified by His-tag affinity chromatography.  While SDS-PAGE and size 
exclusion chromatography indicate that FXIIIa primarily exists in monomer form with 
small amounts of aggregates, dynamic light scattering and analytical ultracentrifuge 
suggest that FXIIIa exists as a trimer in solution.  The expressed FXIIIa had a molecular 
weight of approximately 82 kDa but was rapidly cleaved by thrombin to the 79 kDa.  
After further incubation, thrombin proteolyzed the expressed FXIIIa into two bands at 
approximately 25 and 54 kDa which is equivalent to degradation products of plasma-
derived material.  The recombinant FXIIIa (rFXIIIa) had a specific activity of almost 
7,000 U/mg and successfully crosslinked fibrin(ogen) in the presence and absence of 
thrombin and α2-antiplasmin (A2AP) to fibrinogen.  Thromboelastography showed that 
the addition of rFXIIIa to fibrinogen and thrombin significantly increased clot strength.  
These results indicate that rFXIIIa expressed in Pichia pastoris successfully functions as 
a transglutaminase closely mimicking plasma-derived FXIII and may be a good 
alternative for therapeutic uses.   
63 
Introduction 
Factor XIII (FXIII) is a coagulation protein located in plasma and on platelets at a 
ratio between 1:1
1
 and 5:1;
2
 however, FXIII activity is split evenly between plasma and 
platelets.
3, 4
  Platelet FXIII is a 166 kDa homodimer consisting of two A-chains
3
 linked 
by strong noncovalent bonding.
5
  Plasma FXIII is a 326 kDa noncovalently-bound 
heterogeneous tetramer consisting of two A-chains (82 kDa) and two B-chains (76 kDa)
6-
8
 held together by strong noncovalent bonds.
5
  The A- and B-chains of FXIII are different 
in structure and function (Table 3.1).   
 
Table 3.1.  Structure, function and genetic differences between the A- and B-chains of FXIII.   
 A-chain B-chain 
Molecular weight (kDa)
6-8
 82 76.5 
Amino acids
9, 10
 731 641 
Location
8
 Plasma, platelets, placenta Plasma 
Structure
11
 Globular Kinked, thin, flexible strand 
Carbohydrate
12-14
 None ~8.5% total weight 
Disulfide Bridges
7, 10, 14
 None 20 
Synthesized by
4, 15-17
 
hepatocytes, monocytes, 
megakaryocytes 
hepatocytes 
Function
5, 18
 Enzyme: transglutaminase Stabilization and transport 
Domains
14, 19-21
 
β-sandwich, catalytic core and two 
barrels 
Ten β glycoprotein-1 
Chromosome location
22, 23
 6p24-p25 1q32-q32.1 
Kilobases (kb)
9, 10
 160 28 
Exons
9, 10
 15 12 
 
 
Plasma and platelet FXIII A-chains are identical in structure and function.
2, 24, 25
  
Although the A-chain has six possible asparagine-linked glycosylation sites, none contain 
carbohydrates.
12, 13
  Synthesized by hepatocytes, monocytes and megakaryocytes,
15-17
  the 
A-chain contains four domains:  a β-sandwich, catalytic core and two barrels.20, 21  The B-
chain is secreted as a single chain into plasma by hepatocytes where some form 
complexes with the A-chain
17
 and others circulate freely.
5
  FXIII tetramer circulates in 
plasma at approximately 0.07 µM
18
 while the B-chain circulates at a concentration 
64 
between 14 and 0.24 µM.
26, 27
  The A-chain is the catalytic component of the enzyme;
15-17
 
while the B-chain surrounds the hydrophobic A-chain and is thought to stabilize the 
enzyme during transport.
5, 18
  While A-chain is intertwined into the fibrin clot during its 
formation,
18
 the B-chain is absent.
28
   
When plasma FXIII is in the tetramer form, the 36 amino acid
29
 activation peptide 
of one A-chain protects the cysteine in the active site of the other A-chain.  This 
conformation is secured by hydrogen bonds and salt bridges.
20
  Plasma and platelet FXIII 
can be activated by trypsin,
24
 papain,
24
 platelet acid protease
30
 or calpain;
31
 however, it is 
primarily activated into active FXIII (FXIIIa) by thrombin which binds to the A-chains’ 
4.5 kDa activation peptide
32
 and cleaves at Arg37-Gly38 by hydrolysis.
29
  During this 
cleavage, the activation peptide is released.
33
 Fibrin and calcium ions then initiate the 
dissociation of the B-chain to form FXIIIa (Figure 3.1).   
 
 
 
Figure 3.1.  Schematic representation of thrombin activation of plasma FXIII.  Plasma FXIII is a 
heterogeneous tetramer of two A- and two B-chains.  The activation peptide of each A-chain covers 
the active site of the other A-chain.  Thrombin cleaves the activation peptide exposing the enzymes’ 
active sites.  Calcium and fibrin initiate dissociation of the B-chains leaving activated FXIII 
(FXIIIa).
18
   
 
The presence of calcium greater than 10 mM is critical for activation of FXIII after 
cleavage by thrombin
34, 35
 because it initiates conformational changes resulting in 
HS HS 
SH 
SH 
SH 
Thrombin 
Fibrin 
+ CaCl2 
Activation 
Peptides 
A 
A 
B 
B 
B 
B 
B B 
A 
A A 
A 
+ 
HS 
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dissociation of the B-chains
19
 and exposure of the active site.
34, 36, 37
  The activation to 
FXIIIa by thrombin is hastened by the presence of fibrin polymers
24, 33, 38-41
 which 
apparently changes its conformation, altering the calcium binding site
42
 lowering the 
calcium requirement to 1.5 mM which is the calcium content in plasma
37, 41
 and 
promoting the dissociation of the B-chain.
40, 43
  Both the B-chain of the heterotetramer 
plasma FXIII
44
 and thrombin
45
 bind to the γ-chain of fibrinogen which localizes the three 
integral proteins required to form a fibrin clot in close proximity and disperses FXIII 
throughout the forming clot.
18
  Unlike the fast thrombin activation of platelet FXIII,
46
 
plasma FXIII activation is significantly slower because the rate is limited by B-chain 
dissociation.
40, 46-49
  This is thought to regulate the activation of FXIII in plasma.
42
   
FXIII also known as fibrin-stabilizing factor, is important in establishing 
hemostasis because it plays a key role in the final stage of coagulation.  During this stage, 
thrombin cleaves fibrinogen into fibrin which polymerizes into a soluble fibrin clot.  
Thrombin activated Factor XIII (FXIIIa) creates an insoluble clot by crosslinking fibrin 
polymers.
50
  The manner in which FXIIIa recognizes its substrate is unknown;
18
 however, 
once activated, FXIIIa binds to residues 241 to 476 in the αC-domain of fibrin.51  Fibrin 
polymers in close proximity are crosslinked by the catalytic triad (Cys314, His373 and 
Asp396)
21
 of FXIIIa which creates an intermolecular γ-glutamyl-ε-lysine bridge between 
the side-chains of two aligned fibrin molecules (Figure 3.2).
25, 52-56
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Figure 3.2.  Biochemistry of ε-(γ-glutamyl)lysine crosslinking of fibrin molecules by FXIIIa.18, 25, 37, 54    
FXIIIa forms a thioester bond to a specific glutamine residue of the bound molecule, releasing ammonia.
57
  
This thioester reacts with the primary amine of a lysine residue of another molecule near the catalytic site 
creating an amide bond.
55, 58
   
 
Aggregation of fibrin monomers aligns the proteins easing the crosslinking 
process.
59, 60
  FXIIIa crosslinks antiparallel
61
 fibrin α- and γ-chains with the γ-γ formation 
proceeding at a much faster rate than the α-α crosslinking.18, 62, 63  Gln398 or 399 on one 
fibrin γ-chain crosslinks to Lys406 on an adjacent fibrin γ-chain within 10 minutes64, 65 
which significantly increases clot stiffness.”66, 67  One of four glutamine residues68-70 and 
one of 15 lysine residues
71, 72
 can be involved in α-chain crosslinking which  can take up 
to 24 hours to form
73
 but is important in resisting plasminolysis
74-77
 because it yields high 
viscoelastic strength
18, 62
 and insolubility.
62
  α- and γ-chains can also be crosslinked; 
however, this does not greatly affect clot strength.
67
  FXIIIa can also crosslink the same 
sites of fibrinogen but at a slower rate.
24, 78
   
In addition to fibrin and fibrinogen, FXIIIa is important in crosslinking α2-
antiplasmin,
79
 fibronectin,
80, 81
 collagen,
80, 82
 von Willebrand factor,
83, 84
 Factor V
85, 86
 and 
numerous other substrates necessary for clot stabilization, adhering clot to vessel wall,
42
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67 
resistance to lysis and wound healing (Table 3.2).
18
  FXIIIa also binds directly to 
platelets.
87
  Platelet FXIII appears to play the key role with respect to creating resistance 
to lysis.
88
   
 
Table 3.2.  FXIII substrates, crosslinking sites, crosslinking molecules and function.
18
   
Substrate Cross-linking Site Crosslinked with Function 
Fibrin(ogen) γ-chain64, 65, 89 
Gln398, Gln399 and 
Lys406 
Itself and α-chain Clot stabilization 
Fibrin(ogen) α-chain68-72 
Gln221, Gln237, Gln328, 
Gln366 and 15 potential 
lysines from Lys208 to 
Lys606 
Itself and α-chain Clot stabilization 
α2-Antiplasmin79 Gln2 
Fibrin α-chain 
Lys303 
Resistance to 
fibrinolysis 
TAFI
79
 Gln2, Gln5, Gln292 Fibrin, itself 
Resistance to 
fibrinolysis 
PAI-2
90, 91
 - 
Fibrin α-chain 
Lys148, Lys230, 
Lys413 
Resistance to 
fibrinolysis 
Fibronectin
80, 81
 Gln3 
Itself, fibrin, 
collagen 
Migration of cells 
into the clot; wound 
healing 
Collagen
80, 82
 - Fibronectin, fibrin 
Stabilization of 
extracellular matrix 
Von Willebrand factor
83, 84
 - Fibrin, collagen 
Platelet adhesion to 
clot 
Vitronectin
92, 93
 Gln93 - - 
Thrombospondin
94
 - Fibrin - 
Factor V
85, 86
 - Fibrin, platelets 
Increased thrombin 
generation at the clot 
surface 
Actin
95, 96
 - Fibrin 
Clot retraction, 
stabilization of 
platelet cytoskeleton 
Myosin
97
 - Itself  
Vinculin
98
 - Fibrin  
αIIbβ3
99
 - Fibrin 
Stabilization of 
platelet and fibrin 
clot 
 
 
The depletion of calcium is the only known inhibitor of FXIIIa in physiology;
100
 
however, there are synthetic inhibitors.
101
  FXIIIa is inactivated by thrombin cleaving the 
A-chain at Lys513 or Arg515
42
 resulting in two fragments of 25 and 54 kDa.
8
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The importance of FXIII in the formation of a blood clot is best characterized by 
the description of issues seen with individuals with FXIII deficiency.  Individuals with 
this disease typically show normal clot formation; however, the fibrin polymers are not 
crosslinked and are consequently still soluble resulting in short-lived clots in which 
bleeding recurs 24 to 48 hours after injury.
37, 42, 102
  This bleeding and clotting cycle may 
recur for months.
102
  These patients also suffer from other related issues including death 
from intracranial hemorrhage and atypical wound healing.
42
  FXIIIa appears to have 
several functions:   
1. Crosslink the fibrin clot to yield a clot with high viscoelastic strength.18, 103  
2. Reduce the rate of clot lysis74-77 by forming the strong clot and crosslinking lysis 
inhibitors into the clot.  Clot lysis is directly and inversely related to the amount 
of fibrin α-α crosslinking.24   
3. Weave cell signaling molecules into the clot to encourage wound healing.104   
4. Crosslink the clot to the vessel wall.80, 82   
Thromboelastography indicates that FXIIIa prolongs fibrinolysis,
105
 reduces time to clot 
initiation, speeds clotting kinetics and increases viscoelastic strength.
106, 107
  Platelets 
dispersed throughout the clot probably hasten
108
 and further stabilize the clot
109
 by 
releasing additional FXIII.  Research indicates that FXIII in the platelets is necessary to 
obtain optimal crosslinking.
110
   
A recombinant version of FXIII’s A-chain (rFXIIIA) has been expressed in 
Saccharomyces cerevisiae
111-113
 as a nonglycosylated homodimer
114
 that functions in the 
same manner as platelet FXIII.
46
  This rFXIIIA has been used to examine the kinetic 
details of fibrin γ-chain crosslinking113 and evaluated as a drug for treating FXIII 
69 
deficiency.
115-117
  In clinical trials, the rFXIIIA produced in Saccharomyces cerevisiae 
did not result in serious adverse events or have immunological repercussions after 
single
115, 116
 or multiple
117
 intravenous doses.  Clinical studies indicate that rFXIIIA 
infusion into patients with FXIII deficiency restores clot strength and lysis resistance.
116
  
Preclinical studies also indicate that rFXIII infusion is a beneficial treatment to combat 
depletion of coagulation proteins following cardiopulmonary bypass surgery.
118
  In 
addition to functioning like native FXIII, after injection, rFXIIIA appears to bind to free-
circulating plasma-derived FXIII (pdFXIII) B-chain and circulates as A2B2 like native 
pdFXIII.
115-117
   
The research presented in this chapter was designed to test the hypothesis that 
recombinant FXIII A-chain expressed in Pichia pastoris has the same structure, function 
and activity as its plasma-derived counterpart and rFXIIIA expressed by Saccharomyces 
cerevisiae.  Rather than producing FXIII, N-terminal sequencing indicated that the yeast 
expressed FXIIIa which successfully crosslinked fibrin(ogen) yielding a clot with 
increased viscoelastic strength.   
 
Materials and Methods 
Materials 
Purified, plasma-derived prothrombin and plasma-derived FXIII was bought from 
Enzyme Research Laboratories (South Bend, IN).  Recombinant thrombin (Recothrom
®
) 
was purchased from Zymogenetics.  Materials for the thromboelastograph were 
purchased from Haemoscope (Niles, IL).  Purified recombinant fibrinogen, expressed in 
the milk of transgenic cows, was obtained from Pharming Group NV (Leiden, 
70 
Netherlands).  PPACK was purchased from Haematologic Technologies (Essex Junction, 
VT).  Unless otherwise specified, reagents were purchased from Sigma (St. Louis, MO).   
Vector construction, expression and purification of FXIIIA in Pichia pastoris 
The human Ultimate ORF clone containing the human coagulation factor 
FXIIIA1 cDNA in the pENTR
TM
221 vector was purchased from Invitrogen (Clone ID: 
IOH11901, Carlsbad CA). The following primers were used to obtain FXIIIA gene to 
subclone in pPICZA intracellular Pichia expression vector. (Forward, 5'-
CCAATTGATGCATCATCATCATCATCATTCAGAAACTTCCAGGACCGC-3'; 
Reverse, 5'-GCGGCCGCTCACATGGAAGGTCGTCTTTGAATC-3').  The forward 
primer introduced a methionine and six histidine amino acids at the N-terminal of mature 
FXIIIA peptide. The PCR product was digested with MfeI and NotI and subcloned into 
pPICZA which was digested with the same enzymes.  The DNA sequence of the FXIIIA 
was confirmed by sequencing the insert fragment. One of the confirming plasmid 
pPICZA-FXIIIA was linearized with PmeI and transformed into Pichia pastoris X-33 
host strain and copy number of the clones was determined as described.
119
 Varying copy 
number clones were screened in shake flask culture to confirm intracellular production of 
FXIIIA protein. The highest producing clone was scaled up to 5 L bench scale.  A fed-
batch fermentation protocol was followed to optimize FXIIIa production as described by 
Zhang et al., (2007).
120
  At the end of fermentation process the cells were separated by 
centrifugation (6,000xg)  and pellet was stored at -80
o
C.   
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Figure 3.3.  Schematic of vector pPICZA-FXIIIA.  FXIIIA cDNA (2199 bases) 
with a six histidine tag (17 bases) on the N-terminal was inserted into the pPICZA 
vector containing a 5’ AOX1 promoter (941 bases), multiple cloning site (79 
bases), c-myc epitope (32 bases), six histidine tag (17 bases) and 3’ AOX1 
transcription termination region (341 bases).  The restriction enzyme sites utilized 
are shown with orange arrows.   
 
Frozen cell paste was processed in 300 gram batches.  Cells were lysed in three 
sets of 100 gram batches.  100 grams of cell paste was resuspended in 100 ml of cold 
lysis buffer (50 mM Tris-HCL, 10 mM MgSO4, 1 mM EDTA, 10 mM potassium acetate, 
1 mM DTT (DL-Dithiothreitol), 2 mM PMSF (phenylmethanesulphonylfluoride) in 
methanol, pH 9.5).  100 ml (250 g) of 0.5 mm glass beads (Biospec, Bartlesville, OK) 
were added and the cells.  Surrounded by an ice bath, cells were lysed using a BeadBeater 
Blender (Biospec, Bartlesville, OK) with twenty 20 second on/off cycles.  The cell lysate 
mixture was then centrifuged to remove cellular debris.  The lysate from 300 grams of 
cell paste was combined and purified using the HisBind Purification Kit (EMD 
Chemicals, Inc., San Diego, CA) with 40 ml of resin slurry.  Following purification, 
rFXIII was dialyzed in 10 mM Tris-HCl, 0.1 mM EDTA, 60 µM polysorbate-20, pH 8.0 
in snake-like dialysis membranes and the protein samples were filter-sterilized and 
concentrated using the Amicon tubes (Millipore, Billerica, MA).  The purity of the 
sample was tested by SDS-PAGE (NuPAGE 12% Bis-Tris) (Invitrogen, Carlsbad, CA) 
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and immunoblot.  The concentration of rFXIII was determined by standard Bicinconic 
Acid (BCA) methods.  The molecular weights of the rFXIII expressed by the yeast and 
the activated rFXIIIa were calculated based on the amino acid sequence
8
 and molecular 
weights of the amino acids (Table 3.3).   
Plasma-derived thrombin preparation 
Plasma-derived human prothrombin (Enzyme Research Laboratories, South Bend, 
IN), was thawed at 37
o
C.  Plasma-derived thrombin (Enzyme Research Laboratories, 
South Bend, IN) was added at a 1/10 mass to mass thrombin/prothrombin ratio.  0.35 
grams of sodium citrate per milliliter of solution was added and then incubated at 37
o
C 
on a rotating mixer for five hours.  Sodium citrate was removed with PD-10 desalting 
columns (GE Healthcare, Giles, United Kingdom).  Activation of prothrombin to 
thrombin was confirmed by reducing and nonreducing SDS-PAGE (12% Bis-Tris 
NuPAGE) (Invitrogen, Carlsbad, CA) stained with Colloidal Blue (Invitrogen, Carlsbad, 
CA) and Western blot analysis.  The concentration of the thrombin solution was 
determined by standard Bicinconic Acid (BCA) methods.  The specific activity was 
determined by aPTT analysis.   
Comparison of pdFXIII and rFXIII by SDS-PAGE and Western blot 
Reduced FXIII samples were evaluated by sodium dodecylsulfate-polyacrylamide 
(SDS-PAGE) gel electrophoresis on 4-12% NuPage
®
 Bis-Tris gels with 2-(N-
morpholino)ethanesulfonic acid (MES) running buffer and NuPage
®
 LDS sample buffer 
which were purchased from Invitrogen (Carlsbad, CA).  Reduced samples were treated 
with NuPage
®
 Sample Reducing buffer (β-mercaptoethanol) (Invitrogen).  Samples were 
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incubated at 74
o
C for 10 minutes before loading on the gels which were run at 200 volts 
for one hour.  Gels were stained with Colloidal Blue (Invitrogen) or electroblotted onto 
polyvinylidene fluoride (PVDF) membrane (Millipore, Billerica, MA).  Blots were 
subsequently developed with an anti-human factor XIII subunit A polyclonal antibody 
made in sheep (US Biologicals, Swampscott, MA) and then an anti-sheep IgG peroxidase 
conjugate antibody (Sigma, St. Louis, MO).   
Dynamic light scattering 
Dynamic light scattering was used to identify the radius of gyration of the 
recombinant FXIII and estimate polydispersity of molecular weights in solution.  pdFXIII 
and rFXIII samples were diluted with 10 mM Tris-HCl, 0.1 mM EDTA, 60 µM 
polysorbate-20, pH 8.0 to various dilutions.  Data were collected at 24
o
C by a DynaPro
TM
 
(Protein Solutions
TM
) Titan (Wyatt Technologies, Santa Barbara, CA) dynamic light 
scattering instrument and analyzed by DYNAMICS software (Wyatt Technologies, Santa 
Barbara, CA) which provided data regarding radius of gyrations and estimated molecular 
weights of the particles in solution.  Four measurements were collected for each sample.   
Analytical ultracentrifuge 
Sedimentation velocity experiments were performed using a ProteomeLab XL-I 
analytical ultracentrifuge (Beckman Coulter, Brea, CA) to estimate molecular weights 
and  evaluate aggregation of rFXIII in solution.  rFXIII sample, in 10 mM Tris-HCl, 50 
mM NaCl, 60 µM polysorbate-20, pH 8.0, was tested at 0.1, 0.3 and 0.5 mg/ml and three 
speeds (8,000, 10,000 and 12,000 rpm) and three wave lengths (275, 280 and 285 nm) at 
20
o
C.  110 µl rFXIII and 125 µl of the corresponding buffer were loaded in triplicate into 
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cells with sapphire windows and a 6-channel equilibrium centerpiece.  Cells were spun in 
an An-50 Ti 8-hole rotor and run for 22 hours at each speed collecting data at 20 and 22 
hours.  The partial specific volume of 0.73 ml/g was calculated for the A subunit of FXIII 
was calculated from the amino acid sequence as described by Perkins (1986).
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  Data 
was analyzed using Microcal Origin 6.0 software.   
Size exclusion chromatography 
Size exclusion chromatography (SEC) was also utilized to estimate molecular 
weight and possible aggregation of rFXIII.  Bovine serum albumin (Sigma, St. Louis, 
MO), immunoglobulin A (IgA) (Sigma, St. Louis, MO) and immunoglobulin G (IgG) 
(Green Mountain Antibodies, Burlington, VT) were exchanged into 20 mM Tris-HCl, 
200 mM NaCl, 60 μM Tween 20, pH 7.0 and rendered 1.94 mg/ml by ultracentrifugation.  
After being passed through a 0.20 µm nylon filter (Millipore, Billerica, MA), 0.5 ml of 
each sample were sequentially passed through a TSK-G3000SWxL (Tosoh Biosciences, 
South San Francisco, CA) column (14 ml, 30 cm length, 7.8 mm ID) attached to a Knauer 
HPLC System at 0.5 ml/min for 45 minutes and data were collected by a photodiode 
array (PDA) with a 1 mm flow cell and analyzed by EZChrom Elite software.  rFXIII 
(0.5 ml at 1.94 mg/ml) in 20 mM Tris-HCl, 200 mM NaCl, 60 μM Tween 20, pH 7.0 was 
also subsequently passed through the column using the same method.  The EZChrom 
Elite software was used to overlay the tracings and match the heights of the primary 
peaks.  Retention times of the primary peaks of the known samples were obtained from 
the EZChrom Elite software and plotted in Excel.  A linear trend line was fit and rFXIII 
molecular weights estimated from resultant retention times.  Purification products were 
analyzed by SDS/PAGE and Western blot with an anti-FXIII antibody (US Biologicals, 
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Swampscott, MA).  The percentage of rFXIII at different molecular weights was 
estimated by determining the mass of rFXIII in each peak by SDS-PAGE.   
Activation and inactivation of rFXIII by rFIIa 
The ability of the recombinant FXIII to be activated and inactivated by rFIIa was 
evaluated by SDS-PAGE by a similar procedure previously described.
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  rFXIII (final 
concentration: 0.67 mg/ml) was incubated with rFIIa (60 U/ml) in Ringers solution (155 
mM  NaCl, 5 mM KCl, 2 mM CaCl2, 1 mM MgCl2) for 0, 5, 15, 30, 60, 120, 180, 240 
and 360 minutes at 37
o
C.  The activation/inactivation reaction was halted by the addition 
of PPACK (final concentration: 5 µM).  For the zero time point, rFIIa and PPACK were 
added at the same time.  Samples were evaluated by sodium dodecylsulfate-
polyacrylamide (SDS-PAGE) gel electrophoresis on 4-12% NuPage
®
 Bis-Tris gels with 
2-(N-morpholino)ethanesulfonic acid (MES) running buffer, NuPage
®
 LDS sample 
buffer and NuPage
®
 Sample Reducing buffer (β-mercaptoethanol) (Invitrogen, Carlsbad, 
CA).  Samples were incubated at 74
o
C for 10 minutes before loading on the gels which 
were run at 200 volts for one hour and stained with Colloidal Blue (Invitrogen, Carlsbad, 
CA) or electroblotted onto polyvinylidene fluoride (PVDF) membrane (Millipore, 
Billerica, MA) by applying 30 volts for one hour and stained with Colloidal Blue.  Each 
band was excised and the first ten amino acids in the N-terminal were sequenced by 
Edman degradation with an Applied Biosystems 494 Procise automated sequencer.  N-
terminal sequencing was performed by the University of Nebraska Medical Center’s 
Protein Structure Core Facility. 
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Chromogenic activity assay 
The activity of rFXIII was determined using a Pefakit
®
 Factor XIII Incorporation 
Assay (Pentapharm, CT) by comparing rFXIII to a plasma-derived reference FXIII 
(Enzyme Research Laboratories, South Bend, IN).  rFXIII was diluted to 0.055, 0.55, 5.5, 
55 and 550 ng/ml with Tris buffered saline included in the kit.  FXIII is activated to 
FXIIIa by thrombin in wells coated with fibrinogen in the presence of 5-
biotinamidopentylamin (BAPA).  FXIIIa crosslinks BAPA to fibrin(ogen) which is 
subsequently bound by streptavidine-alkaline phosphatase conjugate (Strept-AP).  
Finally, addition of alkaline phosphatase produces p-nitrophenol and phosphate from p-
nitro phenyl phosphate (pNPP) which can be detected at 405 nm.  
FXIIIa crosslinking ability 
The ability of the recombinant FXIII to catalyze γ-γ crosslinking of fibrinogen 
and fibrin was analyzed by a similar procedure previously described.
122
  Briefly, rFI 
(final concentration: 0.38 mg/ml) was incubated with pdFXIII or rFXIII (final 
concentration: 0.01 mg/ml) and pdFIIa (5 U/ml) in Ringers solution (155 mM  NaCl, 5 
mM KCl, 2 mM CaCl2, 1 mM MgCl2) for 0, 5, 15, 30 and 60 minutes at 37
o
C.  rFI was 
also incubated with pdFIIa without FXIII.  Crosslinking of fibrinogen was also tested by 
incubating rFI (0.38 mg/ml) and rFXIIIa (0.014 mg/ml) in Ringers solution for 0, 5, 15, 
30, 60, 120 and 240 minutes.  The reactions were halted by the addition of NuPage
®
 
Sample Reducing Buffer (β-mercaptoethanol) (Invitrogen, Carlsbad, CA) and NuPage® 
LDS buffer and incubation at 74
o
C for 10 minutes.  For the zero time point, the reaction 
buffers were added immediately after the addition of thrombin.  Crosslinking was studied 
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by reducing SDS-PAGE (12% Bis-Tris NuPAGE) which were run at 200 volts for one 
hour and stained with Colloidal Blue (Invitrogen, Carlsbad, CA).   
The ability of FXIIIa to covalently crosslink α2-antiplasmin (A2AP) to rFI was 
analyzed by SDS-PAGE and immunoblot.  rFI (0.38 mg/ml) was incubated with rFXIIIa 
(98 U/ml, 0.014 mg/ml) in the presence and absence of A2AP (0.51 mg/ml, 1 mol A2AP 
per mol rFI) in Ringers solution (155 mM  NaCl, 5 mM KCl, 2 mM CaCl2, 1 mM MgCl2) 
for 90 minutes at 37
o
C.  The crosslinking reaction was halted by the addition of NuPage
®
 
Sample Reducing Buffer (β-mercaptoethanol) (Invitrogen, Carlsbad, CA) and NuPage® 
LDS buffer and incubation at 74
o
C for 10 minutes.  Crosslinking was studied by reducing 
SDS-PAGE (4-12% Bis-Tris NuPAGE) stained with Colloidal Blue (Invitrogen, 
Carlsbad, CA) and immunoblot with an anti-A2AP antibody (US Biologicals, 
Swampscott, MA).   
Clot formation by thromboelastography 
The ability of the recombinant FXIII to catalyze crosslinks and thereby increasing 
clot stiffness was evaluated by thromboelastography (TEG) which was performed on 
solutions containing purified rFXIII, rFI and pdFIIa with a Thromboelastograph
®
 (TEG
®
) 
Hemostasis System 5000 series (Haemoscope Corp., Niles, IL).  Clotting strength and 
kinetics of purified rFXIII with rFI and pdFIIa were evaluated.  rFI (final concentration: 
8.56 mg/ml) was transferred to a single-use TEG cup maintained at 37
o
C by the 
instrument.  rFXIII (final concentration: 2,429 U/ml, 0.35 mg/ml) was added.  CaCl2 
(final concentration: 11 mM) and Ringers solution (155 mM  NaCl, 5 mM KCl, 2 mM 
CaCl2, 1 mM MgCl2, added to standardize volume in cup) was added followed quickly by 
pdFIIa (final concentration: 52.8 U/ml) to initiate clot formation.  Data were collected 
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every five seconds for 30 minutes by the TEG interfaced with a computer.  The TEG 
Analytical Software (version 4.2.2, Haemoscope, Niles, IL) collected the time to clot 
initiation (R), the time to achieve a clot firmness of 20mm (K) and the maximal clot 
strength (MA).  The instrument was calibrated each day of use.  Each sample was run in 
triplicate so means and standard deviations could be calculated.  The data was exported 
and analyzed in Microsoft
®
 Excel.   
 
Results 
rFI and pdFIIa characterization 
SDS-PAGE and immunoblots indicated rFI had a purity of greater than 98% (data 
not shown).  The pdFIIa prepared by citrate activation was comprised of α-thrombin and 
fragments as per SDS-PAGE.  Chromogenic assay yielded a specific activity of 528 U 
per mg.   
Expression and purification of rFXIII 
DNA sequencing indicated that the gene of the FXIII A-chain was successfully 
inserted into the cassette prior to transformation into Pichia pastoris.  Clones had 
between one and five gene copies.  rFXIII was produced at greater than 0.24 mg per gram 
of cell mass by clones with four gene copies.  rFXIII was located in the cell inclusion 
body and could be successfully extracted and purified by His-tag with affinity 
chromatography.  Typical purification products are shown in Figure 3.4.  When grown in 
a flask, the yeast produced a 36 kDa protein that is also purified (Figure 3.4, lane 9); 
however, this protein did not alter rFXIII’s activity and could be removed by size 
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exclusion chromatography.  This protein was not present when the yeast was grown in a 
fermentor (data not shown) yielding a greater than 98% purity.  The final yield following 
purification, dialysis and concentration steps were approximately 0.24 mg rFXIII per 
gram cell paste.   
 
 
Figure 3.4.  Purification of rFXIII as analyzed by reducing SDS-PAGE and immunoblot.  SDS-
PAGE (A) and immunoblot (B) under reducing conditions.  Lane 1:  molecular weight marker.  Lanes 
2, 3 and 4: 0.5, 1, and 2 µg purified rFXIII.  Lane 5: cell lysate.  Lane 6: loading flow through.  Lanes 7 
and 8: wash 1 and 2.  Lane 9: elution.  Lane 10: bovine serum albumin.   
 
Comparison of pdFXIII and rFXIII by SDS-PAGE and western blot 
The rFXIII A-chain is almost identical to the A-chain of plasma-derived FXIII 
(pdFXIIIA) by SDS-PAGE analysis.  Under nonreducing (Figure 3.5A) and reducing 
(Figure 3.5B) conditions, rFXIII is at the same molecular weight (~82,000 Da) as 
pdFXIIIA.  pdFXIII also has a B-chain that is visible at a molecular weight of 
approximately 60 kDa under nonreducing conditions but is approximately 80 kDa under 
reducing conditions due to the numerous disulfide bridges.  Only the A-chain is 
expressed in the yeast.   
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Figure 3.5.  Plasma-derived and recombinant Factor XIII by SDS-
PAGE.  SDS-PAGE gels under nonreducing (A) and reducing (B) 
conditions.  Lane 1: molecular weight marker.  Lane 2:  pdFXIII.  Lanes 3:  
rFXIII.   
 
Molecular weight estimates of expressed protein 
The recombinant protein expressed by the yeast should be FXIII with the His-tag 
designed into the gene and the myc epitope and His-tag from the yeast vector (Figure 
3.3).  When the activation peptide of FXIII is cleaved by thrombin, the resulting protein 
should contain FXIIIa with the myc epitope and His-tag from the yeast vector.  The 
molecular weights of these two products were calculated based on the amino acid 
sequence
8
 and molecular weights of the amino acids (Table 3.3).  The expressed rFXIII 
should have an approximate molecular weight of 85 kDa.  The pPICZA vector does not 
contain any known thrombin cleavage sites; therefore, once cleaved by thrombin, the 
molecular weight should drop to 82 kDa.   
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Table 3.3.  Molecular weight estimations of expressed rFXIII and rFXIIIa.   
Amino Acids 
Molar 
Mass 
(g/mol) 
rFXIII* rFXIIIa* 
myc epitope 
+ His-tag 
rFXIIIa without 
myc epitope + 
His-tag 
Alanine 71.08 38 34 1 33 
Arginine 156.19 45 41 0 41 
Asparagine 114.10 41 38 1 37 
Aspartic Acid 115.09 49 47 2 45 
Cysteine 103.14 9 9 0 9 
Glutamic Acid 129.12 52 49 3 46 
Glutamine 128.13 27 26 1 25 
Glycine 57.05 50 47 0 47 
Histidine 137.14 20 20 6 14 
Isoleucine 113.16 39 39 1 38 
Leucine 113.16 50 48 2 46 
Lysine 128.17 39 39 1 38 
Methionine 131.20 18 18 0 18 
Phenylalanine 147.18 32 31 0 31 
Proline 97.12 33 29 0 29 
Serine 87.08 48 45 2 43 
Threonine 101.11 45 42 0 42 
Tryptophan 186.21 15 15 0 15 
Tyrosine 163.18 29 29 0 29 
Valine 99.13 72 68 1 67 
Estimated Molecular 
Weights (Da) 
 85,483 81,591 2,495 79,097 
*  The expressed rFXIII should contain two His-tags and the myc epitope.  rFXIIIa should contain one His-
tag and the myc epitope.   
 
Aggregation/molecular weight analysis (SDS-PAGE, DLS, AUC, SEC) 
SDS-PAGE, dynamic light scattering (DLS), analytical ultracentrifuge (AUC) 
sedimentation equilibrium and size exclusion chromatography were utilized to identify 
different molecular weight species of rFXIII in solution (Table 3.3).  Dynamic light 
scattering indicated that rFXIII existed in solution as a single molecular weight species 
with a mean molecular weight estimate of 228.75 ± 18.39 kDa for rFXIII compared to 
381.20 ± 110.63 for pdFXIII.  Analytical ultracentrifuge estimated FXIII in solution at 
241.0 ± 48.6 kDa.  SDS-PAGE and SEC suggested rFXIII exists primarily as a monomer 
with some aggregates (Table 3.4).  SDS-PAGE shows rFXIII with a molecular weight of 
approximately 80 and 160 kDa (Figure 3.4B, Lanes 2, 3 and 4).   
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Table 3.4.  Molecular weight estimates of rFXIII in solution by multiple techniques.   
Technique 
Estimated MW 
Mean ± Standard 
Deviation 
(kDa) 
Primary Species Secondary Species 
SDS-PAGE ~80 and ~160 Monomer Dimer 
    
Dynamic Light Scattering 229 ± 18 Trimer  
    
Analytical Ultracentrifuge 241 ± 49 Trimer  
    
Size Exclusion Chromatography 58, 183, 255, 365 Monomer 
Trimer, Tetramer, 
Hexamer 
 
The retention time of rFXIII in a size exclusion column was compared to 
retention times of three proteins with known molecular weights:  BSA (~66 kDa 
monomer), IgG (~150 kDa) and IgA (~300 kDa) (Figure 3.6).  IgA (blue) yielded a single 
peak while IgG (green) yielded one primary peak and two small peaks.  BSA (black) 
yielded a primary monomer peak and a secondary peak which appears to be aggregation 
of two molecules.  The retention times of the primary peaks of BSA, IgG and IgA were 
plotted against their molecular weights and a linear trend line (R
2
 = 0.9992) was fit.   
rFXIII molecular weights estimated from resultant retention times of peaks seen in the 
SEC tracing (Figure 3.6 inset) were calculated using the equation for the trend line.  SEC 
suggests multiple molecular weights.  61.0% of the rFXIII exited the column at 18.10 
minutes (~58 kDa),  36.6% at 15.28 minutes (~183 kDa), 1.7% at 13.68 minutes (~255 
kDa) and 0.7% at 11.22 minutes (~365 kDa).   
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Figure 3.6.  Overlaid tracing of proteins analyzed by size exclusion chromatography and 
individual tracing of rFXIII (insert).  BSA (~66 kDa monomer, black), IgG (~150 kDa, green) 
and IgA (~300 kDa, blue) were passed through an SEC column to yield tracings of known 
molecular weights.  rFXIII was then passed through the column (red) and estimated molecular 
weights calculated from a linear trend line (R
2
 = 0.9992) produced with results from the known 
samples.   
 
Activation and inactivation of rFXIII by thrombin 
The activation and inactivation of rFXIII by thrombin was evaluated by SDS-
PAGE by a similar procedure previously described and yielded similar results (Figure 
3.7).
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  Before being treated with rFIIa, rFXIII consisted of a single band at 
approximately 82 kDa.  Within five minutes of incubation with thrombin, a second band 
appears with a molecular weight approximately 3 kDa lower than the original band.  By 
15 minutes, a majority of the protein is approximately 79 kDa; however, very little has 
been inactivated.  Between 30 and 360 minutes incubation, the protein is degraded into 
two fragments visible at approximately 25 and 54 kDa.   
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Figure 3.7.  Recombinant Factor XIII cleavage by thrombin.  
SDS-PAGE gel analysis of rFXIII (0.67 mg/ml) and rFIIa (60 
IU/ml) under reducing conditions.  Lane 1:  molecular weight 
marker; Lanes 2 through 9:  Time periods 0, 5, 15, 30, 60, 120, 240 
and 360 minutes.  Lane 10:  rFIIa.   
 
The N-terminal amino acids of the bands at ~82, ~79, ~54 and ~25 kDa were sequenced 
(Table 3.5 and Figure 3.8).  The first 10 residues of the bands at approximately 54 and 79 
kDa are consistent with the primary FIIa cleavage site that yields FXIIIa and the first 
fragment.  The first 10 residues of the 25 kDa band is consistent with the second FIIa 
cleavage site.  N-terminal amino acid sequence analysis of the 82 kDa band, however, 
indicates the presence of multiple proteins.  The most abundant protein in that band has a 
10 residue sequence consistent with FXIIIa.  The other possible sequences do not match 
the zymogen or any other expected sequence.   
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Table 3.5.  N-terminal amino acid sequences of purified FXIII expressed by yeast.   
Approximate Molecular 
Weight by SDS-PAGE 
 (kDa) 
Amino Acid 
Sequence 
Identity 
~82 GVNLQEFLNVTI FXIIIa + c-myc epitope and His tag? 
   
~79 GVNLQEFLNV FXIIIa 
   
~54 GVNLQEFLNV FXIIIa N-terminal after FIIa clip (K513-S514) 
   
~25 SPSNVDMXFE FXIIIa C-terminal after FIIa clip (K513-S514) 
 
 
 
Figure 3.8.  Linear model of the expected and actual molecules expressed by 
yeast and the subsequent degradation products.  Schematic of the expected 
FXIII expressed by yeast (A), FXIIIa molecule purified from yeast (B), and 
degradation products of FXIIIa (C).  FXIII is composed of an activation peptide 
(green) and the remainder of the molecule (blue) which is designated FXIIIa in the 
absence of the activation peptide.  His-tags are designated in yellow and the c-myc 
epitope in grey.  The known thrombin cleavage sites are indicated by red arrows 
and the suspected site by a black arrow.   
 
Chromogenic activity assay 
The activity of rFXIIIa was determined using a Pefakit
®
 Factor XIII Incorporation 
Assay.  The activity of rFXIIIa purified within two months of the activity test yielded a 
specific activity of 6,940 ± 2,272 U/mg.   
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γ-γ crosslinking of fibrin(ogen) by FXIIIa 
γ-γ crosslinking of fibrinogen by FXIIIa was analyzed by SDS-PAGE as 
previously described.
122
  γ-chain dimers begin forming within a couple of seconds when 
catalyzed by either pdFXIII (Figure 3.9A) or rFXIIIa (Figure 3.9B).  After 5 minutes, a 
majority of the γ-chains were crosslinked and the remaining chains were slowly 
converted to γ-γ dimers over the next 55 minutes.  pdFXIII and rFXIIIa catalyze the 
formation of γ-γ dimers at similar rates as seen by the disappearance of the monomer and 
appearance of the dimer.  The α-chain monomer is also disappearing for both samples 
resulting in higher molecular weight bands.  γ-γ dimers were not formed when pdFXIII or 
rFXIIIa were added (Figure 3.9A and B, lane 8).  When rFI and rFXIIIa are incubated in 
the absence of thrombin, γ-γ crosslinking is visible within seconds (Figure 3.9C, lane 3).  
Over the following 60 minutes, the α- (~67 kDa) and γ-chains (~47 kDa) gradually 
decrease while the band at ~94 kDa and smearing at the top of the wells darken.   
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Figure 3.9.  Ability of rFXIIIa to crosslink fibrin and fibrinogen γ-chain by reducing SDS-PAGE.  
Formation of fibrin γ-chain crosslinks was analyzed by SDS-PAGE gels under reducing conditions for 
clots created with rFI, pdFIIa and pdFXIII (A), rFI, pdFIIa and rFXIIIa (B), and rFI and rFXIIIa in the 
absence of thrombin (C).  Lane 1: molecular weight marker.  Lane 2: rFI sample prior to incubation 
with FXIII and pdFIIa.  For panels A and B, Lanes 3 through 7: rFI, FXIII and pdFIIa incubated for 2 
seconds, 5, 15, 30 and 60 minutes.  Lane 8: rFI incubated with pdFIIa for 60 minutes.  Lane 9: FXIII 
sample prior to incubation with rFI and pdFIIa.  Lane 10: pdFIIa sample prior to incubation with FXIII 
and rFI.  For panel C, Lanes 3 through 9: rFI and rFXIIIa incubated for 2 seconds, 5, 15, 30, 60, 120 
and 240 minutes.  Lane 10: FXIII sample prior to incubation with rFI and pdFIIa.   
 
The ability of rFXIIIa to covalently crosslink α2-antiplasmin (A2AP) to rFI was 
analyzed by SDS-PAGE and immunoblot (Figure 3.10).  rFI incubated with A2AP in the 
absence of rFXIIIa have multiple bands all below approximately 70 kDa (Figure 3.10A, 
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lane 7) with the A2AP band at ~62 kDa (Figure 3.10B, lane 7).  When rFI is incubated 
with rFXIIIa in the presence or absence of A2AP, bands appear above 70 kDa (Figure 
3.10A, lanes 8 and 9, respectively).  Incubation of rFI with rFXIIIa and A2AP results in 
multiple A2AP bands (Figure 3.10A, lane 9).  The largest band is at approximately 62 
kDa followed by bands at ~130 and ~200 kDa indicating A2AP crosslinking to 
fibrinogen’s α-chain and α-α crosslinking.   
 
Figure 3.10.  Ability of rFXIIIa to covalently crosslink A2AP to rFI by SDS-PAGE and immunoblot.  
The ability of A2AP to covalently bind to rFI was analyzed by SDS-PAGE (A) and an anti-A2AP 
immunoblot (B).  Lane 1: molecular weight marker.  Lanes 2, 3 and 4: 0.5, 1.0 and 1.5 µg A2AP, 
respectively.  Lane 5: rFI.  Lane 6: rFXIIIa.  Lane 7: rFI incubated with A2AP.  Lane 8: rFI incubated with 
rFXIIIa.  Lane 9: rFI incubated with rFXIIIa and A2AP.   
 
Clot formation by thromboelastography 
The role FXIII plays in clot formation was evaluated by thromboelastography 
(TEG) (Figure 3.11).  The kinetics and strength of polymerized fibrin formed by rFI and 
rFIIa were measured when in the presence or absence of rFXIII.  The time to clot 
initiation of rFI treated with rFIIa in the absence of rFXIII was 21.7 ± 2.9 seconds 
compared to 18.3 ± 5.8 seconds in the presence of rFXIII.  Maximal clot strength 
increased from 1,345.2 ± 298.2 to 8,637.3 ± 867.2 dynes/sec when rFXIII is added.   
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Figure 3.11.  Analysis of the effect of rFXIIIa on clot strength by thromboelastography.  TEG 
monitored the change in clot strength over time of recombinant fibrinogen (8.56 mg/ml) activated by 
recombinant thrombin (52.8 U/ml) with (blue) and without (red) rFXIII (0.35 mg/ml).  Data are 
expressed as mean +/- standard deviation. 
 
 
Discussion 
Pichia pastoris is widely used to produce recombinant proteins for research and 
medical purposes because it can be cultivated to high density and efficiently secrete 
protein.
123, 124
  The FXIII A-chain does not exhibit glycosylation; therefore, differences in 
glycosylation between mammalian cells and yeast is not a concern.
125
  Consequently, this 
production system was selected as a possibility to produce abundant quantities of FXIII 
for use as therapeutics.   
Initially, the gene to the A-chain of FXIII (FXIIIA) was inserted into yeast in a 
vector designed to secrete the recombinant protein into the culture medium.  Numerous 
researchers have successfully used the same α-factor secretion signal from 
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Saccharomyces cerevisiae to secrete recombinant proteins from Pichia pastoris.
126-128
  
FXIII was expressed by the yeast but not secreted.  This may indicate that the protein was 
not folded properly by the endoplasmic reticulum (ER).
127, 129, 130
  Consequently, FXIIIA 
gene was inserted into a vector for intracellular expression.  The PCR amplified DNA 
indicated that the full and unmutated FXIIIA gene was present when inserted into the 
yeast.   
Initial analyses of the expressed and purified protein were consistent with 
naturally occurring inactivate FXIII.  The molecular weight of the expressed protein was 
approximately 82 kDa; however, N-terminal sequencing identified this band as the 
activated enzyme: FXIIIa.  Molecular weight estimates of the protein that should have 
been expressed and its active form support the identification of the purified protein as 
FXIIIa.  The yeast should have expressed rFXIII at a molecular weight of approximately 
85 kDa because of the inclusion of the myc epitope and His-tag attached by the yeast 
vector (Table 3.3).  82 kDa is consistent with the estimate of rFXIIIa with the added 
peptides.  When activated by thrombin, the 85 kDa protein should have become ~82 kDa.  
Instead, the yeast expressed an 82 kDa which dropped to 79 kDa when cleaved by 
thrombin.  79 kDa is consistent with rFXIIIa after the removal of the myc epitope and 
His-tag.  N-terminal sequencing identified both bands as FXIIIa.  This was further 
supported by rFXIIIa’s rapid crosslinking of fibrinogen’s γ-chains (Figure 3.9C).  While 
FXIII and FXIIIa both yield γ-γ and α-α crosslinks, FXIIIa crosslinks at a faster rate131 
more consistent with our results.  The high specific activity of rFXIIIa of almost 7,000 
U/mg compared to the activity of pdFXIII of approximately 50 U/mg also supports the 
data indicating that the active form of rFXIII is the protein purified from the yeast.   
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The yeast most likely expresses FXIII which is cleaved by a protease in the cell to 
FXIIIa.  The protease is extremely efficient.  Although multiple proteins were detected 
during N-terminal sequencing of the 82 kDa band, the primary sequence was FXIIIa.  
The tentative secondary sequence did not correspond to FXIII or any other expected 
sequence.  The cleavage site to remove the activation peptide from FXIII to produce 
FXIIIa is a thrombin site as is the degradation site at K513-S514.  While the activation 
peptide appears to be removed from a vast majority of the FXIII molecules, none have 
been degraded into the 54 and 25 kDa fragments.  The protein purified from yeast cell 
lysate has a molecular weight of approximately 82 kDa which consists of the 79 kDa 
FXIIIa, the 1 kDa His-tag and the 1.2 kDa c-myc epitope.  Since N-terminal sequencing 
indicates that the band at 79 kDa is the same as that of the 82 kDa band, it appears that 
the His-tag and c-myc epitope are cleaved very rapidly when incubated with thrombin 
leaving only FXIIIa; however, there is no known thrombin cleavage site.  Despite the 
presence of the extra peptide region on the C-terminal, FXIIIa is active and functional 
when not treated with thrombin.   
While pdFXIII exists as a heterotetramer in plasma and homodimer in platelets,
24
  
rFXIII produced in Saccharomyces cerevisiae was secreted and maintained as a dimer.
111
  
While SDS-PAGE and size exclusion chromatography indicate that rFXIIIa expressed in 
Pichia pastoris primarily exists as a monomer with small amounts of aggregates, 
dynamic light scattering and analytical ultracentrifuge indicate the existence of a trimer 
(Table 3.4).  The harsh conditions of SDS and mechanical stress of size exclusion 
chromatography appears to disrupt rFXIIIa aggregation; therefore, dynamic light 
scattering and analytical ultracentrifuge, which analyze aggregation without significant 
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disturbance of the solution, may provide more accurate estimates of molecular weight 
species.  Dynamic light scattering yielded a molecular weight estimate of approximately 
381 kDa for pdFXIII which is consistent with the heterotetramer in plasma from which 
the reference material was derived.  rFXIIIa purified from yeast does not appear to exist 
as a homodimer as is seen under natural conditions.  This could be related to the buffer 
composition or improper folding which has been shown to result in abnormal aggregation 
due to hydrophobic interactions.
132
   
When incubated with thrombin, rFXIIIa expressed and purified from Pichia 
pastoris was cleaved at K513-S514 yielding fragments of approximately 25 and 54 kDa.  
N-terminal sequences of these two degradation bands is consistent with the second 
thrombin cleavage site observed for plasma-derived FXIIIa.
8
  These results were similar 
to those seen with a rFXIII produced in Saccharomyces cerevisiae that is currently in 
clinical trials.
115, 117
   
rFXIIIa expressed by yeast was functionally active.  rFXIIIa successfully 
catalyzed γ-dimer formation when incubated with rFI (Figure 3.9C) or fibrin (Figure 
3.9B).  It was also able to covalently bind A2AP to rFI (Figure 3.10).  Previous research 
has shown that FXIII is critical for the formation of a strong, elastic clot in whole blood, 
platelet rich and platelet poor plasma by thromboelastography.
4, 116
  rFXIIIa produced in 
the yeast significantly increased clot strength compared to rFI and rFIIa alone.   
The production of rFXIIIa rather than FXIII may be beneficial for therapeutic 
uses.  Expression of the A-chain alone is beneficial because it significantly increases its 
rate of activation by eliminating the rate limiting dissociation of the B-chain.
40, 46-49
  
Unlike the rFXIII produced in Saccharomyces cerevisiae, our rFXIIIa is already in active 
93 
form with a high specific activity of 6,940 ± 2,272 U/mg.  Consequently, it does not need 
to be activated by thrombin before achieving optimal crosslinking potential.  This could 
be beneficial for certain therapies such as a component for fibrin sealants because FXIIIa 
immediately begins crosslinking fibrin.   
This research characterized rFXIII expressed in Pichia pastoris.  Rather than 
producing FXIII, N-terminal sequencing indicated that the yeast expressed the active 
FXIIIa.  This recombinant protein was produced at approximately 0.24 mg per gram of 
cell mass and purified by His-tag affinity chromatography.  While SDS-PAGE and size 
exclusion chromatography indicate that FXIIIa primarily exists in monomer form with 
small amounts of aggregates, dynamic light scattering and analytical ultracentrifuge point 
toward FXIIIa in trimer form in solution.  The expressed FXIIIa had a molecular weight 
of approximately 82 kDa but is rapidly cleaved by thrombin to the expected 79 kDa.  
After further incubation, thrombin proteolyzed the expressed FXIIIa into two bands at 25 
and 54 kDa which is identical to degradation products of plasma-derived material.  The 
recombinant FXIIIa had a specific activity of almost 7,000 U/mg and successfully 
crosslinked γ-chains of fibrin(ogen) and A2AP to fibrinogen.  rFXIIIa significantly 
increased clot strength.  These results indicate that rFXIIIa expressed in Pichia pastoris 
closely mimic plasma-derived FXIII and may be a good alternative for therapeutic uses; 
however, further research will further elucidate the efficacy of rFXIIIa as a therapeutic.    
 
Acknowledgements 
I would like to thank Dr. Mehmed Inan and Vijay Jain for cloning the A-chain of 
FXIII gene into yeast and identifying a purification process.  I would also like to thank 
94 
Sarah Conrad, Weijie Xu, Mohammed Halhouli and Ayman Ismail for assisting in 
rFXIIIa purification.  I am also very grateful to Dr. Donald Becker for allowing us the use 
of his analytical ultracentrifuge and assistance in analyzing the results.  I would also like 
to thank Mostafa Fatemi for assisting me with SEC.  UNMC’s Protein Structure Core 
Facility conducted the N-terminal sequencing.  This work was supported by a grant from 
the Department of Defense titled “Production and Purification of Fibrinogen Components 
for the Production of a Fibrin Sealant Hemostatic Dressing.” 
 
 
  
95 
References 
 
1. Loewy, A.G. [Mechanism of action of factor XIII]. Thromb Diath Haemorrh 
Suppl 28, 1-12; discussion; 23-54 (1968). 
2. Kiesselbach, T.H. & Wagner, R.H. Fibrin-stabilizing factor: a thrombin-labile 
platelet protein. Am J Physiol 211, 1472-1476 (1966). 
3. McDonagh, J.M., McDonagh, R.P., Jr., Delage, J.M. & Wagner, R.H. Factor XIII 
in human plasma and platelets. J.Clin.Invest. 48, 940 (1969). 
4. McDonagh, J., McDonagh, R.P., Jr., Delage, J.M. & Wagner, R.H. Factor XIII in 
human plasma and platelets. J Clin Invest 48, 940-946 (1969). 
5. McDonagh, J. in Hemostasis and Thrombosis: Basic Principles and Clinical 
Practice, Edn. Third Edition. (eds. R.W. Colman, J. Hirsh, V.J. Marder & E.W. 
Salzman) (J.B. Lippincott Company, Philadelphia; 1994). 
6. Grundmann, U., Amann, E., Zettlmeissl, G. & Kupper, H.A. Characterization of 
cDNA coding for human factor XIIIa. Proc Natl Acad Sci U S A 83, 8024-8028 
(1986). 
7. Ichinose, A., Hendrickson, L.E., Fujikawa, K. & Davie, E.W. Amino acid 
sequence of the a subunit of human factor XIII. Biochemistry 25, 6900-6906 
(1986). 
8. Takahashi, N., Takahashi, Y. & Putnam, F.W. Primary structure of blood 
coagulation factor XIIIa (fibrinoligase, transglutaminase) from human placenta. 
Proc Natl Acad Sci U S A 83, 8019-8023 (1986). 
9. Ichinose, A. & Davie, E.W. Characterization of the gene for the a subunit of 
human factor XIII (plasma transglutaminase), a blood coagulation factor. Proc 
Natl Acad Sci U S A 85, 5829-5833 (1988). 
10. Bottenus, R.E., Ichinose, A. & Davie, E.W. Nucleotide sequence of the gene for 
the b subunit of human factor XIII. Biochemistry 29, 11195-11209 (1990). 
11. Carrell, N.A., Erickson, H.P. & McDonagh, J. Electron microscopy and 
hydrodynamic properties of factor XIII subunits. J Biol Chem 264, 551-556 
(1989). 
12. Schwartz, M.L., Pizzo, S.V., Hill, R.L. & McKee, P.A. The subunit structures of 
human plasma and platelet factor XIII (fibrin-stabilizing factor). J Biol Chem 246, 
5851-5854 (1971). 
13. Ashcroft, A.E., Grant, P.J. & Ariens, R.A. A study of human coagulation factor 
XIII A-subunit by electrospray ionisation mass spectrometry. Rapid Commun 
Mass Spectrom 14, 1607-1611 (2000). 
14. Bohn, H., Haupt, H. & Kranz, T. [Molecular structure of human fibrin stabilizing 
factors]. Blut 25, 235-248 (1972). 
15. Weisberg, L.J., Shiu, D.T., Conkling, P.R. & Shuman, M.A. Identification of 
normal human peripheral blood monocytes and liver as sites of synthesis of 
coagulation factor XIII a-chain. Blood 70, 579-582 (1987). 
16. Muszbek, L., Adany, R., Kavai, M., Boda, Z. & Lopaciuk, S. Monocytes of 
patients congenitally deficient in plasma factor XIII lack factor XIII subunit a 
antigen and transglutaminase activity. Thromb.Haemost. 59, 231-235 (1988). 
17. Nagy, J.A., Kradin, R.L. & McDonagh, J. Biosynthesis of factor XIII A and B 
subunits. Adv Exp Med Biol 231, 29-49 (1988). 
96 
18. Ariens, R.A., Lai, T.S., Weisel, J.W., Greenberg, C.S. & Grant, P.J. Role of factor 
XIII in fibrin clot formation and effects of genetic polymorphisms. Blood 100, 
743 (2002). 
19. Yee, V.C. et al. Structure and function studies of factor XIIIa by x-ray 
crystallography. Semin Thromb Hemost 22, 377-384 (1996). 
20. Weiss, M.S., Metzner, H.J. & Hilgenfeld, R. Two non-proline cis peptide bonds 
may be important for factor XIII function. FEBS Lett 423, 291-296 (1998). 
21. Yee, V.C. et al. Three-dimensional structure of a transglutaminase: human blood 
coagulation factor XIII. Proc Natl Acad Sci U S A 91, 7296-7300 (1994). 
22. Board, P.G., Webb, G.C., McKee, J. & Ichinose, A. Localization of the 
coagulation factor XIII A subunit gene (F13A) to chromosome bands 6p24----
p25. Cytogenet Cell Genet 48, 25-27 (1988). 
23. Webb, G.C., Coggan, M., Ichinose, A. & Board, P.G. Localization of the 
coagulation factor XIII B subunit gene (F13B) to chromosome bands 1q31-32.1 
and restriction fragment length polymorphism at the locus. Hum Genet 81, 157-
160 (1989). 
24. Schwartz, M.L., Pizzo, S.V., Hill, R.L. & McKee, P.A. Human Factor XIII from 
plasma and platelets. Molecular weights, subunit structures, proteolytic activation, 
and cross-linking of fibrinogen and fibrin. J Biol Chem 248, 1395-1407 (1973). 
25. Folk, J.E. & Finlayson, J.S. The epsilon-(gamma-glutamyl)lysine crosslink and 
the catalytic role of transglutaminases. Adv Protein Chem 31, 1-133 (1977). 
26. Yorifuji, H., Anderson, K., Lynch, G.W., Van de Water, L. & McDonagh, J. B 
protein of factor XIII: differentiation between free B and complexed B. Blood 72, 
1645-1650 (1988). 
27. Kroll, J. The subunit composition of factor XIII proteins in normal and factor XIII 
deficient plasma and serum analysed by line immunoelectrophoresis. Clin Chim 
Acta 179, 279-284 (1989). 
28. Greenberg, C.S., Dobson, J.V. & Miraglia, C.C. Regulation of plasma factor XIII 
binding to fibrin in vitro. Blood 66, 1028 (1985). 
29. Takagi, T. & Doolittle, R.F. Amino acid sequence studies on factor XIII and the 
peptide released during its activation by thrombin. Biochemistry (N.Y.) 13, 750-
756 (1974). 
30. Lynch, G.W. & Pfueller, S.L. Thrombin-independent activation of platelet factor 
XIII by endogenous platelet acid protease. Thromb.Haemost. 59, 372-377 (1988). 
31. Ando, Y. et al. Platelet factor XIII is activated by calpain. Biochem Biophys Res 
Commun 144, 484-490 (1987). 
32. Freyssinet, J.M., Lewis, B.A., Holbrook, J.J. & Shore, J.D. Protein-protein 
interactions in blood clotting. The use of polarization of fluorescence to measure 
the dissociation of plasma factor XIIIa. Biochem J 169, 403-410 (1978). 
33. Lewis, S.D., Janus, T.J., Lorand, L. & Shafer, J.A. Regulation of formation of 
factor XIIIa by its fibrin substrates. Biochemistry 24, 6772-6777 (1985). 
34. Curtis, C.G. et al. Calcium-dependent unmasking of active center cysteine during 
activation of fibrin stabilizing factor. Biochemistry (N.Y.) 13, 3774-3780 (1974). 
35. Hornyak, T.J. & Shafer, J.A. Role of calcium ion in the generation of factor XIII 
activity. Biochemistry 30, 6175-6182 (1991). 
97 
36. Lewis, B.A., Freyssinet, J.M. & Holbrook, J.J. An equilibrium study of metal ion 
binding to human plasma coagulation factor XIII. Biochem J 169, 397-402 
(1978). 
37. Lorand, L., Losowsky, M.S. & Miloszewski, K.J. Human factor XIII: fibrin-
stabilizing factor. Prog.Hemost.Thromb. 5, 245 (1980). 
38. Janus, T.J., Lewis, S.D., Lorand, L. & Shafer, J.A. Promotion of thrombin-
catalyzed activation of factor XIII by fibrinogen. Biochemistry 22, 6269-6272 
(1983). 
39. Greenberg, C.S., Miraglia, C.C., Rickles, F.R. & Shuman, M.A. Cleavage of 
blood coagulation factor XIII and fibrinogen by thrombin during in vitro clotting. 
J.Clin.Invest. 75, 1463 (1985). 
40. Greenberg, C.S., Achyuthan, K.E. & Fenton, J.W., II Factor XIIIa formation 
promoted by complexing of a-thrombin, fibrin, and plasma factor XIII. Blood 69, 
867 (1987). 
41. Credo, R.B., Curtis, C.G. & Lorand, L. Ca2+-related regulatory function of 
fibrinogen. Proc Natl Acad Sci U S A 75, 4234-4237 (1978). 
42. McDonagh, J.M. in Hemostasis and Thrombosis: Basic Principles and Clinical 
Practice. (eds. R.W. Colman, J. Hirsh, V.J. Marder & E.W. Salzman) 301-313 
(J.B. Lippincott Company, Philadelphia; 1994). 
43. Credo, R.B., Curtis, C.G. & Lorand, L. Alpha-chain domain of fibrinogen 
controls generation of fibrinoligase (coagulation factor XIIIa). Calcium ion 
regulatory aspects. Biochemistry 20, 3770-3778 (1981). 
44. Siebenlist, K.R., Meh, D.A. & Mosesson, M.W. Plasma factor XIII binds 
specifically to fibrinogen molecules containing gamma chains. Biochemistry 35, 
10448-10453 (1996). 
45. Meh, D.A., Siebenlist, K.R. & Mosesson, M.W. Identification and 
characterization of the thrombin binding sites on fibrin. J Biol Chem 271, 23121-
23125 (1996). 
46. Hornyak, T.J., Bishop, P.D. & Shafer, J.A. Alpha-thrombin-catalyzed activation 
of human platelet factor XIII: relationship between proteolysis and factor XIIIa 
activity. Biochemistry 28, 7326-7332 (1989). 
47. Lorand, L. et al. Dissociation of the subunit structure of fibrin stabilizing factor 
during activation of the zymogen. Biochem Biophys Res Commun 56, 914-922 
(1974). 
48. Chung, S.I. & Folk, J.E. Kinetic studies with transglutaminases. The human blood 
enzymes (activated coagulation factor 13 and the guinea pig hair follicle enzyme. 
J Biol Chem 247, 2798-2807 (1972). 
49. Chung, S.I., Lewis, M.S. & Folk, J.E. Relationships of the catalytic properties of 
human plasma and platelet transglutaminases (activated blood coagulation factor 
XIII) to their subunit structures. J Biol Chem 249, 940-950 (1974). 
50. Lorand, L. Fibrin clots. Nature 166, 694-695 (1950). 
51. Procyk, R., Bishop, P.D. & Kudryk, B. Fibrin--recombinant human factor XIII a-
subunit association. Thromb Res 71, 127-138 (1993). 
52. Lorand, L. Fibrinoligase: the fibrin-stabilizing factor system of blood plasma. 
Ann.N.Y.Acad.Sci. 202, 6-30 (1972). 
98 
53. Lorand, L., Downey, J., Gotoh, T., Jacobsen, A. & Tokura, S. The transpeptidase 
system which crosslinks fibrin by gamma-glutamyle-episilon-lysine bonds. 
Biochem Biophys Res Commun 31, 222-230 (1968). 
54. Pisano, J.J., Finlayson, J.S. & Peyton, M.P. [Cross-link in fibrin polymerized by 
factor 13: epsilon-(gamma-glutamyl)lysine.]. Science 160, 892-893 (1968). 
55. Matacic, S. & Loewy, A.G. The identification of isopeptide crosslinks in 
insoluble fibrin. Biochem Biophys Res Commun 30, 356-362 (1968). 
56. Chen, R. & Doolittle, R.F. Isolation, characterization, and location of a donor-
acceptor unit from cross-linked fibrin. Proc Natl Acad Sci U S A 66, 472-479 
(1970). 
57. Loewy, A.G., Dunathan, K., Kriel, R. & Wolfinger, H.L., Jr. Fibrinase. I. 
Purification of substrate and enzyme. J Biol Chem 236, 2625-2633 (1961). 
58. Lorand, L. et al. Lysine as amine donor in fibrin crosslinking. Biochem Biophys 
Res Commun 25, 629-637 (1966). 
59. Achyuthan, K.E., Dobson, J.V. & Greenberg, C.S. Gly-Pro-Arg-Pro modifies the 
glutamine residues in the alpha- and gamma-chains of fibrinogen: inhibition of 
transglutaminase cross-linking. Biochim Biophys Acta 872, 261-268 (1986). 
60. Lorand, L., Parameswaran, K.N. & Murthy, S.N. A double-headed Gly-Pro-Arg-
Pro ligand mimics the functions of the E domain of fibrin for promoting the end-
to-end crosslinking of gamma chains by factor XIIIa. Proc Natl Acad Sci U S A 
95, 537-541 (1998). 
61. Doolittle, R.F., Chen, R. & Lau, F. Hybrid fibrin: proof of the intermolecular 
nature of - crosslinking units. Biochem Biophys Res Commun 44, 94-100 (1971). 
62. Schwartz, M.L., Pizzo, S.V., Hill, R.L. & McKee, P.A. The effect of fibrin-
stabilizing factor on the subunit structure of human fibrin. J Clin Invest 50, 1506-
1513 (1971). 
63. Shen, L.L., Hermans, J., McDonagh, J., McDonagh, R.P. & Carr, M. Effects of 
calcium ion and covalent crosslinking on formation and elasticity of fibrin cells. 
Thromb Res 6, 255-265 (1975). 
64. Purves, L., Purves, M. & Brandt, W. Cleavage of fibrin-derived D-dimer into 
monomers by endopeptidase from puff adder venom (Bitis arietans) acting at 
cross-linked sites of the gamma-chain. Sequence of carboxy-terminal cyanogen 
bromide gamma-chain fragments. Biochemistry 26, 4640-4646 (1987). 
65. Spraggon, G., Everse, S.J. & Doolittle, R.F. Crystal structures of fragment D from 
human fibrinogen and its crosslinked counterpart from fibrin. Nature 389, 455-
462 (1997). 
66. Standeven, K.F. et al. Functional analysis of fibrin {gamma}-chain cross-linking 
by activated factor XIII: determination of a cross-linking pattern that maximizes 
clot stiffness. Blood 110, 902-907 (2007). 
67. Standeven, K.F. et al. Functional analysis of fibrin g-chain cross-linking by 
activated factor XIII: determination of a cross-linking pattern that maximizes clot 
stiffness. Blood 110, 902 (2007). 
68. Cottrell, B.A., Strong, D.D., Watt, K.W. & Doolittle, R.F. Amino acid sequence 
studies on the alpha chain of human fibrinogen. Exact location of cross-linking 
acceptor sites. Biochemistry 18, 5405-5410 (1979). 
99 
69. Fretto, L.J., Ferguson, E.W., Steinman, H.M. & McKee, P.A. Localization of the 
alpha-chain cross-link acceptor sites of human fibrin. J Biol Chem 253, 2184-
2195 (1978). 
70. Matsuka, Y.V., Medved, L.V., Migliorini, M.M. & Ingham, K.C. Factor XIIIa-
catalyzed cross-linking of recombinant alpha C fragments of human fibrinogen. 
Biochemistry 35, 5810-5816 (1996). 
71. Lorand, L. Factor XIII: structure, activation, and interactions with fibrinogen and 
fibrin. Ann.N.Y.Acad.Sci. 936, 291-311 (2001). 
72. Sobel, J.H. & Gawinowicz, M.A. Identification of the alpha chain lysine donor 
sites involved in factor XIIIa fibrin cross-linking. J Biol Chem 271, 19288-19297 
(1996). 
73. Gaffney, P.J. et al. Fibrin subunits in venous and arterial thromboembolism. 
Cardiovasc Res 10, 421-426 (1976). 
74. McDonagh, R.P., Jr., McDonagh, J. & Duckert, F. The influence of fibrin 
crosslinking on the kinetics of urokinase-induced clot lysis. Br J Haematol 21, 
323-332 (1971). 
75. Gaffney, P.J. & Whitaker, A.N. Fibrin crosslinks and lysis rates. Thromb Res 14, 
85-94 (1979). 
76. Francis, C.W., Marder, V.J. & Barlow, G.H. Plasmic degradation of crosslinked 
fibrin. Characterization of new macromolecular soluble complexes and a model of 
their structure. J Clin Invest 66, 1033-1043 (1980). 
77. Muller, M.F., Ris, H. & Ferry, J.D. Electron microscopy of fine fibrin clots and 
fine and coarse fibrin films. Observations of fibers in cross-section and in 
deformed states. J Mol Biol 174, 369-384 (1984). 
78. Kanaide, H. & Shainoff, J.R. Cross-linking of fibrinogen and fibrin by fibrin-
stablizing factor (factor XIIIa). J Lab Clin Med 85, 574-597 (1975). 
79. Valnickova, Z. & Enghild, J.J. Human procarboxypeptidase U, or thrombin-
activable fibrinolysis inhibitor, is a substrate for transglutaminases. Evidence for 
transglutaminase-catalyzed cross-linking to fibrin. J Biol Chem 273, 27220-27224 
(1998). 
80. Mosher, D.F., Schad, P.E. & Vann, J.M. Cross-linking of collagen and fibronectin 
by factor XIIIa. Localization of participating glutaminyl residues to a tryptic 
fragment of fibronectin. J Biol Chem 255, 1181-1188 (1980). 
81. Procyk, R., Adamson, L., Block, M. & Blomback, B. Factor XIII catalyzed 
formation of fibrinogen-fibronectin oligomers--a thiol enhanced process. Thromb 
Res 40, 833-852 (1985). 
82. Mosher, D.F. & Schad, P.E. Cross-linking of fibronectin to collagen by blood 
coagulation Factor XIIIa. J Clin Invest 64, 781-787 (1979). 
83. Hada, M., Kaminski, M., Bockenstedt, P. & McDonagh, J. Covalent crosslinking 
of von Willebrand factor to fibrin. Blood 68, 95-101 (1986). 
84. Bockenstedt, P., McDonagh, J. & Handin, R.I. Binding and covalent cross-linking 
of purified von Willebrand factor to native monomeric collagen. J Clin Invest 78, 
551-556 (1986). 
85. Francis, R.T., McDonagh, J. & Mann, K.G. Factor V is a substrate for the 
transamidase factor XIIIa. J Biol Chem 261, 9787-9792 (1986). 
100 
86. Huh, M.M., Schick, B.P., Schick, P.K. & Colman, R.W. Covalent crosslinking of 
human coagulation factor V by activated factor XIII from guinea pig 
megakaryocytes and human plasma. Blood 71, 1693-1702 (1988). 
87. Greenberg, C.S. & Shuman, M.A. Specific binding of blood coagulation factor 
XIIIa to thrombin-stimulated platelets. J.Biol.Chem. 259, 14721 (1984). 
88. McDonagh, J., Kiesselbach, T.H. & Wagner, R.H. Factor 13 and antiplasmin 
activity in human platelets. Am J Physiol 216, 508-513 (1969). 
89. Weisel, J.W., Francis, C.W., Nagaswami, C. & Marder, V.J. Determination of the 
topology of factor XIIIa-induced fibrin gamma-chain cross-links by electron 
microscopy of ligated fragments. J Biol Chem 268, 26618-26624 (1993). 
90. Ritchie, H., Lawrie, L.C., Crombie, P.W., Mosesson, M.W. & Booth, N.A. Cross-
linking of plasminogen activator inhibitor 2 and alpha 2-antiplasmin to 
fibrin(ogen). J Biol Chem 275, 24915-24920 (2000). 
91. Ritchie, H., Lawrie, L.C., Mosesson, M.W. & Booth, N.A. Characterization of 
crosslinking sites in fibrinogen for plasminogen activator inhibitor 2 (PAI-2). 
Ann.N.Y.Acad.Sci. 936, 215-218 (2001). 
92. Sane, D.C. et al. Vitronectin is a substrate for transglutaminases. Biochem 
Biophys Res Commun 157, 115-120 (1988). 
93. Skorstengaard, K., Halkier, T., Hojrup, P. & Mosher, D. Sequence location of a 
putative transglutaminase cross-linking site in human vitronectin. FEBS Lett 262, 
269-274 (1990). 
94. Bale, M.D., Westrick, L.G. & Mosher, D.F. Incorporation of thrombospondin into 
fibrin clots. J Biol Chem 260, 7502-7508 (1985). 
95. Mui, P.T. & Ganguly, P. Cross-linking of actin and fibrin by fibrin-stabilizing 
factor. Am J Physiol 233, H346-349 (1977). 
96. Cohen, I., Blankenberg, T.A., Borden, D., Kahn, D.R. & Veis, A. Factor XIIIa-
catalyzed cross-linking of platelet and muscle actin. Regulation by nucleotides. 
Biochim Biophys Acta 628, 365-375 (1980). 
97. Cohen, I., Young-Bandala, L., Blankenberg, T.A., Siefring, G.E., Jr. & Bruner-
Lorand, J. Fibrinoligase-catalyzed cross-linking of myosin from platelet and 
skeletal muscle. Arch Biochem Biophys 192, 100-111 (1979). 
98. Asijee, G.M. et al. Platelet vinculin: a substrate of activated factor XIII. Biochim 
Biophys Acta 954, 303-308 (1988). 
99. Cohen, I. et al. Disulfide-linked and transglutaminase-catalyzed protein 
assemblies in platelets. Blood 66, 143-151 (1985). 
100. Feddersen, J.C. & Gormsen, J. gamma-dimerization, alpha-polymerization, and 
plasmin degradation of human fibrin. Effect of various inhibitors of factor XIII on 
the patterns in SDS-electrophoresis and crossed immunoelectrophoresis. 
Thromb.Haemost. 36, 27-36 (1976). 
101. Curtis, C.G. & Lorand, L. Fibrin-stabilizing factor (factor XIII). Methods Enzymol 
45, 177-191 (1976). 
102. Gootenberg, J.E. Factor concentrates for the treatment of factor XIII deficiency. 
Curr Opin Hematol 5, 372-375 (1998). 
103. Shen, L. & Lorand, L. Contribution of fibrin stabilization to clot strength. 
Supplementation of factor XIII-deficient plasma with the purified zymogen. J 
Clin Invest 71, 1336-1341 (1983). 
101 
104. Grinnell, F., Feld, M. & Minter, D. Fibroblast adhesion to fibrinogen and fibrin 
substrata: requirement for cold-insoluble globulin (plasma fibronectin). Cell 19, 
517-525 (1980). 
105. Nielsen, V.G., Steenwyk, B.L. & Gurley, W.Q. Contact activation prolongs clot 
lysis time in human plasma: role of thrombin-activatable fibrinolysis inhibitor and 
Factor XIII. J.Heart Lung Transplant. 25, 1247 (2006). 
106. Nielsen, V.G., Gurley, W.Q., Jr. & Burch, T.M. The impact of factor XIII on 
coagulation kinetics and clot strength determined by thrombelastography. 
Anesth.Analg. 99, 120 (2004). 
107. Nielsen, V.G., Kirklin, J.K., Hoogendoorn, H., Ellis, T.C. & Holman, W.L. 
Thrombelastographic method to quantify the contribution of factor XIII to 
coagulation kinetics. Blood Coagul.Fibrinolysis 18, 145 (2007). 
108. Devine, D.V., Andestad, G., Nugent, D. & Carter, C.J. Platelet-associated factor 
XIII as a marker of platelet activation in patients with peripheral vascular disease. 
Arterioscler Thromb 13, 857-862 (1993). 
109. Devine, D.V. & Bishop, P.D. Platelet-associated factor XIII in platelet activation, 
adhesion, and clot stabilization. Semin Thromb Hemost 22, 409-413 (1996). 
110. Francis, C.W. & Marder, V.J. Rapid formation of large molecular weight alpha-
polymers in cross-linked fibrin induced by high factor XIII concentrations. Role 
of platelet factor XIII. J Clin Invest 80, 1459-1465 (1987). 
111. Bishop, P.D. et al. Expression, purification, and characterization of human factor 
XIII in Saccharomyces cerevisiae. Biochemistry 29, 1861 (1990). 
112. Bishop, P.D., Lasser, G.W., Le Trong, I., Stenkamp, R.E. & Teller, D.C. Human 
recombinant factor XIII from Saccharomyces cerevisiae. Crystallization and 
preliminary x-ray data. J.Biol.Chem. 265, 13888 (1990). 
113. Lewis, K.B., Teller, D.C., Fry, J., Lasser, G.W. & Bishop, P.D. Crosslinking 
kinetics of the human transglutaminase, factor XIII A2 , acting on fibrin gels and 
gamma-chain peptides. Biochemistry 36, 995 (1997). 
114. Radek, J.T., Jeong, J.M., Wilson, J. & Lorand, L. Association of the A subunits of 
recombinant placental factor XIII with the native carrier B subunits from human 
plasma. Biochemistry 32, 3527-3534 (1993). 
115. Reynolds, T.C. et al. Safety, pharmacokinetics, and immunogenicity of single-
dose rFXIII administration to healthy volunteers. J.Thromb.Haemost. 3, 922 
(2005). 
116. Lovejoy, A.E. et al. Safety and pharmacokinetics of recombinant factor XIII-A2 
administration in patients with congenital factor XIII deficiency. Blood 108, 57 
(2006). 
117. Visich, J.E. et al. Safety and pharmacokinetics of recombinant factor XIII in 
healthy volunteers: a randomized, placebo-controlled, double-blind, multi-dose 
study. Thromb.Haemost. 94, 802 (2005). 
118. Ponce, R. et al. Safety of recombinant human factor XIII in a cynomolgus 
monkey model of extracorporeal blood circulation. Toxicol.Pathol. 33, 702 
(2005). 
119. Inan, M. et al. Saturation of the secretory pathway by overexpression of a 
hookworm (Necator americanus) protein (Na-ASP1). Methods in Molecular 
Biology (Totowa, NJ, United States) 389, 65 (2007). 
102 
120. Zhang, W., Inan, M. & Meagher, M.M. Rational design and optimization of fed-
batch and continuous fermentations. Methods in Molecular Biology (Totowa, NJ, 
United States) 389, 43 (2007). 
121. Perkins, S.J. Protein volumes and hydration effects. The calculations of partial 
specific volumes, neutron scattering matchpoints and 280-nm absorption 
coefficients for proteins and glycoproteins from amino acid sequences. Eur J 
Biochem 157, 169-180 (1986). 
122. Gorkun, O.V., Veklich, Y.I., Weisel, J.W. & Lord, S.T. The conversion of 
fibrinogen to fibrin: recombinant fibrinogen typifies plasma fibrinogen. Blood 89, 
4407-4414 (1997). 
123. Bretthauer, R.K. & Castellino, F.J. Glycosylation of Pichia pastoris-derived 
proteins. Biotechnol Appl Biochem 30 ( Pt 3), 193-200 (1999). 
124. De Schutter, K. et al. Genome sequence of the recombinant protein production 
host Pichia pastoris. Nat Biotechnol 27, 561-566 (2009). 
125. Hamilton, S.R. & Gerngross, T.U. Glycosylation engineering in yeast: the advent 
of fully humanized yeast. Curr Opin Biotechnol 18, 387-392 (2007). 
126. Ogunjimi, A.A., Chandler, J.M., Gooding, C.M., Recinos, A., III & Choudary, 
P.V. High-level secretory expression of immunologically active intact antibody 
from the yeast Pichia pastoris. Biotechnol. Lett. 21, 561-567 (1999). 
127. Inan, M., Aryasomayajula, D., Sinha, J. & Meagher, M.M. Enhancement of 
protein secretion in Pichia pastoris by overexpression of protein disulfide 
isomerase. Biotechnol. Bioeng. 93, 771-778 (2006). 
128. Wang, Y. et al. Expression, purification, and characterization of recombinant 
human keratinocyte growth factor-2 in Pichia pastoris. J. Biotechnol. 132, 44-48 
(2007). 
129. Gething, M.J. & Sambrook, J. Protein folding in the cell. Nature (London, U. K.) 
355, 33-45 (1992). 
130. Gilbert, H.F. Protein disulfide isomerase. Methods Enzymol. 290, 26-50 (1998). 
131. Siebenlist, K.R., Meh, D.A. & Mosesson, M.W. Protransglutaminase (factor XIII) 
mediated crosslinking of fibrinogen and fibrin. Thromb.Haemost. 86, 1221-1228 
(2001). 
132. Lord, J.M., Davey, J., Frigerio, L. & Roberts, L.M. Endoplasmic reticulum-
associated protein degradation. Semin. Cell Dev. Biol. 11, 159-164 (2000). 
 
 
103 
 
 
 
Chapter 4 
Optimization of a Liquid Fibrin Sealant to Achieve its Maximal Strength and 
Activation Speed 
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Abstract 
To meet future demands for hemostatic therapies, liquid fibrin sealants (LFS) will 
likely include recombinant human fibrinogen (rFI) and recombinant human Factor XIII 
(rFXIII).  The research described here optimizes the components of a LFS containing rFI 
produced in the milk of transgenic cows, active rFXIII (rFXIIIa) expressed in genetically 
engineered Pichia pastoris, plasma-derived thrombin (pdFIIa) and CaCl2.  Each 
component was optimized individually while maintaining the levels of other ingredients.  
The optimal concentration of rFXIIIa and CaCl2 were selected to provide the highest 
viscoelastic strength.  The optimal level of thrombin was selected to provide the fastest 
initiation of clot formation and clotting kinetics.  rFI concentrations were selected to 
provide the necessary clot strength while minimizing material used.  The molecular 
behavior of rFI with rFXIIIa catalyzed by FIIa was similar to the respective human 
plasma analogues as judged by molecular weight changes by SDS-PAGE, polymerization 
kinetics by turbidity, and formation of γ-γ chain crosslinked fibrin.  rFXIIIa to rFI ratios 
greater than 0.15 yield maximal clot strength.  FIIa to rFI ratios greater than 0.09 yield 
the fastest clot onset time and 0.14 ratio yields the greatest clot strength.  rFXIIIa and 
FIIa ratios to FI of 0.16 and 0.18, respectively, were selected for the optimal LFS for 
future research.  Fibrin clots made with rFI, rFXIII and FIIa yielded 5.0-fold greater shear 
elastic modulus strength than clots formed from NHB alone.  The addition of rFXIIIa 
significantly increased clot strength thereby reducing the amount of FI need in the LFS.  
The clotting kinetics and viscoelastic strength of our optimized LFS was equivalent to 
those of a commercially available LFS; however, it uses approximately 75% less 
fibrinogen and thrombin.  These results suggest that rFI and rFXIII in combination with 
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FIIa can be combined to create a LFS with equivalent or better kinetic and viscoelastic 
properties as currently available products.   
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Introduction 
Trauma deaths are a result of hemorrhage in 37% of civilians
1
 and 47% military 
personnel
2
 and are the primary cause of death for individuals under 44 years of age.
3
  
For the past 2000 years, the same techniques have been used to stop hemorrhage:  
packing with gauze, direct pressure and tourniquet.
4
  This method is inadequate for 
treating severe hemorrhage.  The Department of Defense Combat Casualty Care 
Research Program is focused on developing more effective options for treating 
hemorrhage.
5
   
Several hemostatic products are currently used or under development.  
Cyanoacrylates are utilized as hemostatic aides in oral surgery but can cause 
inflammation and necrosis.
6
  Gelatin-resorcinol-formaldehyde (GRF) glue is frequently 
used as a sealant and yields excellent tensile strength but has less clotting ability, 
inferior clots to other sealants and results in fibroblast infiltration.
7
  QuikClot speeds 
clot formation by creating an exothermic reaction when absorbing water; however, it is 
not biodegradable requiring its removal post-treatment.
8, 9
  Compared to other treatment 
options, fibrin sealants (FS), also known as fibrin glues, are viewed as the best sealant
10
 
because they are biocompatible,
6, 11, 12
 biodegradable
6
 and safe
11
 and are not linked to 
excessive inflammation, immune responses or necrosis.
6, 12
  Because they mimic natural 
clotting mechanisms, FS provide similar functions as endogenous components: creating 
hemostatic clots
13
 and providing a scaffold for cellular infiltration needed to regenerate 
tissue
13, 14
 and dissolve the clot.
13
   
FS reproduce the final stage of the clotting cascade to assist in hemostasis.  
Fibrin sealants contain fibrinogen (FI), thrombin (FIIa) and calcium chloride and on 
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occasion Factor XIII (FXIII) which are the elements in the last step of the cascade 
required to produce a fibrin clot.  When applied to a wound, these exogenous 
components can assist the same endogenous proteins in achieving hemostasis.  FIIa 
catalyzes the conversion of FI to soluble fibrin monomer and FXIII to activated FXIII 
(FXIIIa).
15-18
  FXIIIa then catalyzes the formation of the cross-linked, insoluble fibrin 
clot that is melded with the platelet-based, primary hemostatic plug.
17, 19-21
  In addition 
to binding other fibrin molecules and creating the fibrin clot, fibrin adheres the clot to 
the wound by binding to collagen exposed at the site of tissue injury in addition to 
platelets, endothelial and other cells.
11
   
Fibrin has been utilized for 100 years for numerous biomedical therapies but 
was first used as an adhesive with addition of bovine thrombin
11
 in the early 1940s for 
skin grafts for burn patients.
22
  Unfortunately, the fibrin glue was a source of infection
22
 
and failed to provide the necessary strength required to maintain its function until tissue 
repair
11
 resulting in a loss of interest in FS as treatment options for hemorrhage.  In the 
early 1970s, researchers again began refining FS.
11
  Today, multiple products are 
commercially available in the United States and Europe.
11
  The first FS approved by the 
FDA was Baxter’s Tisseel® in 1998.23  Vitagel (Orthovita) and Crosseal (Johnson & 
Johnson) were subsequently approved in 2000 and 2003, respectively.
23
  All of these 
products use plasma-derived proteins.  Tisseel,
®
 like most FS,
11
  is a two-component 
system: one containing FI and plasminolysis inhibitor and the second containing human 
thrombin and calcium chloride.   
FS are used as hemostatic agents,
23
 matrices for wound healing,
12, 23
 adherents 
for tissues
23
 and drug deliveries
23
 in a variety of settings (Figure 4.1).  With respect to 
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hemostasis, FS can be used alone or in combination with a dressing to stop blood 
oozing from holes, incisions and raw surfaces which cannot be stopped by suturing.
7
  
Research indicates that liquid fibrin sealants (LFS) can be used as a drug delivery 
device for high doses of antibiotics and growth factors.
11, 24
  Historically, FS were 
primarily used in trauma situations
24
 and during cardiac
7, 24
 and vascular surgeries
24
 but 
are now frequently used in general surgery.
11, 25
  FS has been shown to be useful in 
various surgical settings including cardiovascular,
11, 26
 vascular,
27
 thoracic,
28, 29
 
plastic,
11, 30
 reconstructive,
31
 oncologic,
23
 ophthalmologic,
23
 dental,
23
 orthopedic,
11, 23
 
hepatic
7
 and urologic surgeries,
32, 33
 microsurgical procedures
11
 and neurosurgery.
11, 34, 
35
  The use of FS has been shown to reduce blood loss,
23, 36
 fluid loss,
23
 transfusion 
occurrence,
37
 operative time,
36
 mortality,
36
 hospital stay
24
 and treatment costs.
23
   
 
Figure 4.1.  Uses for fibrin sealant.  Based on the schematic published by Spotnitz and Prabhu.
23
   
 
Despite its usefulness, FS have drawbacks.  Current FS are relatively expensive.  
For example, Tisseel
®
 is over $130 per ml FI
36
 which makes it economically infeasible 
for use as a dressing coating or for widespread use in the field.  In addition, commercial 
sealants use plasma-derived materials.  In 1978, the Food and Drug Administration 
Fibrin Sealant
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Trauma, cardiovascular
surgery, vascular 
surgery ...
Tissue 
Engineering
Scaffold for 
wound/bone 
repair
Tissue 
Adherence
Suture support, 
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endothelialization, 
pneumostasis, fluid 
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Drug Delivery
Antibiotics, growth 
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chemotherapeutic agents, 
local anesthetics
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(FDA) suspended the use of fibrin sealants due to contamination with hepatitis.
38
  
Treatments have been developed to minimized viral contaminants;
24
 however, there is 
still some concern of contamination with viruses or prions able to withstand current 
treatments.
6, 23
  For example, human parovirus B19 is not killed by current 
pasteurization processes.
23
  Tisseel, Crosseal and Vitagel, the three FDA approved 
fibrin sealants, and frequently used “home-made” fibrin sealants each have their own 
issues.  Vitagel
23
 and the home-made FS prepared by some medical centers use bovine 
thrombin.
24
  Although relatively rare, bovine proteins in FS can initiate immune 
responses.
23, 24
  While Crosseal contains only human proteins, it contains tranexamic 
acid which has been linked to severe reactions that contraindicate its use when it may 
come in contact with dura matter or cerebral spinal fluid.
23, 39
  Consequently, a safer, 
more abundant source of material for FS is needed.   
The objective of this chapter is three-fold: (1) characterize the importance of 
FXIII in LFS; (2) optimize the concentrations of each LFS component to create the 
strongest clot in the fastest time; and (3) compare recombinant human fibrinogen-based 
to commercially available plasma-derived human fibrinogen-based LFS.  Due to 
limitations in the availability of cost effective, safe supplies from human plasma, future 
FS will be more often derived from recombinant technology which can produce 
products more economically and in abundance.
40-45
  This study utilizes recombinant 
human fibrinogen (rFI) purified from the milk of cloned, transgenic cows and 
recombinant human activate factor XIII (rFXIIIa) expressed in yeast.  Initial studies 
used pdFIIa; however, final experiments utilized rFIIa from CHO cells.  Experiments 
were designed to evaluate the role of FXIII in FS.  Most FS on the market contain FI 
110 
and FIIa in similar amounts; however, FXIII content ranges.
46
  The ratio of FXIII to FI 
in human plasma is approximately 0.4 U/mg; however, some commercial products 
contain no FXIII or 0.1 U/mg except for Beriplast P which contains approximately 0.44 
to 0.89 U/mg.
46
  We vary FXIII activity from 0 to 274 U rFXIIIa per mg FI.  In addition 
to testing the efficacy of our recombinant proteins and importance of FXIII in FS, the 
ratios of components have never been optimized with the availability of highly active 
FXIIIa.  This research was designed to test the hypotheses that (1) the addition of 
rFXIIIa will increase clot strength thereby reducing the amount of FI need in FS; and 
(2) our LFS containing optimized ratios of rFI, rFXIIIa and FIIa will yield equivalent 
clot kinetics and strengths as plasma-derived LFS.   
 
Materials and Methods 
Materials 
Purified, plasma-derived prothrombin was bought from Enzyme Research 
Laboratories (South Bend, IN).  Recombinant thrombin (Recothrom
®
) was purchased 
from Zymogenetics.  Purified recombinant fibrinogen, expressed in the milk of transgenic 
Swiss Brown cows, was obtained from Pharming Group NV (Leiden, Netherlands).  
Materials for the thromboelastograph were purchased from Haemoscope (Niles, IL).  
Unless otherwise specified, reagents were purchased from Sigma (St. Louis, MO).   
Vector construction, expression and purification of FXIIIA in Pichia pastoris 
The human Ultimate ORF clone containing the human coagulation factor 
FXIIIA1 cDNA in the pENTR
TM
221 vector was purchased from Invitrogen (Carlsbad 
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CA). The following primers were used to obtain FXIIIa gene to subclone in pPICZA 
intracellular Pichia expression vector. (Forward, 5'-
CCAATTGATGCATCATCATCATCATCATTCAGAAACTTCCAGGACCGC-3'; 
Reverse, 5'-GCGGCCGCTCACATGGAAGGTCGTCTTTGAATC-3').  The forward 
primer introduced a methionine and 6 histidine amino acids at the N-terminus of mature 
FXIIIa peptide. The PCR product was digested with MfeI and NotI and subcloned into 
pPICZA which was digested with the same enzymes.  The DNA sequence of the FXIIIA 
was confirmed by sequencing the insert fragment. One of the confirming plasmid 
pPICZAFXIIIa was linearized with PmeI and transformed into P. pastoris X-33 host 
strain and copy number of the clones was determined as described.
47
 Varying copy 
number clones were screened in shake flask culture to confirm intracellular production of 
FXIIIa protein. The highest producing clone was scaled up to 5 L bench scale. A fed-
batch fermentation protocol was followed to optimize FXIIIa production as described by 
Zhang et al., (2007).
48
  At the end of fermentation process the cells were separated by 
centrifugation (6,000g)  and pellet was stored at -80
o
C.   
Frozen cell paste was processed in 300 gram batches.  Cells were lysed in three 
sets of 100 gram batches.  100 grams of cell paste was resuspended in 100 ml of cold 
lysis buffer (50 mM Tris-HCL, 10 mM MgSO4, 1 mM EDTA, 10 mM potassium acetate, 
1 mM DTT (DL-Dithiothreitol), 2 mM PMSF (phenylmethanesulphonylfluoride) in 
methanol, pH 9.5).  100 ml (250 g) of 0.5 mm glass beads (Biospec, Bartlesville, OK) 
were added and the cells.  Surrounded by an ice bath, cells were lysed using a BeadBeater 
Blender (Biospec, Bartlesville, OK) with twenty 20 second on/off cycles.  The cell lysate 
mixture was then centrifuged to remove cellular debris.  The lysate from 300 grams of 
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cell paste was combined and purified using the HisBind Purification Kit (EMD 
Chemicals, Inc., San Diego, CA) with 40 ml of resin slurry.  Following purification, 
rFXIII was dialyzed in 10 mM Tris-HCl, 0.1 mM EDTA, 60 µM polysorbate-20, pH 8.0 
in snake-like dialysis membranes and the protein samples were filter-sterilized and 
concentrated using the Amicon tubes (Millipore, Billerica, MA).  The purity of the 
sample was tested by SDS-PAGE (NuPAGE 12% Bis-Tris) (Invitrogen, Carlsbad, CA) 
and immunoblot.  The concentration of rFXIII was determined by standard Bicinconic 
Acid (BCA) methods.   
FIIa preparation 
Frozen, plasma-derived human prothrombin (Enzyme Research Laboratories, 
South Bend, IN), was thawed at 37
o
C.  Plasma-derived thrombin (Enzyme Research 
Laboratories, South Bend, IN) was added at a 1/10 mass to mass thrombin/prothrombin 
ratio.  0.35 grams of sodium citrate per milliliter of solution was added (Lanchantin 
1965).  This solution was incubated at 37
o
C on a rotating mixer for five hours.  Sodium 
citrate was removed using PD-10 desalting columns (GE Healthcare, Giles, United 
Kingdom).  Activation of prothrombin to thrombin was confirmed by reducing and 
nonreducing SDS-PAGE (12% Bis-Tris NuPAGE) (Invitrogen, Carlsbad, CA) stained 
with Colloidal Blue (Invitrogen, Carlsbad, CA).  The concentration of the thrombin 
solution was determined by standard Bicinconic Acid (BCA) methods.  The specific 
activity was determined by aPTT analysis.   
113 
γ-γ crosslinking of FI by FXIIIa 
γ-γ crosslinking of FI by FXIIIa was analyzed by a similar procedure previously 
described.
49
  Briefly, rFI (final concentration: 0.38 mg/ml) was incubated with rFXIII 
(final concentration: 0.01 mg/ml), pdFIIa or rFIIa (5 U/ml) in Ringer’s solution (155 mM  
NaCl, 5 mM KCl, 2 mM CaCl2, 1 mM MgCl2) for 0, 5, 15, 30 and 60 minutes at 37
o
C.  
rFI was also incubated with pdFIIa or rFIIa without rFXIII.  The reactions were halted by 
the addition of NuPage
®
 Sample Reducing Buffer (β-mercaptoethanol) (Invitrogen, 
Carlsbad, CA) and NuPage
®
 LDS buffer and incubation at 74
o
C for 10 minutes.  For the 
zero time point, the reaction buffers were added immediately after the addition of 
thrombin.  Crosslinking was studied by reducing SDS-PAGE (12% Bis-Tris NuPAGE) 
run at 200 volts for one hour and stained with Colloidal Blue (Invitrogen, Carlsbad, CA).   
Thromboelastography analysis of fibrin clot formation 
Clotting strength and kinetics of various tri-component mixtures of purified rFI or 
plasma-derived human fibrinogen (pdFI), rFXIII and pdFIIa or rFIIa were evaluated by 
thromboelastography (TEG) (Thromboelastograph
®
 Hemostasis System 5000 series, 
Haemoscope Corp., Niles, IL).  The effect of FI on clot strength and kinetics was 
evaluated by maintaining rFXIII (0.35 mg/ml, 2408 U/ml) and pdFIIa (0.10 mg/ml, 52.8 
U/ml) levels while varying rFI concentrations (0, 3, 6, 9, 12 and 15 mg/ml).  The effect of 
rFXIII on clot strength and kinetics was evaluated by maintaining FI (8.56 mg/ml) and 
pdFIIa (0.10 mg/ml, 52.8 U/ml) levels while varying rFXIII concentrations (0, 0.03, 0.13, 
0.23, 0.28, 0.35 and 0.42 mg/ml).  The effect of pdFIIa on clot strength and kinetics was 
also evaluated by maintaining FI (8.56 mg/ml) and rFXIII (0.35 mg/ml, 2408 U/ml) 
levels while varying pdFIIa concentrations (0, 0.03, 0.05, 0.10, 0.15, 0.20 and 0.25 
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mg/ml).  For all experiments, FI then FXIII was transferred to a single-use TEG cup and 
warmed to 37
o
C by the TEG instrument.  Calcium chloride (Sigma, St. Louis, MO) was 
then added to the cups and clot formation was initiated by adding pdFIIa.   
Using the same method, stoichiometric molar ratio based experiments were 
performed.  Once the optimal ratio was established, experiments were also performed that 
maintained stoichiometric molar ratios of rFXIII/rFI (0.16) and pdFIIa/rFI (0.18) while 
increasing rFI concentrations (9, 12, 12.5 and 15 mg/ml) to determine the effect of 
increasing FI.  To determine whether the rFXIII/rFI ratio of 0.16 was optimal at a higher 
rFI concentration (12.5 mg/ml), experiments were performed that maintained rFI and FIIa 
(FIIa/FI = 0.18) while increasing rFXIII/FI (0.16, 0.18 and 0.20).   
Clotting parameters of several tri-component solutions consisting of different 
levels of rFI, pdFI (Enzyme Research, Laboratories, South Bend, IN) or pdFI (Tisseel
®
, 
Baxter, Deerfield, IL) and rFXIII were compared to human blood.  Tisseel’s sealant and 
thrombin solutions were reconstituted as per manufacturer’s instructions.  Tisseel’s 
overall protein concentration was determined by standard Bicinconic Acid (BCA) 
methods.  FI (2.9 or 8.6 mg/ml) were combined with rFXIII (0.03 or 0.35 mg/ml), pdFIIa 
(52.8 U/ml) and 11 mM CaCl2 and analyzed by TEG.  Fresh, normal whole human blood 
(NHB) from 22 healthy, medication-free individuals, collected in tubes containing 3.2% 
citrate, was obtained from Research Blood Components (Brighton, MA).  340 µl of blood 
was transferred to a single-use TEG cup and warmed to 37
o
C by the TEG instrument.  20 
µl of 200 mM CaCl2 solution was then added to the cups to initiate clotting.   
The optimized rLFS was compared to the commercially available Tisseel® which 
was reconstituted as per manufacturer’s instructions used as intended by mixing the 
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sealant and thrombin solutions in equal proportions.  180 µl of Tisseel’s sealant, which 
consists of between 67 and 106 mg/ml pdFI and 2,250 and 3,750 KIU/ml inhibitor, was 
transferred to a single-use TEG cup and warmed to 37
o
C by the TEG instrument.  180 µl 
of Tisseel’s thrombin solution, which contains 400 to 625 U/ml pdFIIa and 36 to 44 mM 
CaCl2, was then added to the cups containing sealant.  These results were compared to 
clotting parameters obtained with combining rFI (15 mg/ml), rFXIII (0.59 mg/ml, 4,095 
U/ml, rFXIII/rFI = 0.16), rFIIa (0.33 mg/ml, 176.7 U/ml, rFIIa/rFI = 0.18) and 12 mM 
CaCl2 in a TEG cup as described above.  
The TEG Analytical Software (version 4.2.2, Haemoscope, Niles, IL) collected 
time to clot initiation (R), time to achieve a clot firmness of 20mm (K) and maximal clot 
strength (MA).  Results were compared by ANOVA and t test with an α of 0.05.  The 
instrument was calibrated each day of use.  All tests described above include a minimum 
of three replicate samples in each treatment group.  All NHB samples were tested within 
36 hours of the blood draw of each individual donor.   
Clot lysis by thromboelastography 
Percent lysis by added plasmin was determined by thromboelastography which 
was performed on solutions containing purified rFI or pdFI, rFXIII and rFIIa with a 
Thromboelastograph
®
 (TEG
®
) Hemostasis System 5000 series (Haemoscope Corp., 
Niles, IL).  Clotting strength and kinetics of purified rFI or pdFI with rFXIIIa and rFIIa 
with added plasmin was evaluated.  rFI or pdFI (final concentration: 9 mg/ml) transferred 
to a single-use TEG cup maintained at 37
o
C by the instrument.  rFXIIIa (final 
concentration: 2,429 U/ml, 0.35 mg/ml rFXIIIa/FI = 0.16) and various amounts of 
plasmin (final concentrations: 0, 8.4, 17, 84 and 842 mU/ml, 0.002 to 0.216 mg/ml) were 
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added.  CaCl2 (final concentration: 12 mM) and Ringers solution (155 mM  NaCl, 5 mM 
KCl, 2 mM CaCl2, 1 mM MgCl2, added to standardize volume in cup) was added 
followed quickly by pdFIIa (final concentration: 105.6 U/ml, FIIa/FI = 0.18) to initiate 
clot formation.  Data was collected every five seconds for 30 minutes by the TEG 
interfaced with a computer.  Each sample was run in triplicate so means and standard 
deviations could be calculated.  The data was exported and analyzed in Microsoft
®
 Excel.   
 
Results 
rFXIIIa and pdFIIa characterization 
SDS-PAGE and N-terminal sequencing indicated that the purified protein from 
the yeast was rFXIIIa rather than rFXIII.  These and immunoblots indicated rFXIIIa had 
a purity of greater than 98% (data not shown).  The Pefakit
®
 Factor XIII Incorporation 
Assay (Pentapharm, CT) yielded a specific activity of almost 7,000 U/mg for rFXIIIa.  
The pdFIIa prepared by citrate activation was comprised of α-thrombin and fragments as 
per SDS-PAGE (Figure 6.2A, lane 10) and chromogenic assay yielded a specific activity 
of 528 U per mg.   
γ-γ crosslinking of FI by FXIIIa 
γ-γ crosslinking of rFI by rFXIIIa was analyzed by SDS-PAGE as previously 
described.
49
  γ-chain dimers begin forming within a couple of seconds when rFI and 
rFXIII were activated by pdFIIa (Figure 4.2A) and rFIIa (Figure 4.2B) as seen by the 
disappearance of the monomer and appearance of the dimer.  The α-chain monomer is 
also disappearing for both rFI samples and by 5 minutes, most of the rFI α-chain 
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monomer has disappeared resulting in smearing at the top of the lanes.  γ-γ dimers were 
not observed in the rFI sample treated with pdFIIa (Figure 4.2A, lane 8) or rFIIa (Figure 
4.2B, lane 8).   
 
Figure 4.2.  Formation of fibrin γ-chain crosslinks as analyzed by reducing SDS-PAGE.  SDS-PAGE 
gels under reducing conditions.  Formation of fibrin γ-chain cross-links was analyzed for clots created with 
components used to optimize the LFS:  rFI, rFXIII and pdFIIa (A) or rFIIa (B).  Lane 1:  a molecular 
weight marker.  Lane 2:  rFI prior to incubation with rFXIII and FIIa.  Lanes 3 through 7:  rFI, rFXIII and 
FIIa incubated for 2 seconds, 5, 15, 30 and 60 minutes.  Lane 8:  rFI incubated with FIIa for 60 minutes.  
Lane 9: rFXIII sample prior to incubation with rFI and FIIa.  Lane 10: FIIa sample prior to incubation with 
rFXIII and rFI.   
Thromboelastography (TEG) analysis of fibrin clot formation 
The effect of increasing FI concentration was analyzed by TEG.  While rFXIIIa 
(0.35 mg/ml) and pdFIIa (52.8 U/ml) were held constant, rFI was increased from zero to 
15 mg/ml (Figure 4.3).  As expected, rFXIIIa treated with pdFIIa did not yield any 
change in viscosity.  Increase in rFI concentration did not greatly affect time to clot 
initiation (R) which ranged from 16.67 ± 2.89 seconds for 6 and 12 mg/ml and 21.67 ± 
2.89 mg/ml for 3 mg/ml rFI.  Clotting kinetics were also relatively consistent for 6 (K = 
51.67 ± 2.89, α = 79.83 ± 1.5), 9 (K = 50.00 ± 0, α = 81.90 ± 0.56), 12 (K = 50.00 ± 0, α 
= 82.50 ± 0.69) and 15 mg/ml (K = 50.00 ± 0, α = 83.10 ± 0.50).  Maximum clot strength 
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increased significantly with the increase in FI concentration (p < 0.001).  At 0, 3, 6, 9, 12, 
and 15 mg/ml, clot strengths increased: 0 ± 0, 1,355.9 ± 556.4, 4,610.8 ± 127.9, 9,856.0 ± 
1,093.0, 19,946.8 ± 2,343.3 and 25,283.2 ± 3,861.9 dynes/sec.   
 
 
Figure 4.3.  Effect of increasing rFI concentration on clot parameters by thromboelastography.  
Thromboelastographic data was collected on solutions containing constant concentrations of pdFIIa (52.8 
U/ml) and rFXIIIa (0.35 mg/ml) with varying concentrations of rFI of 0, 3, 6, 9, 12 and 15 mg/ml.  Data 
were expressed as mean +/- standard deviation. 
 
Clotting strength and kinetics of various tri-component mixtures of rFI and pdFI 
(from Enzyme Research and Baxter- Tisseel
®
), rFXIIIa and pdFIIa at different 
concentrations were evaluated by thromboelastography.  The first experiment added 
variable concentrations of pdFIIa (0, 0.03, 0.05, 0.10, 0.15, 0.20, and 0.25 mg/ml) while 
maintaining constant concentrations of rFI or pdFI (8.56 mg/ml) and rFXIII (0.35).  
Increasing pdFIIa significantly sped clot initiation time (R) and time to clot firmness (K) 
and increased clot strength (MA) for both rFI and pdFI (p < 0.001 for all) (Figure 4.4).  
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At the highest pdFIIa level, time to clot initiation was equivalent for all three FI: 10.0 ± 0 
seconds.   
 
 
 
 
Figure 4.4.  FIIa dependent maximal clot strength (MA) and clot initiation time (R) with constant FI 
and rFXIIIa.  Thromboelastographic data was collected on solutions containing constant concentrations of 
pdFI or rFI (8.56 mg/ml) and rFXIIIa (0.35 mg/ml, 2,408 U/ml, stoichiometric molar ratio (rFXIIIa/FI) = 
0.17) with varying concentrations of added pdFIIa of 0, 0.03, 0.05, 0.10, 0.15, 0.20 and 0.25 mg/ml 
(stoichiometric molar ratios: 0, 0.03, 0.06, 0.13, 0.19, 0.26 and 0.32).  At the various levels of pdFIIa, pdFI 
from Enzyme Research result in stronger clot strengths (red, R
2
 = 0.82) than pdFI (Tisseel®) from Baxter 
(green, R
2
 = 0.83).  rFI yields clot strengths lower than both pdFI samples with low pdFIIa levels but 
exceeds strengths of pdFI (Tisseel®) at high levels of pdFIIa (blue, R
2
 = 0.96).  The addition of increasing 
units of pdFIIa resulted in faster clot initiation times for pdFI from Enzyme Research (orange, R
2
 = 0.91), 
pdFI from Baxter (gray, R
2
 = 0.91) and rFI (pale blue, R
2
 = 0.91).  Data were expressed as mean +/- 
standard deviation. 
 
The second experiment added variable concentrations of rFXIII (0, 0.03, 0.13, 
0.23, 0.28, 0.35 and 0.42 mg/ml) while maintaining constant concentrations of rFI or 
pdFI (8.56 mg/ml) and pdFIIa (52.8 U/ml).  Increasing rFXIIIa did not greatly alter the 
clot initiation time (R); however, it did significantly increase clot strength (MA) for rFI 
(p < 0.001) and both pdFI samples (Tisseel p , Enzyme Research p < 0.001) (Figure 4.5).  
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At the highest level of rFXIIIa, pdFI from Tisseel
®
 yielded the lowest clot strength 
(4,367.3 ± 761.8 dynes/sec), pdFI (Enzyme Research Laboratories) yielded the highest 
(12,347.5 ±1,429.5 dynes/sec) and rFI fell between (6,904.8 ± 566.2 dynes/sec).  Times 
to clot initiation were similar for the three FI samples.   
 
 
 
 
Figure 4.5.  rFXIIIa dependent maximal clot strength (MA) and clot initiation time (R) with constant 
FI and pdFIIa concentrations.  Thromboelastographic data was collected on solutions containing constant 
concentrations of plasma-derived or recombinant fibrinogen (8.56 mg/ml) and pdFIIa (0.10 mg/ml, 
stoichiometric molar ratio (FIIa/FI) = 0.13) with varying concentrations of added rFXIIIa of 0, 0.03, 0.13, 
0.23, 0.28, 0.35 and 0.42 mg/ml  (stoichiometric molar ratios: 0, 0.01, 0.07, 0.12, 0.14 and 0.17).  At the 
various levels of rFXIIIa, pdFI from Enzyme Research yielded almost two-fold greater clot strengths (red, 
R
2
 = 0.97) than pdFI (Tisseel
®
) from Baxter (green, R
2
 = 0.74).  rFI yielded clot strengths lower than both 
pdFI samples with low rFXIIIa exceeds strengths of pdFI (Tisseel
®
) at high levels of rFXIIIa (blue, R
2
 = 
0.96).  The addition of rFXIIIa to resulted in minimal changes in clot initiation times for pdFI from Enzyme 
Research (orange, R
2
 = 0.98), pdFI from Baxter (gray, R
2
 = 0.61) and rFI (pale blue, R
2
 = 0.82).  Data were 
expressed as mean +/- standard deviation. 
 
Increasing the concentration of rFXIIIa (Figure 4.5) and FIIa (Figure 4.4) both yielded 
asymptotic approaches to maximal clot strength for rFI and both FI samples.  Ratios of 
rFXIIIa (0.16, 0.039 mg rFXIIIa per mg FI) and FIIa (0.18, 11.7 U FIIa per mg FI) with 
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respect to fibrinogen, located at the asymptote for clot strength, were selected for the 
remaining experiments. 
The optimal level of calcium was also determined by maintaining rFI at 15 mg/ml 
and rFXIIIa and pdFIIa molar ratios to FI at 0.16 and 0.18, respectively.  Calcium was 
added at 0, 3, 6, 9, 11, 12 and 15 mM.  Calcium concentration did not alter time to clot 
initiation (R) or coagulation time (K); however, maximum clot strength was dependent 
on calcium.  At 0 mM CaCl2, clot strength was 3,399 dynes/sec.  Maximum clot strength 
was not significantly different for CaCl2 at 3 mM or greater (p = 0.876) (Figure 4.6).  
Further experiments used 12 mM CaCl2.   
 
Figure 4.6.  CaCl2 dependent maximal clot strength (MA) with constant rFI, rFXIIIa and pdFIIa 
concentrations.  Thromboelastographic data was collected on solutions containing constant concentrations 
of rFI (15 mg/ml), rFXIIIa (0.59 mg/ml, stoichiometric molar ratio (FXIIIa/FI) = 0.16) and pdFIIa (0.33 
mg/ml, stoichiometric molar ratio (FIIa/FI) = 0.18) with varying concentrations of CaCl2 of 0, 3, 6, 9, 11, 
12, and 15 mM.  Data were expressed as mean +/- standard deviation. 
 
Once the optimal ratio was established, experiments were also performed to 
identify whether the ratios were optimal at higher FI concentrations and whether an 
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increase in rFXIIIa helped in the presence of higher rFI.  The first experiment maintained 
stoichiometric molar ratios of rFXIIIa/rFI (0.16) and pdFIIa/rFI (0.18) while increasing 
rFI concentrations (9, 12, 12.5 and 15 mg/ml).  Increasing FI resulted in an increase in 
clot strength (p = 0.017); however, 15 mg/ml was not significantly greater than that of 
12.5 mg/ml (p = 0.262) (Figure 4.7).  Time to clot initiation was not affected.   
 
Figure 4.7.  Effect of increasing rFI while maintaining stoichiometric molar ratios of rFXIIIa/rFI and 
pdFIIa/rFI of 0.16 and 0.18, respectively.  Thromboelastographic data was collected on solutions 
containing increasing concentrations of rFI (9, 12, 12.5 and 15 mg/ml) while maintaining stoichiometric 
molar ratios of rFXIIIa/rFI and pdFIIa/rFI at 0.16 and 0.18, respectively.  Data were expressed as mean +/- 
standard deviation. 
 
To determine whether the rFXIIIa/rFI ratio of 0.16 was optimal at a higher rFI 
concentration (12.5 mg/ml), experiments were performed that maintained rFI and FIIa 
(FIIa/FI = 0.18) while increasing rFXIIIa/FI (0.16, 0.18 and 0.20).  Increasing the ratio of 
rFXIII/rFI did not alter clot strength (p = 0.292), kinetics (p < 0.001) or time to clot 
initiation (p < 0.001) (Figure 4.8).   
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Figure 4.8.  Effect of increasing rFXIIIa concentration.  Thromboelastographic data was collected on 
solutions containing constant concentrations of rFI (12.5 mg/ml) and pdFIIa (stoichiometric molar ratio 
(FIIa/FI) = 0.18) with varying stoichiometric molar ratios of rFXIIIa of 0.16, 0.18 and 0.2.  Data were 
expressed as mean +/- standard deviation. 
 
Thromboelastographic properties of clots made by tri-component mixtures of rFI, 
rFXIII and pdFIIa were compared to the average values (N = 22) of clots made by fresh 
citrated human whole blood (Figure 4.9).  Clots consisting of 8.6 mg/ml rFI, 0.35 mg/ml 
rFXIIIa and 52.8 U/ml pdFIIa had maximum clot strengths 3.5 ± 0.2 -fold greater (11,550 
± 560 dyne/sec) than clots formed by NHB alone (3,330 ± 810 dyne/sec).  Clot onset (R) 
and time to clot firmness (K) were also much faster for this tri-component mixture (R = 
12 ± 3 seconds, K = 50 ± 0 seconds) than NHB (R = 412 ± 68 seconds, K = 375 ± 136 
seconds).  A tri-component mixture that replaced 8.6 mg/ml rFI with 8.6 mg/ml FI 
(Tisseel
®
, Baxter) and contained equivalent amounts of rFXIIIa and pdFIIa yielded 
slower clot onset time and time to clot firmness (R = 22 ± 6 seconds, K = 60 ± 17 
seconds) and significantly lower clot strength (4,367 ± 762 dyne/sec) than the rFI 
version.   
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Figure 4.9.  Thromboelastographic properties of NHB and tri-component mixtures of rFI, pdFIIa 
and rFXIIIa.  Clots consisting of 8.6 mg/ml  plasma-derived fibrinogen from a commercial LFS, 0.35 
mg/ml rFXIII and 52.8 U/ml pdFIIa (black) have maximal clot strengths 18% greater than the average 
maximal strength of clots from whole blood of 22 normal donors (red).  Replacing the plasma-derived 
fibrinogen with recombinant fibrinogen (blue) yielded clot strengths 67% greater than blood and 41% 
greater than that of the fibrinogen from the commercially available LFS.  Data were expressed as mean +/- 
standard deviation.   
 
Finally, the optimal fully-recombinant LFS was compared to a commercially 
available pdLFS (Tisseel,
®
 Baxter) used as intended.  The fibrin sealant and thrombin 
portions of Tisseel
®
 were mixed in equal portions yielding a pdLFS containing between 
67 and 106 mg/ml pdFI and 400 to 625 U/ml pdFIIa and 36 to 44 mM CaCl2.  These 
results were compared to clotting parameters obtained with combining rFI (15 mg/ml), 
rFXIII (0.59 mg/ml, rFXIII/rFI = 0.16), rFIIa (0.33 U/ml, rFIIa/rFI = 0.18) and 12 mM 
CaCl2 (Figure 4.10).  The time to clot initiation (R) was slightly slower for the optimized 
rLFS (10.0 ± 0 seconds) than Tisseel® (8.3 ± 2.89 seconds) (p = 0.374); however, the 
time to clot firmness (K) were equivalent (50.0 ± 0 seconds).  Maximum clot strengths 
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were similar at 24,424.9 ± 3,821.9 and 26,374.6 ± 6,242.6 dynes/sec, respectively (p = 
0.728).   
 
Figure 4.10.  Thromboelastographic properties of the optimized tri-component rLFS and a pdLFS 
(Tisseel
®
).  Clots consisting of 15 mg/ml  rFI, 0.59 mg/ml (4,095 U/ml) rFXIIIa and 0.33 mg/ml (176.7 
U/ml) rFIIa (FXIIIa/FI = 0.16, FIIa/FI = 0.18) (blue) have faster clot kinetics and equivalent maximal clot 
strengths as a pdLFS (Tisseel®) as prepared by its manufacturer’s instructions (red).  Tisseel contains 33.5 
to 53 mg/ml pdFI and 200 to 312.5 U/ml pdFIIa.  Data were expressed as mean +/- standard deviation.   
 
Clot lysis by thromboelastography 
Plasminolysis of clots formed by rFI- and pdFI-based LFS were examined by 
TEG.  Plasmin did not greatly affect the initiation of clot onset but altered clot strength 
greatly for both pdFI and rFI (Table 4.1).  Addition of 8.4 and 84 U/ml plasmin to 
Tisseel
®
 results in no alteration in clotting kinetics and no lysis.  Addition of 8.4 or 17 
U/ml of plasmin to pdFI-based clots, resulted in a 62% and 57% decreases in maximal 
clot strength (from 10,334.0 ± 3,599.3 to 3,914.1 ± 691.1 and 4,423.1 ± 450.0 dynes/sec, 
respectively) with a 0 and 1.9% lysis 60 minutes after maximal clot strength was reached.  
Increasing plasmin to 84 U/ml resulted in a 77% decrease (2,388.2 ± 476.1 dynes/sec) 
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from the untreated sample with 8.2% lysis.  Strength of rFI-based clots decreased 49%, 
41%, and 92% with the addition of 8.4, 17, and 84 U/ml (from 5,632.3 ± 1,151.4 to 
2,896.6 ± 729.8, 3,315.6 ± 1,682.3 and 474.4 ± 105.5 dynes/sec, respectively) with 
subsequent lysis of 31.4%, 59.7% and 94.1% 60 minutes after maximal clot strength was 
reached.  Addition of 842 mU/ml resulted in no clot formation.   
 
Table 4.1.  Effects of plasmin on clotting parameters of Tisseel
®
, pdFI- and rFI-based clots by TEG.  
Zero to 842 mU/ml of plasmin were added to solutions containing pdFI- (Tisseel and Enzyme Research) 
and rFI-based LFS components.  Values listed are means ± standard deviation.   
 Sample 
Time to Clot 
Initiation (sec) 
Maximal Clot 
Strength (dynes/sec) 
Lysis (%) 
 0 mU/ml plasmin 8.3 ± 2.9 26,374.6 ± 6,242.6 0 ± 0 
     
Tisseel® 8.4 mU/ml plasmin 10.0 ± 0 19,381.7 ± 1,185.9 0 ± 0 
     
 84 mU/ml plasmin 10.0 ± 0 23,486.9 ± 1,771.9 0 ± 0 
     
 0 mU/ml plasmin 10.0 ± 0 10,334.0 ± 3,599.3 0 ± 0 
     
 8.4 mU/ml plasmin 13.3 ± 2.9 3,914.1 ± 691.5 0 ± 0 
pdFI-based LFS     
 17 mU/ml plasmin 11.7 ± 2.9 4,423.1 ± 450.0 1.9 ± 1.8 
     
 84 mU/ml plasmin 15.0 ± 0 2,388.2 ± 476.1 8.2 ± 7.7 
     
 0 mU/ml plasmin 10.0 ± 0 5,632.3 ± 1,151.4 0 ± 0 
     
 8.4 mU/ml plasmin 10.0 ± 0 2,896.6 ± 729.8 31.4 ± 4.8 
     
rFI-based LFS 17 mU/ml plasmin 10.0 ± 0 3,315.6 ± 1,683.2 59.7 ± 7.9 
     
 84 mU/ml plasmin 15.0 ± 3.2 474.4 ± 105.5 94.1 ± 3.6 
     
 842 mU/ml plasmin No clot No clot No clot 
 
 
Discussion 
The objective of the research presented in this chapter was to optimize the 
components of and identify the importance of FXIII in a LFS.  Fibrinogen is the key 
factor that provides FS their adhesive
6, 14, 50
 and hemostatic abilities and tensile strength.
14
   
All research concurs regarding the import of fibrinogen in FS.  Our data supported earlier 
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findings that increases in fibrinogen result in stronger clots;
23
  however, we observed 
diminishing returns while increasing FI concentration.  Increasing FI from 3 to 6 mg/ml 
resulted in a 2.4-fold increase in maximal clot strength; however, increasing from 12 to 
15 mg/ml did not yield significantly different maximum clot strengths (p = 0.110).  Thus, 
the extremely high FI levels in many FS, like Tisseel
®
 which contains up to 53 mg/ml, 
may not be necessary unless the protein’s preparation lowers FI clotability.   
Thrombin is also a key factor in FS.  Previous research found that FIIa 
significantly increases the rate of fibrin formation
14, 23, 51
 and also plays a role in tensile 
strength.
11, 14
  The ratio of FI to FIIa is important.
52
  Our results support these findings.  
The increase of FIIa sped clot formation and kinetics and also significantly increased 
maximum clot strength (Figure 4.4); however, excess FIIa can deleteriously affect 
clotting.  Researchers found that if FIIa is too high, inhomogeneous clots are formed.
52
  
We found that high levels of thrombin could reduce maximum clot strength (data not 
shown) probably due to the rapid increase in viscosity lowering the diffusion of FXIII 
required to create a strong clot; however, more research needs to be conducted to clarify 
this phenomenon.   
The import of FXIII is debated.  Some researchers found that the ratio of FI to 
FXIII was important
52
 while others did not see differences when FXIII was added to 
FS.
11, 53
  Biochemical studies indicate that α-α and γ-γ crosslinking by FXIIIa increases 
clot strength 3.5-fold;
18
 therefore, FXIII should be included in FS if clot strength is 
desired.  Researchers found that the rate of fibrin crosslinking was faster in FS 
containing more FXIII
46
 and thereby increased the clot’s resistance to fibrinolysis.46, 54  
In addition, research found that FXIII was critical in FS for fibroblast migration.
12
 In 
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challenging situations where blood flow was not easily disrupted requiring FS to clot 
and adhere to tissue quickly, sealants that included FXIII had significantly better results 
than those without FXIII.
46
   
Most FS on the market contain FI and FIIa in similar amounts; however, FXIII 
content ranges.
46
  The ratio of FXIII to FI in human plasma is approximately 0.4 U/mg; 
however, some commercial products contain no FXIII or 0.1 U/mg except for Beriplast 
P which contains approximately 0.44 to 0.89 U/mg.
46
  Dickneite et al. found that a 
FXIII to FI ratio of 0.78 U/mg (70 U/ml FXIII) resulted in a slightly greater tensile 
strength than concentrations above or below this range.
46
  They concluded that the 
addition of FXIII hastens crosslinking and increases clot strength.
46
  Their research 
suggested 40 to 80 U/ml (0.44 to 0.89 U/mg) FXIII concentration in FS.
46
   
We added multiple levels of rFXIIIa to our LFS and found even our lowest 
addition of 23.13 U rFXIIIa per mg FI (208 U/ml) yielded a significantly higher 
maximal clot strength than rLFS without rFXIIIa (Figure 4.5).  This lowest treatment is 
almost 24-fold greater than the highest levels added to commercial FS.  Our optimal 
rLFS contains 274 U rFXIIIa per mg FI (2,464 U/ml) which is 308-fold greater than 
commercial FS.  Previous research has not added FXIII to the levels that we have 
because this requires a production source that can create abundant amounts of rFXIIIa.  
Thromboelastography indicates that the addition of FXIII prolongs fibrinolysis,
54
 
reduces time to clot initiation and increases clotting kinetics and viscoelastic strength.
55, 
56
  While our results supported the increase in clot strength, kinetics and time to clot 
initiation were not greatly affected.   
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Byrne et al. varied FS components FI (23 to 58 g/l), FXIII (1 to 12.5 U/ml, 
FXIII/FI ratio: 0.16 to 0.24) and FIIa (50 to 1000 U/ml) to identify the optimal mixture.  
This research found that FS with 39 mg/ml FI, no added FXIII and 200 to 600 U/ml FIIa 
yielded the best viscoelastic properties.
53
  Higher FI and FIIa concentrations inhibited 
wound healing and lower levels were not effective sealants.
11, 53
  Our optimal FI and FIIa 
levels are significantly lower than the published optimal mixture and commercially 
available products.   
Our optimal LFS contains 9 mg/ml FI, 0.36 mg/ml FXIIIa (FXIIIa/FI molar ratio 
of 0.16), 105.6 U/ml FIIa (FIIa/FI molar ratio of 0.18) and 12 mM CaCl2.  While 15 
mg/ml rFI yielded slightly higher clot strength, it was not statistically significant (Figure 
4.3); therefore, we selected 9 mg/ml rFI for our optimal rLFS.  The optimal ratio of 
FXIIIa to FI (0.16) was selected to provide the highest viscoelastic strength (Figure 4.4 
and 4.8).  The optimal ratio of FIIa to FI (0.18) was selected to provide the fastest 
initiation of clot formation and clotting kinetics.  rFI concentrations were selected to 
provide the necessary clot strength while minimizing material use.  12 mM CaCl2 was 
selected to ensure that when applied to a wound an ample amount of the required 
component was available to both exogenous and endogenous proteins.  Our results 
indicate that rLFS is unaffected by increases in calcium concentration greater than 3 mM 
(slightly above physiological levels of ~2 mM) which contradicts previous research that 
indicated that reducing calcium below 10 mM resulted in reduction in viscoelastic 
strength.
11
  Fibrin clots made with rFI, rFXIII and FIIa yielded 5.0-fold greater shear 
elastic modulus strength than clots formed from NHB alone.  The clotting kinetics and 
viscoelastic strength of our optimized LFS was equivalent to those of a commercially 
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available LFS; however, it uses approximately 75% less fibrinogen and thrombin.  Initial 
preclinical testing indicates that this optimal rLFS is effective as a sealant alone and in 
combination with a dressing on multiple liver and femoral arteriotomy models.   
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Chapter 5 
Ex vivo Evaluation of the Liquid Fibrin Sealant Components 
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Abstract 
Commercial scale biosynthesis has been demonstrated for recombinant fibrinogen 
(rFI) in the milk of transgenic cows, thrombin (FIIa) by mammalian cell culture and 
Factor XIII by cell culture (rFXIII).  These recent developments will enable the use of 
therapeutics that require abundant production schemes that could not previously be met 
by plasma sources.  One possible use for these three proteins is as components in a 
recombinant liquid fibrin sealant (rLFS).  The function of fibrin sealants is based on 
complicated interactions between other pro- and anticoagulant proteins, blood cells and 
vessel surface under flow and viscosity conditions; therefore, our optimized rLFS and its 
components needed to be tested ex vivo.  Each individual component and all 
combinations of the LFS components were dosed into citrated normal human blood 
(NHB) and its respective platelet rich (PRP) and platelet poor plasma (PPP) fractions to 
analyze its effects on blood coagulation.  Thromboelastographic analysis showed: 
 rFI at near-hyperfibrinogenemic levels can increase clot strength when dosed into 
NHB, PRP and PPP.  rFI alone or with rFXIII increases time to clot initiation 
when added to PRP or PPP.   
 FIIa in combination with other components or alone significantly decreases the 
time to clot initiation for NHB, PRP and PPP.  The addition of FIIa alone or with 
rFXIII to NHB, PRP or PPP significantly reduces clot strength; however, addition 
of rFI reverses the loss in clot strength.   
 rFXIII alone or in combination with rFI increases clot strength when added to 
PPP but not when added to NHB and PRP indicating that blood-borne platelets 
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play a large role by providing FXIII.  When added to NHB, rFXIII speeds time to 
clot initiation by a median of 24%.   
With regard to therapeutic uses, both rFI and rFXIIIa have advantages.  rFI dosed in 
NHB alone did not significantly alter time to clot initiation or coagulation time but did 
increase clot strength.  Consequently, rFI may be useful for infusion therapy following 
haemodilution.  rFXIIIa reduced time to clot initiation slightly but did not significantly 
change clot strength or kinetics; therefore, it may be an effective infusion therapy for 
FXIII deficiency.  The research presented in this chapter is the first detailed evaluation of 
the effects of haemodilution on PRP and PPP coagulation parameters.  In addition, it is 
also the first report of detailed in vitro effects of doping FI, FXIIIa and FIIa into NHB, 
PRP and PPP.   
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Introduction 
Commercial scale biosynthesis has been demonstrated for recombinant fibrinogen 
(rFI) in the milk of transgenic cows, thrombin (FIIa) by mammalian cell culture and 
Factor XIII by cell culture (rFXIII).  These recent developments will enable the use of 
therapeutics that require abundant production schemes that could not previously be met 
by plasma sources.  One possible use for these three proteins is as components in a 
recombinant liquid fibrin sealant (rLFS).  Fibrin sealants (FS) mimic natural clotting 
mechanisms thereby providing similar functions as endogenous plasma components such 
as creating hemostatic clots
1
 and providing a scaffold for cellular infiltration needed to 
regenerate tissue.
1, 2
  FS, which contain fibrinogen (FI), thrombin (FIIa) and calcium 
chloride and occasionally Factor XIII (FXIII), reproduce the final stage of the clotting 
cascade to aid hemostasis.  FIIa catalyzes the conversion of FI to soluble fibrin monomer 
and FXIII to activated FXIII (FXIIIa).
3-6
  FXIIIa then catalyzes the formation of the 
crosslinked, insoluble fibrin clot that is melded with the platelet-based, primary 
hemostatic plug.
5, 7-9
  FS function is based on complicated interactions between other pro- 
and anticoagulant proteins, blood cells and vessel surface under flow and viscosity 
conditions;
10
  therefore, our optimized rLFS and its components should be tested ex vivo.   
Very little research has been performed on the effects of LFS components on 
hemostasis in ex vivo situations.  Thromboelastographic (TEG) analysis of blood samples 
taken after rFXIII administration showed increased clot strength and decreased 
fibrinolysis with lesser effects on the speed of clot formation.
11
   Detailed analysis of the 
impact of rFI dosing into blood (in vitro or in vivo) on clotting kinetics and viscoelastic 
strength requires gram amounts of rFI and thus has not been reported to date.  The 
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objective of the research presented in this chapter was to evaluate our optimized rFI, 
rFXIIIa and rLFS ex vivo.  In particular, rFI was evaluated as a replacement therapy 
following near exsanguination by examining the interaction of rFI with endogenous 
proteins.  Each component of the rLFS was added individually and in combination with 
the others to normal human blood (NHB) and platelet rich (PRP) and platelet poor plasma 
(PPP) to evaluate interactions between exogenous and endogenous proteins and cellular 
components.  The research presented in this chapter is the first detailed evaluation of the 
effects of haemodilution on PRP and PPP coagulation parameters.  In addition, this is the 
first report of detailed testing of kinetics and viscoelastic strength of clots formed by 
endogenous and individual and combined exogenous components of a LFS.    
 
Materials and Methods 
Materials 
Purified, plasma-derived prothrombin was bought from Enzyme Research 
Laboratories (South Bend, IN).  Recombinant thrombin (Recothrom
®
) was purchased 
from Zymogenetics.  Purified recombinant fibrinogen, expressed in the milk of transgenic 
Swiss Brown cows, was obtained from Pharming Group NV (Leiden, Netherlands).  
Materials for the thromboelastograph were purchased from Haemoscope (Niles, IL).  
Unless otherwise specified, reagents were purchased from Sigma (St. Louis, MO).   
Vector construction, expression and purification of FXIIIA in Pichia pastoris 
The human Ultimate ORF clone containing the human coagulation factor 
FXIIIA1 cDNA in the pENTR
TM
221 vector was purchased from Invitrogen (Carlsbad 
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CA). The following primers were used to obtain FXIIIa gene to subclone in pPICZA 
intracellular Pichia expression vector. (Forward, 5'-
CCAATTGATGCATCATCATCATCATCATTCAGAAACTTCCAGGACCGC-3'; 
Reverse, 5'-GCGGCCGCTCACATGGAAGGTCGTCTTTGAATC-3').  The forward 
primer introduced a methionine and 6 histidine amino acids at the N-terminus of mature 
FXIIIa peptide. The PCR product was digested with MfeI and NotI and subcloned into 
pPICZA which was digested with the same enzymes.  The DNA sequence of the FXIIIA 
was confirmed by sequencing the insert fragment. One of the confirming plasmid 
pPICZAFXIIIa was linearized with PmeI and transformed into P. pastoris X-33 host 
strain and copy number of the clones was determined as described.
12
 Varying copy 
number clones were screened in shake flask culture to confirm intracellular production of 
FXIIIa protein. The highest producing clone was scaled up to 5 L bench scale. A fed-
batch fermentation protocol was followed to optimize FXIIIa production as described by 
Zhang et al., (2007).
13
  At the end of fermentation process the cells were separated by 
centrifugation (6,000g)  and pellet was stored at -80
o
C.   
Frozen cell paste was processed in 300 gram batches.  Cells were lysed in three 
sets of 100 gram batches.  100 grams of cell paste was resuspended in 100 ml of cold 
lysis buffer (50 mM Tris-HCL, 10 mM MgSO4, 1 mM EDTA, 10 mM potassium acetate, 
1 mM DTT (DL-Dithiothreitol), 2 mM PMSF (phenylmethanesulphonylfluoride) in 
methanol, pH 9.5).  100 ml (250 g) of 0.5 mm glass beads (Biospec, Bartlesville, OK) 
were added and the cells.  Surrounded by an ice bath, cells were lysed using a BeadBeater 
Blender (Biospec, Bartlesville, OK) with twenty 20 second on/off cycles.  The cell lysate 
mixture was then centrifuged to remove cellular debris.  The lysate from 300 grams of 
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cell paste was combined and purified using the HisBind Purification Kit (EMD 
Chemicals, Inc., San Diego, CA) with 40 ml of resin slurry.  Following purification, 
rFXIII was dialyzed in 10 mM Tris-HCl, 0.1 mM EDTA, 60 µM polysorbate-20, pH 8.0 
in snake-like dialysis membranes and the protein samples were filter-sterilized and 
concentrated using the Amicon tubes (Millipore, Billerica, MA).  The purity of the 
sample was tested by SDS-PAGE (NuPAGE 12% Bis-Tris) (Invitrogen, Carlsbad, CA) 
and immunoblot.  The concentration of rFXIII was determined by standard Bicinconic 
Acid (BCA) methods.   
FIIa preparation 
Frozen, plasma-derived human prothrombin (Enzyme Research Laboratories, 
South Bend, IN), was thawed at 37
o
C.  Plasma-derived thrombin (Enzyme Research 
Laboratories, South Bend, IN) was added at a 1/10 mass to mass thrombin/prothrombin 
ratio.  0.35 grams of sodium citrate per milliliter of solution was added (Lanchantin 
1965).  This solution was incubated at 37
o
C on a rotating mixer for five hours.  Sodium 
citrate was removed using PD-10 desalting columns (GE Healthcare, Giles, United 
Kingdom).  Activation of prothrombin to thrombin was confirmed by reducing and 
nonreducing SDS-PAGE (12% Bis-Tris NuPAGE) (Invitrogen, Carlsbad, CA) stained 
with Colloidal Blue (Invitrogen, Carlsbad, CA).  The concentration of the thrombin 
solution was determined by standard Bicinconic Acid (BCA) methods.  The specific 
activity was determined by aPTT analysis.   
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Human blood sampling and processing 
Fresh, normal whole human blood (NHB) from 20 healthy, medication-free 
individuals, collected in tubes containing 3.2% citrate, was obtained from Research 
Blood Components (Brighton, MA).  Each individual NHB sample was divided in thirds.  
The NHB sample remained unprocessed while the other two were processed into platelet-
rich plasma (PRP) and platelet-poor plasma (PPP). PRP was prepared by centrifuging 
NHB at 160xg for 8 minutes at 22
o
C.  NHB was centrifuged at 2300xg for 15 minutes at 
22
o
C to obtain PPP.  All blood fractions were used within 36 hours of being drawn and 
were stored at 0
o
C until analyzed at which time the samples were warmed to 37
o
C.   
Thromboelastography analysis of fibrin clot formation 
TEG analysis was conducted on individual fresh, citrated NHB, and respectively 
derived PRP and PPP samples from 20 individuals.  Aliquots of each NHB, PRP and PPP 
sample were dosed with purified rFI, rFXIII and/or pdFIIa alone or combination.  All 
blood fractions were diluted to 1.3x to provide volume for addition of the biologics.  
Control samples were performed to determine the affects of diluting NHB, PRP and PPP 
on time to clot initiation (R), coagulation time (K, time to reach clot firmness of 20 mm) 
and maximal clot strength (MA) as evaluated by TEG.  Each NHB and respective plasma 
samples (429.72 µl) were transferred to single-use TEG cups that had been enlarged by 
boring with a 0.406 inch bit (650 µl final volume).  Combinations of solutions containing 
rFI (1.42 mg, 2.32 mg/ml rFI in cup), rFXIII (0.11 mg, 0.18 mg/ml rFXIIIa in cup, 
rFXIII/rFI molar ratio = 0.16), FIIa (0.08 mg, 0.13 mg/ml FIIa in cup, FIIa/rFI molar 
ratio = 0.25), and CaCl2 (11 mM) were added to the TEG cups.  Ringer’s solution was 
used to normalize mixture volumes.   
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The TEG Analytical Software (version 4.2.2, Haemoscope, Niles, IL) collected 
the time to clot initiation (R), the time to achieve a clot firmness of 20mm (K) and the 
maximal clot strength (MA) for blood products collected from 20 donors.  Samples were 
run until program termination to collect percent lysis 60 minutes after reaching maximum 
clot strength (LY60) on blood products from 3 of the 20 donors.  Data was exported from 
the TEG Analytical Software to Microsoft Excel for analysis.  ANOVA and two tail T 
test (equal variance) analyses were performed to identify statistical significance between 
treatment groups of raw data.  An α of 0.05 was used for all statistical analyses.  The 
percent change of TEG values resulting from treatment with biologics was normalized 
relative to the averaged respective sample (N = 20) treated with Ringer’s solution alone.   
The instrument was calibrated each day of use.  All tests described above include 
three replicate samples in each treatment group.  All NHB and respective plasma samples 
were tested within 36 hours of the blood draw of each individual donor.   
NHB, PRP and PPP samples from 20 donors were tested untreated and treated 
with rFI alone, rFI and FIIa together, rFI and rFXIIIa together, rFI, rFXIIIa and FIIa 
together.  NHB, PRP and PPP samples from 10 donors were tested when treated with 
FIIa alone, FXIIIa alone and FIIa and FXIIIa in combination.   
 
Results 
rFXIIIa and pdFIIa characterization 
SDS-PAGE and N-terminal sequencing indicated that the purified protein from 
the yeast was rFXIIIa rather than rFXIII.  These and immunoblots indicated rFXIIIa had 
a purity of greater than 98% (data not shown).  The Pefakit
®
 Factor XIII Incorporation 
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Assay (Pentapharm, CT) yielded a specific activity of almost 7,000 U/mg for rFXIIIa.  
The pdFIIa prepared by citrate activation was comprised of α-thrombin and fragments as 
per SDS-PAGE (Figure 5.2A, lane 10) and chromogenic assay yielded a specific activity 
of 528 U per mg.   
Donor data 
Blood was collected from 20 healthy, drug-free donors from 15 men and 5 women 
with a mean age of 29 (median: 26, maximum: 50, minimum: 20).  11 of the 20 were 
White, 7 Black, 1 Asian and 1 Hispanic.   
TEG analysis of haemodilution 
All blood fractions were diluted 1.3x so that 30% of the TEG cup volume was 
available for addition of the biologics.  The effect of dilution by Ringer’s solution on 
NHB, PRP and PPP was evaluated by thromboelastography for time to clot initiation (R), 
coagulation time (time to reach clot firmness of 20 mm, K) and maximal clot strength 
(MA).  Dilution resulted in statistically significant changes in time to clot initiation for 
PRP and PPP when diluted with Ringer’s solution (p = 0.011 and 0.014) but not for NHB 
(p = 0.087).  Coagulation time was statistically different for NHB (p = 0.002) but not for 
PRP and PPP (p = 0.626 and 0.132).   Maximal clot strength was statistically different for 
PPP (p = 0.026) but not for NHB and PRP (p = 0.288 and 0.245). 
Although not statistically significant, in general, diluting with Ringer’s solution 
reduced R, K and MA for NHB (Figure 5.1).  Percent change in R was reduced in 17 of 
the 23 NHB samples ranging from a 38% reduction to almost 10% increase (Figure 
5.1A).  Similarly, coagulation time (K) was reduced in 19 of 22 with a range from a 52% 
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reduction to an 8% increase (Figure 5.1B).  14 of the 23 NHB samples also had reduced 
clot strength when diluted with Ringer’s solution ranging from a 22% reduction to a 22% 
increase (Figure 5.1C).   
As with NHB, dilution of PRP with Ringer’s solution tended to reduce R, K and 
MA (Figure 5.2).  When diluted with Ringer’s solution, PRP was reduced in all 22 cases 
ranging from a just over 2% to a 33% reduction (Figure 5.2A).  15 of 22 diluted PRP 
samples had reduced coagulation time but ranged from a 47% reduction to 54% increase 
(Figure 5.2B).  Percent changes in clot strength for diluted PRP ranged from a 23% 
reduction to 13% increase; however, 20 of 22 PRP samples had reductions in clot 
strength (Figure 5.2C).   
Like NHB and PRP, R and MA were reduced when PPP was diluted with 
Ringer’s solution; however, coagulation time tended to increase (Figure 5.3).  All but 2 of 
the 22 PPP samples had reduced clot initiation time (R) when diluted with Ringer’s 
solution.  Percent change in R ranged from a 41% reduction to a 3% increase (Figure 
5.3A).  All 22 PPP samples had a reduction in clot strength from 14% to 35% when 
diluted (Figure 5.3C).  Coagulation time of diluted PPP was the only measured parameter 
that showed primarily an increase after dilution (Figure 5.3B).  The six PPP samples with 
zero percent change in K were samples that never reached 20 mm clot strength either 
before or after dilution.  Four of the 22 samples (Donors R, X, Z and AA) reached 20 mm 
clot strength before dilution but not after.  Only two samples showed a reduction in K 
when diluted.  Percent changes of K ranged from a 34% reduction to a 539% increase.   
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Figure 5.1.  Percent change in time to clot initiation (R), clot coagulation time (K) and maximal clot 
strength (MA) when normal human blood (NHB) is diluted 30% with Ringer’s solution.  The bars 
represent average values and the brackets represent the standard deviation.  N = 23 for R and MA, 22 for K.   
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Figure 5.2.  Percent change in time to clot initiation (R), clot coagulation time (K) and maximal clot 
strength (MA) when platelet rich plasma (PRP) is diluted 30% with Ringer’s solution.  The bars 
represent average values and the brackets represent the standard deviation.  N = 22.   
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Figure 5.3.  Percent change in time to clot initiation (R), clot coagulation time (K) and maximal clot 
strength (MA) when platelet poor plasma (PPP) is diluted 30% with Ringer’s solution.  The bars 
represent average values and the brackets represent the standard deviation.  N = 22. 
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The three blood products, NHB, PRP and PPP, diluted by 30% were statistically 
compared.  R, K and MA results for NHB, PRP and PPP were compared by t test if 
significant differences were identified by ANOVA (Table 5.1).  With respect to clot 
initiation time, NHB was not statistically different form PRP or PPP; however, PRP and 
PPP were significantly different from each other.  NHB, PRP and PPP were statistically 
different from each other with respect to both K and MA.  These findings indicate that 
platelets and cellular components contribute to coagulation parameters.   
 
Table 5.1.  p values from t test comparisons of normal human blood (NHB), platelet rich plasma 
(PRP) and platelet poor plasma (PPP) on time to clot initiation (R), time to reach clot firmness of 
20 mm (K) and maximal clot strength (MA).   
Clotting Parameter 
Time to clot initiation 
(R)  
Coagulation time 
(K) 
Maximum clot 
strength (MA) 
NHB vs. PRP 0.572 < 0.001* < 0.001* 
NHB vs. PPP 0.062 < 0.001* < 0.001* 
PRP vs. PPP 0.014* < 0.001* < 0.001* 
*  statistical significance based on α = 0.05 
 
TEG analysis of protein doping into NHB, PRP and PPP 
rFI (final concentration: 2.32 mg/ml), rFXIII (final concentration: 0.18 mg/ml), 
and/or FIIa (final concentration: 0.13 mg/ml, 52.9 U/ml) were dosed into purchased 
citrated, NHB and its respective PRP and PPP.  Time to clot initiation (R), coagulation 
time (time to reach clot firmness of 20 mm, K) and maximal clot strength (MA) were 
evaluated by thromboelastograph (TEG).  ANOVA analysis indicates that dosing NHB, 
PRP and PPP with proteins do result in statistically significant changes in clotting 
parameters (Table 5.2).  t test analyses were performed to identify which proteins 
significantly altered clotting parameters.  The percent change of TEG values resulting 
from treatment with biologics were normalized relative to the averaged respective sample 
(N = 20) treated with Ringer’s solution alone.   
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Table 5.2.  p values from ANOVA analyses on time to clot initiation (R), time to reach clot 
firmness of 20 mm (K) and maximal clot strength (MA) due to treatment with biologics.   
Clotting Parameter 
Normal Human 
Blood  
Platelet Rich 
Plasma 
Platelet Poor 
Plasma 
Time to clot initiation (R) < 0.0001 < 0.0001 < 0.0001 
Coagulation time (K) < 0.0001 < 0.0001 0.0001 
Maximum Clot Strength (MA) < 0.0001 < 0.0001 < 0.0001 
*  statistical significance based on α = 0.05 
 
TEG analysis of time to clot initiation 
ANOVA analyses indicated that protein treatment significantly altered R for 
NHB, PRP and PPP (Table 5.2).  t test analyses indicated that dosing any protein into 
PRP or PPP and all but rFI alone or rFI in combination with rFXIIIa results in a 
significant change in time to clot initiation (Table 5.3).   
 
Table 5.3.  p values from t test analyses on time to clot initiation (R) comparing diluted normal 
human blood (NHB), platelet rich plasma (PRP) and platelet poor plasma (PPP) to samples 
containing biologics.   
Diluted sample vs.: 
Normal Human 
Blood  
Platelet Rich 
Plasma 
Platelet Poor 
Plasma 
rFI dosed sample 0.101 < 0.001* < 0.001* 
rFXIIIa dosed sample 0.003* 0.010* 0.001* 
FIIa dosed sample < 0.001* < 0.001* < 0.001* 
rFI + FIIa dosed sample < 0.001* < 0.001* < 0.001* 
rFXIIIa + FIIa dosed sample < 0.001* < 0.001* < 0.001* 
rFI + rFXIIIa dosed sample 0.950 0.001* < 0.001* 
rFI + rFXIIIa + FIIa dosed sample < 0.001* < 0.001* < 0.001* 
*  statistical significance based on α = 0.05 
 
Percent changes in R indicate that FIIa dominates clot speed (Figure 5.4).  When 
examining percent changes, the addition of rFI alone increased clot initiation by 8%, 
30%, and 39% for NHB, PRP and PPP, respectively. Individual sample values ranged 
from a 42% increase to a 13% decrease in time to clot initiation for NHB, 14% to 49% 
increase for PRP and 15% to 72% increase for PPP. The average standard deviations for 
each sample were 10, 5 and 8 for NHB, PRP and PPP, respectively.   
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The addition of rFXIII alone decreased R by 24%, 12%, and 13% for NHB, PRP 
and PPP, respectively. Individual sample values ranged from 2% to 40% decrease in time 
to clot initiation for NHB, 30% increase to 38% decrease in R for PRP and 2% increase 
to 21% decrease for PPP. The average standard deviations for each sample were 6, 4 and 
6 for NHB, PRP and PPP, respectively.   
Clot initiation time (R) was affected predominantly by FIIa which added alone 
decreased median clot initiation times by 74%, 91% and 91% for NHB, PRP and PPP, 
respectively. Individual sample values ranged from 68% to 83% decrease in time to clot 
initiation for NHB, 87% to 93% decrease for PRP and 67% to 95% decrease for PPP. The 
average standard deviations for each sample were 7, 5 and 5 for NHB, PRP and PPP, 
respectively.   
When FIIa is added with rFI, time to clot initiation decrease by 86%, 95% and 
96% for NHB, PRP and PPP, respectively. The average standard deviations for each 
sample were 2, 3 and 5 for NHB, PRP and PPP, respectively. Individual sample values 
ranged from 82% to 92% decrease in time to clot initiation for NHB, 91% to 96% 
decrease for PRP and 91% to 97% decrease for PPP. The average standard deviations for 
each sample were 6, 5 and 6 for NHB, PRP and PPP, respectively.  
When FIIa is added with rFXIII, time to clot initiation decrease by 81%, 93% and 
94% for NHB, PRP and PPP, respectively. Individual sample values ranged from 76% to 
88% decrease in time to clot initiation for NHB, 87% to 95% decrease for PRP and 81% 
to 96% decrease for PPP. The average standard deviations for each sample were 5, 4 and 
4 for NHB, PRP and PPP, respectively. 
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The addition of rFI with rFXIII did not affect the time to clot initiation for NHB 
but increased it for PRP and PPP by 33% and 25%, respectively. Individual sample 
values ranged from a 13% increase to 22% decrease in time to clot initiation for NHB, 
14% to 72% increase for PRP and 11% to 49% increase for PPP. The average standard 
deviations for each sample were 8, 6 and 4 for NHB, PRP and PPP, respectively. 
Addition of rFI, rFXIII and FIIa decreased clot initiation time by 88%, 94% and 
96% for NHB, PRP and PPP, respectively. Individual sample values ranged from 82% to 
92% decrease in time to clot initiation for NHB, 92% to 96% increase for PRP and 94% 
to 97% increase for PPP. The average standard deviations for each individual sample 
were 4, 5 and 6 for NHB, PRP and PPP, respectively.   
 
 
 
Figure 5.4.  Percent change in time to clot initiation (R) with the addition of recombinant fibrinogen 
(rFI), plasma-derived thrombin (pdFIIa) and/or recombinant FXIIIa (rFXIIIa) to normal human 
blood (NHB), platelet rich plasma (PRP) and platelet poor plasma (PPP).  The bars represent median 
values and the brackets represent the highest and lowest values for the 20 subjects.   
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TEG analysis of coagulation time 
ANOVA analyses indicated that protein treatment significantly altered K for 
NHB, PRP and PPP (Table 5.2).  t test analyses indicated that dosing rFI alone, FIIa 
alone, rFI and FIIa together, rFXIIIa and FIIa together, and rFI, rFXIIIa and FIIa together 
significantly changes maximal clot strength (Table 5.4).  K of PRP was significantly 
altered with the addition of FIIa alone and rFXIIIa and FIIa in combination.  K of PPP 
was significantly altered with the addition of rFI alone, rFI with rFXIIIa, and rFI with 
rFXIIIa, and rFI. 
 
Table 5.4.  p values from t test analyses on coagulation time (K) comparing diluted normal human 
blood (NHB), platelet rich plasma (PRP) and platelet poor plasma (PPP) to samples containing 
biologics.   
Diluted sample vs.: 
Normal Human 
Blood  
Platelet Rich 
Plasma 
Platelet Poor 
Plasma 
rFI dosed sample 0.004* 0.954 0.025* 
rFXIIIa dosed sample 0.568 0.137 0.077 
FIIa dosed sample < 0.001* 0.003*  
rFI + FIIa dosed sample 0.002* 0.064 0.370 
rFXIIIa + FIIa dosed sample < 0.001* 0.036*  
rFI + rFXIIIa dosed sample 0.318 0.790 < 0.001* 
rFI + rFXIIIa + FIIa dosed sample 0.012* 0.117 0.016* 
*  statistical significance based on α = 0.05, FIIa and rFXIIIa + FIIa dosed samples never achieved 20 
mm clot strength.  
 
Percent changes in K indicate that FIIa dominates coagulation time (Figure 5.5).  
Coagulation time (K) was reduced 24% and 54% for NHB and PPP, respectively, and 
increased 14% for PRP when rFI was added.  Individual sample values ranged from a 1% 
increase to a 48% decrease in K time for NHB, a 60% increase and 21% decrease for 
PRP and 0% to 70% decrease for PPP.   
When rFXIIIa was added, the K value was increased 5% for NHB and reduced 
24% and 70% for PRP and PPP, respectively.  Individual sample values ranged from a 
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52% increase to a 32% decrease in coagulation time for NHB, 0% to 43% decrease for 
PRP and 0% to 91% decrease for PPP.   
When FIIa was added, coagulation time 111%, 125% and 0% for NHB, PRP and 
PPP, respectively.  Individual sample values ranged from 48% to 165% increase in 
coagulation time for NHB, 59% to 269% increase for PRP and 0% to 199% increase for 
PPP.  When FIIa was added with rFI, coagulation time increased by 35%, 46% and 0% 
for NHB, PRP and PPP, respectively.  Individual sample values ranged from a 13% 
decrease and 72% increase in K value for NHB, a 126% increase to a 14% decrease for 
PRP and a 199% increase to 61% decrease for PPP.  When FIIa is added with rFXIII, 
coagulation time increased by 90%, 64% and 0% for NHB, PRP and PPP, respectively.  
Individual sample values ranged from 62% to 233% increase in K for NHB, 30% to 
144% increase for PRP and 0% to 199% increase for PPP.  
The addition of rFI with rFXIII decreased NHB and PPP by 16% and 82%, 
respectively, and increased PRP by 17%.  Individual sample values ranged from a 44% 
increase to 43% decrease in K for NHB, a 78% increase to 62% decrease in K for PRP, 
and 37% to 94% decrease for PPP.   
Addition of rFI, rFXIII and FIIa increased coagulation time for NHB and PPP by 
30% and 39%, respectively, and a 57% decrease for PPP. Individual sample values 
ranged from a 5% decrease to a 61% increase in K for NHB, a 29% decrease to a 113% 
increase in K for PRP and a 83% decrease to a 8% increase in K for PPP.   
 
155 
 
Figure 5.5.  Percent change in coagulation time (K) with the addition of recombinant fibrinogen 
(rFI), plasma-derived thrombin (pdFIIa) and/or recombinant FXIIIa (rFXIIIa) to normal human 
blood (NHB), platelet rich plasma (PRP) and platelet poor plasma (PPP).  The bars represent median 
values and the brackets represent the highest and lowest values for the 20 subjects.   
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ANOVA analyses indicated that protein treatment significantly altered MA for 
NHB, PRP and PPP (Table 5.2).  t test analyses indicated that dosing rFI alone, rFXIIIa 
alone, FIIa alone, rFXIIIa and FIIa together, and rFI and rFXIIIa together significantly 
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Table 5.5.  p values from t test analyses on maximal clot strength (MA) comparing diluted normal 
human blood (NHB), platelet rich plasma (PRP) and platelet poor plasma (PPP) to samples 
containing biologics.   
Diluted sample vs.: 
Normal Human 
Blood  
Platelet Rich 
Plasma 
Platelet Poor 
Plasma 
rFI dosed sample < 0.001* 0.935 0.802 
rFXIIIa dosed sample 0.028* 0.212 0.852 
FIIa dosed sample < 0.001* 0.002* < 0.001* 
rFI + FIIa dosed sample 0.850 0.125 0.027* 
rFXIIIa + FIIa dosed sample < 0.001* 0.004* < 0.001* 
rFI + rFXIIIa dosed sample 0.047* 0.817 0.039* 
rFI + rFXIIIa + FIIa dosed sample 0.647 0.452 0.881 
*  statistical significance based on α = 0.05 
 
 
rFI dominated the changes in clot strength as can be observed with percent change 
in MA (Figure 5.6).  When added alone, rFI increased median clot strength by 27%, 6% 
and 26% for NHB, PRP and PPP, respectively.  The individual sample values ranged 
from a 19% to 51% increase in clot strength for NHB, a 14% increase to 20% decrease 
for PRP and 5% to 103% increase in strength for PPP. The average standard deviations 
for each sample were 2, 2 and 1 for NHB, PRP and PPP, respectively.  
rFXIII added alone did not greatly affect clot strength of NHB or PRP but 
increased strength of PPP clots by a median of 48%. The individual sample values ranged 
from a 6% increase to 57% decrease in clot strength for NHB, a 6% increase to 16% 
decrease for PRP and 17% to 95% increase for PPP. The average standard deviations for 
each sample were 3, 3 and 1 for NHB, PRP and PPP, respectively.   
When FIIa was added alone to NHB, PRP and PPP, median clot strength for each 
sample decreased by 30%, 26%, 51%, respectively. The individual sample values ranged 
from 23% to 38% for NHB, 18% to 38% for PRP and 46% to 64% for PPP. The average 
standard deviations for each sample were 2, 2 and 1 for NHB, PRP and PPP, respectively.  
When rFI was added with FIIa, rFI reversed the effects of FIIa resulting in clot 
strengths similar to NHB, PRP and PPP alone.  Median clot strengths were increased 
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11% and 29% for NHB and PPP and decreased 3% for PRP. Individual sample values 
ranged from a 5% decrease to a 25% increase in clot strength for NHB, a 31% decrease to 
5% increase for PRP and 18% decrease to 65% increase for PPP.  The average standard 
deviations for each sample were 2, 2 and 1 for NHB, PRP and PPP, respectively.  
When FIIa was combined with rFXIII to NHB, PRP and PPP, there were similar 
decreases in median clot strength of 32%, 19%, 39%, respectively. The individual sample 
values ranged from 25% to 47% for NHB, 13% to 33% for PRP and 17% to 57% for 
PPP. The average standard deviations for each sample were 2, 3 and 1 for NHB, PRP and 
PPP, respectively.   
When added in combination with rFXIII, rFI increased median clot strength for 
NHB, PRP and PPP by 18%, 5% and 63%, respectively. The individual sample values 
ranged from 3% to 36% increase in clot strength for NHB, a 23% increase to 10% 
decrease for PRP and 5% to 161% for increase in strength for PPP.  The average standard 
deviations for each sample were 3, 3 and 2 for NHB, PRP and PPP, respectively.    
The addition of rFI, rFXIII and FIIa did not change PRP clot strength but 
increased median clot strengths of NHB and PPP by 6% and 61%, respectively. 
Individual sample values ranged from a 5% decrease to a 29% increase in clot strength 
for NHB, a 6% decrease to 14% increase for PRP and a 12% to 22% increase for PPP.  
The average standard deviations for each sample were 3, 4 and 2 for NHB, PRP and PPP, 
respectively.   
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Figure 5.6.  Percent change in maximal clot strength (MA) with the addition of recombinant 
fibrinogen (rFI), plasma-derived thrombin (pdFIIa) and/or recombinant FXIIIa (rFXIIIa) to 
normal human blood (NHB), platelet rich plasma (PRP) and platelet poor plasma (PPP).  The 
bars represent median values and the brackets represent the highest and lowest values for the 20 
subjects.   
 
TEG analysis of lysis 
The percent lysis 60 minutes after achieving maximal clot strength was measured 
by TEG (Figure 5.7).  Undiluted NHB was lysed by 3.7% 60 minutes after achieving 
maximal clot strength with a range of 0% to 4.9%.  Undiluted PRP was lysed by 6% 
ranging from 2.8% to 10.4%.  Undiluted PPP was lysed by 0% ranging from 0% to 1%.  
Diluted NHB, PRP and PPP were lysed by 1.7%, 11.1% and 0%, respectively.  The 
individual sample values ranged from 0.5% to 8.2% for NHB, 8.8% to 13.1% for PRP 
and 0% to 0.1% for PPP.   
When rFI was added, NHB and PRP were lysed by 3.7% and 9.6%, respectively 
with ranges of 0.9% to 3.9% for NHB and 9.5% to 12.7% for PRP.  When rFI and FIIa 
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to 5.2% for NHB and 0.3% to 6.5% for PRP.  When rFI was in combination with rFXIIIa, 
NHB and PRP were lysed by 1.4% and 2.0%, respectively with ranges of 0.6% to 2.1% 
for NHB and 0% to 3.9% for PRP.  When rFI, rFXIIIa and FIIa were added, NHB and 
PRP were lysed by 0% and 6.6%, respectively with no lysis for NHB and a range of 1.7% 
to 8.5% for PRP.  PPP had no detectable lysis when rFI, rFXIIIa and/or FIIa were added.   
ANOVA analyses indicated that treatment with proteins alone or in combination 
did not significantly alter lysis in NHB and PPP (p = 0.620 and 0.533); however, there 
were significant changes in PRP (p = 0.025).  t test analyses indicated that PRP samples 
dosed with rFI with FIIa or rFI with rFXIIIa significantly increased the percent lysis (p = 
0.028 and 0.025, respectively).   
 
160 
  
Figure 5.7.  Percent lysis 60 minutes after reaching maximum clot strength of undiluted or diluted 
normal human blood (NHB), platelet rich plasma (PRP) and platelet poor plasma (PPP) alone or 
with the addition of recombinant fibrinogen (rFI), plasma-derived thrombin (pdFIIa) and/or 
recombinant FXIIIa (rFXIIIa).  The bars represent median values and the brackets represent the highest 
and lowest values for 3 subjects.  Samples with no detectable lysis are marked (*).  Statistical significance 
is identified by ‡.  P values were 0.028 for rFI + pdFIIa and 0.025 for rFI + rFXIIIa. 
 
 
Discussion 
The data presented in this chapter indicate that time to clot initiation (R) and 
maximal clot strength (MA) were not significantly altered by 30% haemodilution but 
coagulation time (K) was significantly reduced for NHB.  These findings partially 
support previous research which showed that 29% dilution of citrated human blood with 
lactated Ringer’s solution did not significantly alter time to clot initiation (R), 
coagulation time (K) and maximal clot strength (MA) as measured by TEG.
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the first report of a detailed analysis of results of dilution of PRP and PPP on clotting 
parameters.  Dilution with Ringer’s solution significantly reduced the time to clot 
initiation for PRP and PPP and maximum clot strength for PPP.   
Coagulation time (K) was significantly altered by haemodilution in NHB only.  
Time to clot initiation (R) was significantly reduced for PRP and PPP and although it was 
not statistically significant, 17 of the 22 NHB samples showed reduced times to clot 
initiation (R).  Dilution of NHB reduces the concentration of fibrinogen
15, 16
 and other 
plasma proteins and also decreases platelet
16
 and other cellular components in the blood.  
By reducing cellular components, the viscosity of blood should decrease thereby easing 
the diffusion of coagulation proteins to the clotting site.  However, both PRP and PPP are 
free of red blood cells but neither are significantly different than NHB with regard to time 
to clot initiation.  Consequently, cellular components may not interfere greatly with 
initiation of clots.  Rather, the dilution of plasma proteins may play a greater role.  While 
the reduction in fibrinogen would hinder clotting, dilution also lowers the concentrations 
of anticoagulant proteins which may interfere with the initiation and rate of clot 
formation.  With respect to viscoelastic strength, dilution with Ringer’s solution resulted 
in a significant reduction in PPP only.  This indicates that platelets play an important role 
in creating clot strength.  This could be due to their inclusion in the clot by providing 
surfaces for the fibrin clot but is also certainly related to their release of FXIII which 
crosslinks the fibrin clot creating viscoelastic strength.  Platelets dispersed throughout the 
clot probably hasten
17
 and further stabilize the clot
18
 by releasing additional FXIII.  
Activated platelets play an essential role in the formation of the primary hemostatic plug 
and clot strength
1, 7, 9, 19-21
 because they supply both dimeric FXIII and the majority of 
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FIIa to the wound surface
9, 21, 22
  Research indicates that FXIII in the platelets is necessary 
to obtain optimal crosslinking.
23
   
This study examines the effects of added rFI, rFXIIIa and pdFIIa on fibrin clot 
formation in NHB, PRP or PPP ex vivo.  The fibrinogen concentration was increased by 
50% in each sample to near hyperfibrinogenemic levels.  rFXIIIa and pdFIIa were 
dosed at optimal LFS concentrations determined in the research in the previous chapter.   
Thrombin played the most dominant role in altering time to clot initiation.  
Addition of pdFIIa alone or in combination with one or both of the other proteins to 
NHB, PRP and PPP resulted in significant reductions in clot initiation times (Figure 
5.4).  The coagulation cascade culminates in the activation of large amounts of 
prothrombin to thrombin which is responsible for activating both endogenous and 
exogenous fibrinogen into fibrin and FXIII into FXIIIa.  The lag observed from the start 
of the test and the formation of a clot is related to the rate limiting activation of 
prothrombin to thrombin.  By adding this key enzyme in the active form, the limiting 
step is removed resulting in near instantaneous clot formation.  rFXIIIa added alone did 
not greatly affect time to clot initiation; whereas rFI alone or with rFXIIIa slowed time 
to clot initiation time in PRP and PPP but not NHB.   
FIIa alone or in combination with rFXIIIa significantly prolonged coagulation 
time for NHB and PRP.  rFXIIIa addition without FIIa resulted in slight decreases in 
coagulation time for PPP but not for NHB or PRP.  This indicates that platelets provide 
enough FXIII to maintain normal coagulation kinetics and the absence of FXIII reduces 
the rate of formation of a crosslinked fibrin clot.   
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The addition of FIIa alone or with rFXIII to NHB, PRP or PPP significantly 
reduced clot strength; however, addition of rFI reversed the loss.  FIIa addition results in 
fast initiation of clot formation resulting in a rapid increase in viscosity which reduces 
diffusivity of FXIIIa required to crosslink the fibrin aggregations creating a stronger clot.  
rFI added alone to yield near-hyperfibrinogenemic levels increased clot strength when 
dosed into NHB and PPP.  However, when rFI was added in combination with rFXIIIa it 
only increased clot strength for PPP but not when added to NHB and PRP indicating that 
blood-borne platelets play a large role by providing FXIII.   
The addition of any of the biologics alone or in combination with any of the 
others did not significantly alter clot lysis for NHB or PPP.  Lysis of PRP was 
significantly reduced with the addition of rFI in combination with pdFIIa or rFXIIIa.  The 
addition of excess rFXIIIa in combination with rFI reduces lysis compared to rFI added 
alone because it ensures ample crosslinking of endogenous and exogenous fibrin(ogen).  
The addition of pdFIIa seems to interfere with fibrinolysis components located in plasma.   
These results suggest that rFI and rFXIII in combination with FIIa can be 
combined to create a LFS with equivalent or better kinetic and viscoelastic properties as 
currently available products.  With regard to therapeutic uses, both rFI and rFXIIIa have 
advantages.  rFI dosed in NHB alone did not significantly alter time to clot initiation or 
coagulation time but did increase clot strength.  Consequently, rFI may be useful for 
infusion therapy following haemodilution.  rFXIIIa reduced time to clot initiation slightly 
but did not significantly change clot strength or kinetics; therefore, it may be an effective 
infusion therapy for FXIII deficiency.   
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Chapter 6 
Preliminary in vivo Testing of the Optimized Liquid Fibrin Sealant 
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Abstract 
The research presented in this chapter evaluates the optimal liquid fibrin sealant 
(LFS) consisting of recombinant human fibrinogen (rFI) and recombinant Factor XIII 
(rFXIIIa) in vivo in multiple injury models.  The rLFS was evaluated for its effectiveness 
in aiding hemostasis alone and in presence of a dressing as assessed in femoral 
arteriotomy and multiple liver models in swine.  A 4 mm femoral arteriotomy model 
described previously was used to evaluate the ability of rLFS to aid in hemostasis when 
exposed to arterial pressure and blood flow.  Three liver injury models were also used to 
test the rLFS:  small wedge-shaped resections and Grade V X-shaped stelate liver 
lacerations and liver lobe resections.  This is the first report of the use of a fully-
recombinant LFS used alone or in combination with a bioresorbable dressing.  We also 
designed and tested a prototype airbrush-based spray device for LFS application and 
compared it to a pressurized air canister and the typical dual syringe applicator.  Stelate 
liver lacerations, major lobe resections and some of the larger wedge resections included 
extensive tissue and vascular damage; however, our optimal LFS successfully achieved 
hemostasis in a significant number of the wounds.  LFS applied without the assistance of 
a dressing was able to stop bleeding of oozing wounds or those with small vessels; 
however, a scaffold was needed when wounds contained large vasculature.  Although the 
results presented in this chapter are promising, more research needs to be conducted to 
develop the best LFS application device and dressing that optimizes hemostatic results 
but is not dependent on the experience of the applicator.   
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Introduction 
Trauma deaths are a result of hemorrhage in 37% of civilians
1
 and 47% military 
personnel
2
 and are the primary cause of death for individuals under 44 years of age.
3
  
For the past 2000 years, the same techniques have been used to stop hemorrhage:  
packing with gauze, direct pressure and tourniquet.
4
  This method is inadequate for 
treating severe hemorrhage.  The Department of Defense Combat Casualty Care 
Research Program is focused on developing more effective options for treating 
hemorrhage
5
  and especially desires a hemostatic dressing.
5
   
Fibrin sealants (FS), also known as fibrin glues, are viewed as the best tissue 
sealant
6
 because they are biocompatible,
7-9
 biodegradable
9
 and safe
7
 and are not linked 
to excessive inflammation, immune responses or necrosis.
8, 9
  Because they mimic 
natural clotting mechanisms, FS provide similar functions as endogenous components 
such as creating hemostatic clots
10
 and providing a scaffold for cellular infiltration 
needed to regenerate tissue
10, 11
 and dissolve the clot.
10
  FS, which contain fibrinogen 
(FI), thrombin (FIIa) and calcium chloride and occasionally Factor XIII (FXIII), 
reproduce the final stage of the clotting cascade to aid hemostasis.  FIIa catalyzes the 
conversion of FI to soluble fibrin monomer and FXIII to activated FXIII (FXIIIa).
12-15
  
FXIIIa then catalyzes the formation of the cross-linked, insoluble fibrin clot that is 
melded with the platelet-based, primary hemostatic plug.
14, 16-18
  In addition to binding 
other fibrin molecules and creating the fibrin clot, fibrin adheres the clot to the wound 
by binding to collagen exposed at the site of tissue injury in addition to platelets, 
endothelial and other cells.
7
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To aid in hemostasis, FS can be used alone or in combination with a dressing to 
stop blood oozing which cannot be stopped by suturing.
19
  FS are typically applied by a 
needle and syringe sequentially or simultaneously in a dual-syringe delivery device.
7, 20
  
Devices have also been designed to deliver FS in aerosol form.
7
  While FS have proved 
useful in innumerable surgical procedures, they have their weakness.  When applied to 
wounds with large vascular damage, FS can be diluted or swept away from the injury.
21
  
The use of a scaffold to provide mechanical support and a matrix on which to clot can 
aid hemostasis by FS.  The composition of the dressing is important and the optimal FS-
bandage will include a bioresorbable material that does not require a subsequent 
operation for its removal which may cause hemorrhage in an already over-taxed system.  
Dressings consisting of dry, lyophilized FI and FIIa on different backings (gauze,
22
 
silicone,
4, 23
 and Vicryl
21, 24
) were evaluated in femoral arteriotomy,
22, 23, 25
 ballistic 
injury
4
 and Grade V liver injury
21
 models.  Under normal, hypothermic and 
coagulopathic conditions, these bandages were significantly better than control 
dressings with respect to minimizing blood loss
4, 22, 23, 25
 and maintaining blood 
pressure.
4, 22
  A liquid fibrin sealant (LFS) has also been tested in combination with a 
dressing.  A resorbable polyglycolide felt dressing in combination with a commercial 
LFS successfully sealed air leaks following pulmonary surgery.
26
   
FS function is based on complicated interactions between other pro- and 
anticoagulant proteins, blood cells and vessel surface under flow and viscosity 
conditions;
19
  therefore, our optimized rLFS must be tested in vivo.  Femoral arterial and 
liver injury models in swine are frequently used to evaluate FS efficacy.  Both femoral 
and liver injuries mimic severe wounds that result in hemorrhagic death.  The liver 
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provides a hemostatic challenge because the parenchymal tissue is highly vascularized
19
 
and the vessel is unable to be constricted.
27
  Most hemorrhage requiring reoperation
28
 and 
death from abdominal organ injury is due to liver injury.
29
  Liver injuries that expose 
significant vascularity and extensive parenchymal tissue damage is considered a “Grade 
V” 30 and 50 to 90% result in death.21  To date, these injuries are best treated by packing 
with gauze and closing the abdomen; however, another operative procedure is required to 
remove the gauze.
31-33
  Consequently, a liver injury model is an excellent test of FS.  
While there is some research on FS use in liver, there is need for control trials testing FS 
in liver injury models that compare FS and compression results.
34
   
The objective of the research presented in this chapter was to evaluate our 
optimized rLFS in vivo in multiple injury models.  The rLFS was evaluated for its 
adherence to injured tissue and its effectiveness in aiding hemostasis alone and in 
presence of a bioresorbable dressing as assessed in femoral arteriotomy and multiple 
liver models in swine.  A 4 mm femoral arteriotomy model described previously
23
 was 
used to evaluate the ability of rLFS to aid in hemostasis when exposed to arterial 
pressure and blood flow.  Three liver injury models were also used to test the rLFS:  
small wedge-shaped resections and Grade V X-shaped stelate liver lacerations and large 
lobe resections.  This is the first report of the use of a fully-recombinant LFS used alone 
or in combination with a bioresorbable dressing.  We also designed and tested a 
prototype airbrush-based spray device for LFS application and compared it to a 
pressurized air canister and the typical dual syringe applicator.   
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Materials and Methods 
Materials 
Purified, plasma-derived prothrombin was bought from Enzyme Research 
Laboratories (South Bend, IN).  Recombinant thrombin (Recothrom
®
) was purchased 
from Zymogenetics.  Purified recombinant fibrinogen, expressed in the milk of transgenic 
Swiss Brown cows, was obtained from Pharming Group NV (Leiden, Netherlands).  
Materials for the thromboelastograph were purchased from Haemoscope (Niles, IL).  
Unless otherwise specified, reagents were purchased from Sigma (St. Louis, MO).   
Vector construction, expression and purification of FXIIIA in Pichia pastoris 
The human Ultimate ORF clone containing the human coagulation factor 
FXIIIA1 cDNA in the pENTR
TM
221 vector was purchased from Invitrogen (Carlsbad 
CA). The following primers were used to obtain FXIIIa gene to subclone in pPICZA 
intracellular Pichia expression vector. (Forward, 5'-
CCAATTGATGCATCATCATCATCATCATTCAGAAACTTCCAGGACCGC-3'; 
Reverse, 5'-GCGGCCGCTCACATGGAAGGTCGTCTTTGAATC-3').  The forward 
primer introduced a methionine and 6 histidine amino acids at the N-terminus of mature 
FXIIIa peptide. The PCR product was digested with MfeI and NotI and subcloned into 
pPICZA which was digested with the same enzymes.  The DNA sequence of the FXIIIA 
was confirmed by sequencing the insert fragment. One of the confirming plasmid 
pPICZAFXIIIa was linearized with PmeI and transformed into P. pastoris X-33 host 
strain and copy number of the clones was determined as described.
35
 Varying copy 
number clones were screened in shake flask culture to confirm intracellular production of 
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FXIIIa protein. The highest producing clone was scaled up to 5 L bench scale. A fed-
batch fermentation protocol was followed to optimize FXIIIa production as described by 
Zhang et al., (2007).
36
  At the end of fermentation process the cells were separated by 
centrifugation (6,000g)  and pellet was stored at -80
o
C.   
Frozen cell paste was processed in 300 gram batches.  Cells were lysed in three 
sets of 100 gram batches.  100 grams of cell paste was resuspended in 100 mL of cold 
lysis buffer (50 mM Tris-HCL, 10 mM MgSO4, 1 mM EDTA, 10 mM potassium acetate, 
1 mM DTT (DL-Dithiothreitol), 2 mM PMSF (phenylmethanesulphonylfluoride) in 
methanol, pH 9.5).  100 ml (250 g) of 0.5 mm glass beads (Biospec, Bartlesville, OK) 
were added and the cells.  Surrounded by an ice bath, cells were lysed using a BeadBeater 
Blender (Biospec, Bartlesville, OK) with twenty 20 second on/off cycles.  The cell lysate 
mixture was then centrifuged to remove cellular debris.  The lysate from 300 grams of 
cell paste was combined and purified using the HisBind Purification Kit (EMD 
Chemicals, Inc.,San Diego, CA) with 40 mL of resin slurry.  Following purification, 
rFXIII was dialyzed in 10 mM Tris-HCl, 0.1 mM EDTA, 60 µM polysorbate-20, pH 8.0 
in snake-like dialysis membranes and the protein samples were filter-sterilized and 
concentrated using the Amicon tubes (Millipore, Billerica, MA).  The purity of the 
sample was tested by SDS-PAGE (NuPAGE 12% Bis-Tris) (Invitrogen, Carlsbad, CA) 
and immunoblot.  The concentration of rFXIII was determined by standard Bicinconic 
Acid (BCA) methods.   
FIIa preparation 
Frozen, plasma-derived human prothrombin (Enzyme Research Laboratories, 
South Bend, IN), was thawed at 37
o
C.  Plasma-derived thrombin (Enzyme Research 
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Laboratories, South Bend, IN) was added at a 1/10 mass to mass thrombin/prothrombin 
ratio.  0.35 grams of sodium citrate per milliliter of solution was added (Lanchantin 
1965).  This solution was incubated at 37
o
C on a rotating mixer for five hours.  Sodium 
citrate was removed using PD-10 desalting columns (GE Healthcare, Giles, United 
Kingdom).  Activation of prothrombin to thrombin was confirmed by reducing and 
nonreducing SDS-PAGE (12% Bis-Tris NuPAGE) (Invitrogen, Carlsbad, CA) stained 
with Colloidal Blue (Invitrogen, Carlsbad, CA).  The concentration of the thrombin 
solution was determined by standard Bicinconic Acid (BCA) methods.  The specific 
activity was determined by aPTT analysis.   
Experimental dressings 
Nanofiberous and macrofiberous made from a racemic poly(D,L-lactide) 
(PDLLA) was obtained from LNK Chemsolutions.  The production process and treatment 
of the bandage are proprietary knowledge of LNK.  The nanofiberous PDLLA has fiber 
diameters of approximately 100 nm and is produced as a 100 µm thick sheet.  8-ply 
bandages were created to yield better handling ability by stacking eight 100 µm layers.  
The smooth and hydrophobic unmodified PDLLA was evaluated.  It was also tested after 
coating with a proprietary treatment to create a hydrophilic dressing.  Both the 
hydrophobic and hydrophilic dressings were modified by adding macropores and 
corrugations to assist its hemostatic capability by allowing blood inflow.  Macropores 
were created by punching several sets of holes using a bed of nails device (Figure 6.1).  
Corrugations were also created by wetting the bandage with water until damp and heating 
it between two plates at approximately 32
o
C for 10 minutes to several hours (Figure 6.2).  
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In many of the experiments, these 8-ply modified bandages were stacked in layers with 
the corrugations laid perpendicular to each other (Figure 6.3).   
.   
 
Figure 6.1.  Device and method for perforating the PDLLA dressing.  This bed of nails (A) was used to 
create macropores in the PDLLA.  PDLLA was laid on a thin stainless steel plate containing holes 
matching the bed of nails (B) and the bed of nails was firmly pressed so that the nails transversed the 
PDLLA and embedded in a layer of styrofoam below the plate (C).  After creating the first set of holes (D), 
the PDLLA was removed, placed back on the plate and the bed of nails carefully aligned to create another 
set of macropores.  This device was used three times on each bandage creating a well perforated bandage 
(E).   
 
   
Distance between nails = 6 mm 
A B 
C D E 
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Figure 6.2.  Plates and method employed to corrugate PDLLA.  Two stainless steel plates were 
designed with peak heights of 1.5 mm and a 3 mm distance between peaks (A, B).  These plates were 
heated to approximately 32
o
C and PDLLA dampened with deionized water was placed between the plates 
(C).  The PDLLA was incubated between the heated plates for 10 minutes to several hours to create 
corrugations (D).   
 
 
 
 
Figure 6.3.  Final PDLLA bandage format.  The perforated, corrugated PDLLA was layered so that the 
corrugations were perpendicular to those in adjacent layers. 
 
LFS application devices 
The LFS was tested alone in two liver injury models and with the aid of a scaffold 
(gauze or PDLLA) in a femoral arteriotomy and massive liver resection.  LFS was 
applied to the wounds or the dressing by numerous methods (Figure 6.4).  LFS was 
applied to the wedges by a dual-syringe system made in the operating room (Figure 6.4A) 
A B 
C D 
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and spray device predecessor to UNL’s device (not shown).  LFS was applied to the 
stelate liver lacerations by Tisseel’s Duploject® system (Figure 6.4B) and the PTI spray 
device (Figure 6.4C).  LFS was applied to dressings by pipette or UNL’s airbrush-based 
spray device (Figure 6.4D and E).   
 
Figure 6.4.  LFS application device used during in vivo experiments.  LFS was applied by two syringes 
taped together with needles bent towards each other (A), Tisseel’s® duploject system (B), PTI’s spray 
device (C), frontal (D) and top (E) views of UNL’s airbrush-based spray device.   
 
A spray device was designed to deliver the rLFS in two atomized components at 
finely-adjustable flow rates over a narrow focus area.  The device consists of two 
modified artist-grade airbrushes (single-action, external mix, Paasche airbrushes), a main 
pressure regulator and two fine control pressure regulators.  The airbrushes were 
modified from delivering liquid by suction to a pressurized flow allowing the use of 
lower air flow.  Both regulators pressurizing the solutions to each airbrush was set at 15 
psi.  Each spray device is equipped with adjustable nibs which control the spray pattern, 
flow rate and the amount of material delivered.  The airbrushes were coupled together 
A B 
D C E 
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and a single trigger bar created to synchronize spraying.  The pressure adjustment module 
consists of a main pressure regulator that adjusts the air pressure from house air which is 
coupled to two fine control pressure regulators that modulate the air flow and pressure 
into each airbrush.   
Animals 
This research used crossbred commercial (domestic) swine obtained from UNL 
Agricultural Research and Development Center (Mead, NE).  All procedures performed 
during this research were approved by the Institutional Animal Care and Use Committee 
of the Omaha VA Hospital.  All animals were treated according to the Guide for the Care 
and Use of Laboratory Animals (National Institutes of Health publication 86-23, revised 
1996).   
TEG evaluation of blood samples throughout surgery 
Multiple blood samples were drawn throughout surgery.  Samples were drawn 
before surgery, after surgery and between procedures that resulted in significant blood 
loss.  One to two milliliters of blood were drawn into tubes containing 3.2% sodium 
citrate and stored on ice until testing by thromboelastography (TEG) which occurred 
within five hours.  340 µl of each sample was loaded into a single-use TEG cup followed 
by 20 µl of 200 mM CaCl2 (final concentration:  11.11 mM) to start the reaction.  The 
TEG Analytical Software (version 4.2.2, Haemoscope, Niles, IL) collected the time to 
clot initiation (R), the time to achieve a clot firmness of 20mm (K) and the maximal clot 
strength (MA) for 30 minutes.  Data was exported from the TEG Analytical Software to 
Microsoft Excel for analysis.  t tests with an α of 0.05 were used to compare pre- and 
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post-surgical clotting parameters for statistical significance.  The percent change of TEG 
values from the initial and final blood samples for each pig were calculated.  The 
instrument was calibrated each day of use.  All tests included three replicate samples in 
each treatment group.   
In vivo evaluation of rLFS 
In vivo experiments on the rLFS were performed on 44 male pigs three months of 
age and a mean weight of 32.1 ± 2.2 kg (range:  27.2 and 38.6 kg).  Pigs were 
anesthetized by inhalation through an endotracheal tube.  Under general anesthesia, a 
catheter was inserted into the right carotid artery and jugular vein of each swine for blood 
pressure monitoring and administration of fluid and medication.  Animals were included 
in results only if their systolic blood pressures were greater than 100 mmHg.  Depending 
on the planned experiments, the liver and/or the femoral arteries were exposed.  The 
femoral artery injury model consisted of a 4 mm hole.  A midline laparotomy was 
performed and the liver pulled up through the incision.  Liver injuries included small 
wedge-shaped excisions, X-shaped stelate liver lacerations and large liver lobe resections.  
A Pringle maneuver was used on the stelate liver lacerations and several of the large liver 
resections to minimize blood loss.  After creating the injury, the planned treatment was 
applied.  The LFS was tested alone or in combination with the PDLLA dressing which 
was also evaluated alone and with various modifications.  rLFS was tested alone on 
wedge-shaped liver resections and stelate liver wounds.  rLFS combined with the PDLLA 
dressings was evaluated on femoral arteriotomy injuries and large liver lobe resections.  
Each swine underwent multiple procedures and were euthanized at the end of testing.  
ANOVA and two tail t test (equal variance) analyses were performed to identify 
180 
statistical significance between treatment groups of raw data.  An α of 0.05 was used for 
all statistical analyses.   
rLFS on hepatic wedge resections 
For the small, wedge-shaped liver resections, a cauterization tool was utilized to 
draw the triangular wedge resections with a base of 1 cm and increasing heights of 0.5, 
1.0, 1.5, 2.0, 2.5 and 3.0 cm (Figure 6.5).  Each wedge was resected with scissors.  rLFS 
(9 mg/ml rFI, 0.36 mg/ml rFXIII (2,463 U/ml, rFXIIIa/FI = 0.16), 105.6 U/ml rFIIa 
(FIIa/FI = 0.18), 12 mM CaCl2) was applied by spray device or by two 3 ml syringes 
taped together with needles bent together to mix the solution approximately 2 cm from 
the tips.  The rLFS was separated into two reservoirs: rFI/rFXIII into one and rFIIa/CaCl2 
in the other and applied at an approximate flow rate of 0.4 ml/sec.  A total of 18 mg rFI, 
0.72 mg rFXIIIa and 211.2 U rFIIa was applied to each wedge.  Hemostasis was 
subsequently evaluated and given a score: 1 indicated complete hemostasis; 2 for mostly 
hemostatic with minor oozing; 3 for partially hemostatic with prominent oozing and 4 for 
minimal effect and complete failure.  Ringer’s solution was applied as a control.   
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Figure 6.5.  Wedges marked on a liver lobe by a cauterization tool.  
Wedges with a base of 1.0 cm and increasing heights of 0.5 to 3.0 cm 
marked on a liver lobe by a cauterization tool for testing rLFS. 
 
rLFS on hepatic stelate laceration 
Grade V stelate liver lacerations were created by making one or two overlapping 
X-shaped wounds using a home-made device (Figure 6.6) with an arm length of ~38 cm 
and  X-shaped blades ~8 cm in length.  The injuries were treated in five pigs with rLFS 
(7.1 mg/ml rFI, 0.25 mg/ml rFXIII (1,735 U/ml, rFXIIIa/FI = 0.16), 84.64 U/ml rFIIa 
(FIIa/FI = 0.18), 12 mM CaCl2).  The solution was applied by Tisseel’s Duploject
®
 two-
syringe system (Figure 6.4B). A total of 6 ml were used to treat four pigs and 10 ml to 
treat the other pig.  With this system, the rLFS was applied over 30 seconds to several 
minutes.   
The rLFS was also applied by Propulsion Technology, Inc.’s (PTI) delivery 
device (Figure 6.4C) in three pigs.  The device separates the rLFS into two reservoirs 
(rFI/ CaCl2 and rFXIIIa/rFIIa/CaCl2) and utilizes air pressure for delivery.  This system 
applied 60 ml of rLFS (9 mg/ml rFI, 0.36 mg/ml rFXIII (2,463 U/ml, rFXIIIa/FI = 0.16), 
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105.6 U/ml rFIIa (FIIa/FI = 0.18), 12 mM CaCl2) in approximately 3 to 30 seconds.  
Each stelate liver laceration was treated with 540 mg rFI, 21.6 mg rFXIIIa and 6,336 U 
rFIIa.  Hemostasis was subsequently evaluated.   
In one pig, LFS (10.2 mg/ml rFI, 0.40 mg/ml rFXIII (2,791 U/ml, rFXIIIa/FI = 
0.16), 119.7 U/ml rFIIa (FIIa/FI = 0.18), 12 mM CaCl2) was applied by the initial spray 
device designed by LNK Chemsolutions.  5 ml LFS was applied intermittently over a 
couple of minutes.  The laceration was treated with 51 mg rFI, 2 mg rFXIIIa and 598.5 U 
rFIIa.  Hemostasis was subsequently evaluated.   
 
 
Figure 6.6.  Device used to create stelate liver laceration.  Home-made, stainless steel device designed 
with ~38 cm arms (A) and sharp X-shaped blades (B) to create a ~8 cm x ~8cm wound. 
 
rLFS dressing on femoral arteriotomy model 
rLFS coated nanofiberous and microfiberous PDLLA was evaluated in a femoral 
arteriotomy model.  After exposing both femoral arteries, blood flow through the artery 
was controlled by applying vessel loops or arterial clamps proximal and distal from the 
site of injury.  While blood flow was occluded, a femoral arteriotomy was created with a 
4 mm aortic punch.  The test dressing was carefully laid over the wound and the blood 
was allowed to flow through the artery.  Manual pressure was held on the bandage for 
four to five minutes.  The success of a dressing was evaluated by the level of hemostasis 
(complete hemostasis, oozing or uncontrolled flow) and adherence to the artery.   
A B 
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Bandages constructed of hydrophobic unaltered PDLLA nanofibers (typically 4 
cm x 4 cm, 8-ply) were tested dry, wet with Ringer’s solution or wet with rLFS (0.44 
mg/cm
2
 per ply rFI, 0.02 mg/cm
2
 per ply rFXIIIa (rFXIIIa/rFI = 0.16), 5.07 U/cm
2
 per 
ply FIIa (FIIa/rFI = 0.18), 12 mM CaCl2).  PDLLA coated with Ringer’s solution and 
FIIa (9.32 mg/cm
2
 pdFIIa, 7 mM CaCl2) were also evaluated.  Hydrophilic, modified 
PDLLA dressings were also tested alone and coated with rLFS at the same levels.  
Microfiberous PDLLA bandages (3 cm x 3 cm with a depth of 1 cm) were coated with 
rFI, rFXIII and pdFIIa (3.87 mg/cm
2
 rFI,  0.15 mg/cm
2
 rFXIII, 0.09 mg/cm
2
 pdFIIa, 7 
mM CaCl2) or Ringers solution alone or with pdFIIa (0.09 mg/cm
2
 pdFIIa, 7 mM CaCl2).  
Liquids were applied to the dressings by pipette.   
rLFS dressing on hepatic resections 
The LFS was tested on hepatic resections of multiple sizes.  Small resections 
excised the tip of the lobe exposing a parenchymal area of 5-7 cm by 2 cm.  Excisions of 
medium resections exposed an area of 10-12 cm by 3 cm.  Large resections exposed an 
area of 15-17 cm by 5-6 cm (25-33% of the liver mass).  After removal of the lobe by 
scissors, blood flow was limited by manual pressure or a Pringle maneuver.  Dressings 
were applied to the exposed tissue and held by manual pressure for three minutes.  When 
released, the success was evaluated by the level of hemostasis (1 indicated complete 
hemostasis; 2 for mostly hemostatic with minor oozing; 3 for partially hemostatic with 
prominent oozing and 4 for minimal effect and complete failure).   
Bandages constructed of hydrophilic, PDLLA nanofibers modified with 
macropores, corrugations and roughing of the wound-side (typically 5 cm x 5 cm, 8-ply) 
were tested dry, wet with Ringer’s solution or wet with approximately 0.43 mg/cm2 per 
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ply rFI, 0.02 mg/cm
2
 per ply rFXIIIa (rFXIIIa/rFI = 0.16), 5.07 U/cm
2
 per ply FIIa 
(FIIa/rFI = 0.18), 12 mM CaCl2.  rLFS was applied to the PDLLA by pipette or by 
UNL’s spray device (Figure 6.4D and E).  After being coated with rLFS, the bandages 
were placed on the wound within 2 to 4 seconds and a small amount of blood was 
allowed to flow through the macropores and infiltrate the bandage.  A series of 5 cm x 5 
cm bandages were coated and applied to the wound.  Small resections typically required 
three or four bandages.  Medium and large bandages typically needed five to seven 
coated dressings.  Therefore, small resections used approximately 33 mg rFI, 1.3 mg 
rFXIIIa and 380 U rFIIa.  Medium and large resections used approximately 78 mg rFI, 3 
mg rFXIIIa and 887 U rFIIa.   
 
Results 
Evaluation of swine clotting factors 
Blood samples for each swine were drawn before, during and after surgical 
procedures and evaluated within five hours by thromboelastography (TEG).  This was 
used to identify pigs with abnormal clotting parameters and to monitor changes in 
endogenous coagulation parameters throughout the surgery due to blood loss or 
haemodilution (Table 6.1).  t tests indicated that average pre- and post-surgical clotting 
parameters were not significantly different for time to clot initiation (p = 0.242), 
coagulation time (p = 0.319) or maximum clot strength (p = 0.185).  Consequently, all 
procedures on each swine can typically be included; however, this was determined for 
each individual swine.  A representative TEG tracing is shown (Figure 6.7).  Even after 
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significant blood loss, few post-surgical TEG results differed significantly from initial 
samples.   
 
Table 6.1.  Average time to clot initiation (R), coagulation time (K) and maximum amplitude of pre-
surgical and post-surgical blood samples and the subsequent percent change.  Data presented as 
average ± standard deviation, N = 35 for pre-surigical, 33 for post-surgical and % change. 
 
Time to Clot 
Initiation (sec) 
Coagulation Time 
(sec) 
Maximum Amplitude 
(mm) 
Pre-surgical blood sample 328.71 ± 93.03 100.98 ± 28.58 67.92 ± 4.82 
Post-surgical blood samples 362.60 ± 140.31 109.32 ± 39.36 65.48 ± 9.58 
% Change 0.12 ± 0.32 0.13 ± 0.36 -0.04 ± 0.14 
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Figure 6.7.  Representative TEG tracings of blood samples from a pig before, during and at the 
conclusion of the surgery.  Thromboelastographic comparison of clotting parameters of presurgical 
blood samples from five swine (A); and comparisons of bloods drawn from the same swine throughout 
the surgical procedure (B).   
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LFS on hepatic wedge resections 
The optimized rLFS was applied to wedge resections of the liver with a base of 
1.0 cm and heights from 0.5 to 3.0 cm.  Wedge resections were performed on 16 pigs and 
rLFS was applied by spray device (Figure 6.8) on 9 pigs and the two-syringe system 
(Figure 6.9) on the remaining 7 pigs.   
 
 
Figure 6.8.  Wedge resection treated with rLFS applied by spray-device.  Triangular-shaped wedges 
with bases of 1.0 cm and 0.5 to 3.0 cm heights were resected (A) resulting in profuse bleeding (B) which 
was treated with rLFS applied by a spray-device (C).  This application resulted in complete hemostasis. 
 
 
 
Figure 6.9.  Wedge resection treated with rLFS applied by double barrel syringe.  Triangular-shaped 
wedges with bases of 1.0 cm and 0.5 to 3.0 cm heights were resected resulting in profuse bleeding (A) 
which was treated with rLFS applied by a spray-device (B).  The rLFS created a solid, white clot (C). This 
application resulted in complete hemostasis. 
 
The two application techniques yielded similar results.  ANOVA indicates that 
hemostatic results obtained at different depths are statistically different (p < 0.001).  
A B C 
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Complete hemostasis was achieved most frequently in the smaller wedges (Figure 6.10, 
Table 6.2).  82% of the 0.5 cm height wedge cuts were completely hemostatic while the 
remaining two cuts were mostly hemostatic.  64% of the 1.0 cm height resections were 
mostly hemostatic with the other 5 being completely hemostatic.  At a depth of 1.5 cm, 
27% were completely hemostatic, 45% mostly hemostatic, 18% less hemostatic and 9% 
failed.  At 2.0 cm, 9% were completely hemostatic, 45% were mostly hemostatic and 
45% were less hemostatic.  9% were mostly hemostatic while 91% of 2.5 cm depths 
resulted in minimal hemostasis.  At a depth of 3.0 cm, 75% were minimally hemostatic 
with the remaining 25% resulting in no hemostasis.   
 
 
Figure 6.10.  Frequency of hemostasis scores at each excision depth.  The frequency of complete 
hemostasis (green), mostly hemostatic (blue), less hemostatic (yellow) and minimal effect (red) is shown at 
each excision depth.  
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Table 6.2.  Average hemostasis scores for excision depths.  
Data presented as average ± standard deviation. 
Depth (cm) N Hemostasis Score 
0.5 11 1.18 ± 0.40 
1.0 14 1.64 ± 0.50 
1.5 11 2.09 ± 0.94 
2.0 11 2.36 ± 0.67 
2.5 10 2.90 ± 0.32 
3.0 8 3.25 ± 0.46 
 
The approximate areas of the parenchymal tissue were estimated at each depth 
and volume of LFS needed to create hemostasis estimated (Table 6.3).  This data was 
used to calculate the approximate volume of LFS needed per cm
2
 of tissue injury.  At 
wedge depths of 0.5, 1.0 and 1.5 cm, 5.0, 3.8 and 2.8 ml LFS per cm
2
 is needed to 
typically yield complete hemostasis, respectively.  Consequently, the average volume of 
LFS needed is 3.88 ± 1.09 ml/cm
2
 using 34.9 mg/cm
2
 rFI, 1.4 mg/cm
2
 rFXIIIa and 409.7 
U/cm
2
 rFIIa.  These values are true for wedges with a depth of 1.5 cm or less.  Unlike the 
smaller wedges, the larger wounds contained large blood vessels up to 1 cm in diameter 
(Figure 6.11) that interfered with hemostasis.  The LFS was unable to stop bleeding of 
large vessels.  LFS formed a clot over the large vessels; however, the LFS was unable to 
adhere to the parenchymal tissue surrounding the vessel most likely due to the pressure of 
the blood pouring out of the vessel.  This resulted in significant bleeding from under the 
clotted layer of LFS.   
 
Table 6.3.  Estimated areas of the wound created by the wedge excisions.   
Depth 
(cm) 
Approximate 
Thickness 
(cm) 
Estimated 
Area (cm
2
) 
LFS needed 
for hemostasis 
(ml) 
Estimated LFS 
(ml) per cm
2
 
needed 
0.5 0.3 0.12 0.6 5 
1.0 0.4 0.37 1.4 3.78 
1.5 0.5 0.71 2.0 2.8 
2.0 0.6 1.14 > 2.0  
2.5 0.7 1.68 > 2.0  
3.0 0.8 2.31 > 2.0  
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Figure 6.11.  Sizeable vessel transected in larger wedge resections.  The  
wedges with depths of 2.5 an 3.0 cm typically had sizeable vasculature at the 
apex of the wedge up to 1 cm in diameter.   
 
rLFS on hepatic stelate laceration 
The optimal LFS was tested on grade V stelate liver lacerations in nine pigs 
(Figure 6.12).  The average hemostasis score was calculated based on the number of X-
shaped wounds (Table 6.3).  One X-shaped wound had an average hemostasis score of 
1.50 ± 0.55.  Two X-shaped wounds had an average hemostasis score of 1.67 ± 0.58.  
One X-shaped wound was created in the five pigs treated with LFS applied by Tisseel’s 
Duploject
®
 system. Three of the five resulted in complete hemostasis.  The last two were 
mostly hemostatic with minor oozing that was subsequently stopped by packing with 
gauze and pressure.  Two overlapping X-shaped wounds were created in two of the three 
stelate lacerations treated by PTI’s application device.  The last pig had only one X-
shaped wound created.  After the four to five minute hold, all three were mostly 
hemostatic with minor oozing that was stopped by gauze and pressure.  The one pig 
treated with LFS applied by LNK’s spray device had two overlapping X-shaped wounds 
that was completely hemostatic.   
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Figure 6.12.  Grade 5 stelate liver injury treated with LFS.  Stelate liver laceration before (A) and after 
(B) treatment with 7.05 mg/ml rFI, 0.28 mg/ml rFXIII, 0.16 mg/ml pdFIIa (84.5 U/ml), 6 mM CaCl2 
applied by Duploject system (see Figure 6.5).   
 
Table 6.3.  Average hemostasis scores for number X-shaped 
wounds.  Data presented as average ± standard deviation. 
# X-shaped 
Wounds 
N Hemostasis Score 
1 6 1.50 ± 0.55 
2 3 1.67 ± 0.58 
 
rLFS dressing on femoral arteriotomy model 
Numerous versions of the PDLLA bandage and gauze were tested alone, wet with 
Ringer’s solution and coated in various components of LFS on a 4 mm femoral 
arteriotomy (Figure 6.13) in 13 pigs.  Two forms of PDLLA were tested:  nanofiberous 
(Figure 6.13B) and microfiberous (Figure 6.13C).  The nanofiberous PDLLA was tested 
in its original smooth, hydrophobic form (Figure 6.13B) and in a hydrophilic, modified 
form (Figure 6.3).  Only 14.7% of nanofiberous PDLLA were hemostatic (Figure 6.13D); 
however, 60% of treatments with the microfiberous PDLLA were hemostatic (Figure 
6.13E, Table 6.4).  Four of the five successful nanofiberous PDLLA dressings were 
coated with all of the components of the LFS and were modified with corrugations; 
however, a majority of those treatments failed.  A significantly larger percentage of the 
A B 
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microfiberous PDLLA dressings were successful and the best results were observed when 
treated with rFXIIIa and FIIa and with all components of the LFS.   
 
 
Figure 6.13.  4 mm arteriotomy treated with bandages soaked in LFS.  A 4 mm hole was made in the 
femoral artery (A) and treated with bandages constructed of PDLLA nanofibers (B) and microfibers (C).  
Nanofiberous bandages (4 cm x 4 cm, 8-ply) were coated with rFI, rFXIII and pdFIIa (0.44 mg/cm
2
 per ply 
rFI,  0.02 mg/cm
2
 per ply rFXIII, 0.004 mg/cm
2
 per ply pdFIIa, 7 mM CaCl2) (D).  Microfiberous bandages 
(3 cm x 3 cm with a depth of 1 cm) were coated with rFI, rFXIII and pdFIIa (3.87 mg/cm
2
 rFI,  0.15 
mg/cm
2
 rFXIII, 0.09 mg/cm
2
 pdFIIa, 7 mM CaCl2) (E).   
 
A 
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Table 6.4.  Hemostatic results of PDLLA treated with Ringer’s or various components of LFS 
applied to femoral arteriotomies.   
PDLLA 
form 
Modifications Treatment N 
% 
hemostatic 
Microfiberous None None 10 50 
Microfiberous None Ringer’s 11 64 
Microfiberous None FIIa 4 50 
Microfiberous None rFXIIIa + FIIa 1 100 
Microfiberous None rFI + rFXIIIa + FIIa  4 75 
Nanofiberous None Ringer’s 7 0 
Nanofiberous None FIIa 1 0 
Nanofiberous None rFXIIIa 1 0 
Nanofiberous None rFXIIIa + FIIa 2 0 
Nanofiberous None rFI + rFXIIIa + FIIa 4 0 
Nanofiberous corrugation rFXIII + FIIa 4 0 
Nanofiberous corrugation rFI + rFXIIIa + FIIa 4 50 
Nanofiberous macropores, corrugation None 1 0 
Nanofiberous macropores, corrugation, surface roughing None 1 0 
Nanofiberous macropores, corrugation, surface roughing rFI 2 50 
Nanofiberous macropores, corrugation, surface roughing rFI + rFXIIIa + FIIa 7 29 
 
rLFS dressing on hepatic resections 
Three large hepatic resections were made, covered with gauze and sprayed with 
LFS (Figure 6.14).  All three were completely hemostatic.  Three small, one medium and 
35 large resections were treated with PDLLA alone or coated with LFS (Table 6.5).  
Once the lobe was resected, 5 cm x 5 cm dressings coated with LFS were applied one by 
one to the wound surface.  53.3% of the LFS coated dressings were completely 
hemostatic (Figure 6.15) while 43.3% were mostly hemostatic and the remaining 3.3% 
were less hemostatic.  Some applications successfully adhered to the entire wound 
surface and were not affected by the large vessels (Figure 6.15C); however, pockets 
frequently formed over the largest vessels apparently due to the pressure from the blood 
flow.  The cases that were not completely hemostatic oozed from under the dressing 
apparently from these large vessels.  These had less adhesion then those resulting in 
complete hemostasis.  The method of application of the LFS to the PDLLA did not 
appear to affect the success.   
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Figure 6.14.  Treatment of large hepatic resection with gauze coated with rLFS.  A fatal injury was 
created by removing an ~12 cm long section (A) which was covered with gauze (B) and then rLFS (C).   
 
Table 6.5.  Hemostatic results of PDLLA treated with LFS applied to hepatic resections.  All bandages 
were modified by adding macropores, corrugations and roughing the surface.   
PDLLA 
form 
Size of 
Resection 
Hydrophobicity N 
Completely 
Hemostatic 
Mostly 
Hemostatic 
Less 
Hemostatic 
Failed 
Nanofiberous Small Hydrophobic 1 1 0 0 0 
Nanofiberous Small Hydrophilic 2 2 0 0 0 
Nanofiberous Medium Hydrophobic 1 1 0 0 0 
Nanofiberous Large Hydrophobic 1 1 0 0 0 
Nanofiberous Large Hydrophilic 30 16 13 1 0 
 
 
A B C 
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Figure 6.15.  Treatment of a large hepatic resection with nanofiberous PDLLA coated with rLFS.  
The planned resection, consisting of ~25% of the liver mass, was marked by a cauterization tool (A).  
Following removal, 5 cm x 5 cm nanofiberous PDLLA dressings coated with rLFS were applied to the 
wound and held for 3 minutes under pressure.  When the pressure was removed, the wound was hemostatic 
(B) despite the presence of large vasculature as visualized in the removed portion of the liver (C).  After the 
surgery, the bandage was removed and the level of adherence evaluated.  The adherence was strong enough 
to lift the liver by the bandage (D).  Clot is clearly visible on the surface of the dressing (E).   
 
Dry PDLLA without LFS was also applied to three liver resections resulting in 
complete hemostasis in one and minor oozing in another.  Although these results are 
similar to that achieved with LFS coated PDLLA, the dressings alone were not as 
adhered to the wound as those treated with LFS.  We also applied larger (10 cm x 5 cm) 
rather than multiple small dressings coated with LFS; however, both attempts resulted in 
A B 
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minimal hemostasis.  The large bandages tended to have creases and were difficult to lay 
flat on the wound resulting in tunneling of blood under the dressing.  Consequently, the 
dressings failed to adhere to the tissue.   
 
Discussion 
Our optimal LFS was tested alone and in combination with a PDLLA dressing on 
multiple injury models.  The LFS was effective in stopping bleeding in wedge resections 
with shallow depths but failed in deeper cuts.  Depths of 2.0 or more centimeters 
typically had large vasculature at the apex of the wedge (Figure 6.11).  The LFS 
successfully formed a clot over the large vessels; however, the LFS was unable to adhere 
to the parenchymal tissue surrounding the vessel most likely due to the pressure of the 
blood pouring out of the vessel.  This resulted in significant bleeding from under the 
clotted layer of LFS.  Consequently, LFS can effectively treat oozing tissue and wounds 
containing small vasculature; however, requires a scaffold when large vessels are present.   
Research indicates that the fibrinogen in FS is critical for adhesion and the best 
results are attained at 40 to 70 mg/ml;
8
  however, we achieved good hemostasis with 9 
mg/ml as seen in the stelate liver laceration model (Figure 6.12).  All of the grade V 
stelate lacerations resulted in complete hemostasis or only slight oozing which was 
subsequently stopped by pressure and gauze.  Although all of the treatments were 
considered successful, the best results were achieved with the minimal amount of sealant 
implying that application is the key.  Three of the five resulting in complete hemostasis 
were treated with 6 ml LFS and the one with two X-shaped wounds that ended in 
complete hemostasis was treated with 5 ml LFS.  Three of the four treatments resulting in 
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slight oozing were treated with 60 ml of LFS.  Hence, the Duploject® and spray device 
applicators were significantly better than PTI’s device which mixed large volumes of FS 
in a nozzle. 
Application with the spray device appears to lower the amount of LFS required to 
achieve hemostasis.  This is probably true because the device focuses the application to a 
targeted area, judiciously supplies the proteins, and better mixes the two components of 
the LFS.  The spray device was designed for possible uses such as: 
1. treating wounds not containing major blood vessels; 
2. coating the PDLLA dressing with LFS immediately prior to application; 
3. applying LFS to the top of a wound already covered with PDLLA;  
4. precoating the wound prior to mesh application.   
The spray device has two chambers that keep the rFI/rFXIIIa solution separate from the 
rFIIa solution until application and can administer as little as 0.5 ml volumes of LFS.  Its 
efficiency is a result of the spray pattern which focuses the spray to a 1 to 3 cm diameter 
target area without spurious atomization and thoroughly mixes the clotting factors for 
immediate clot formation.   
Our bioengineering paradigm for bandage design focuses on the use of a 
resorbable mesh to efficiently deliver expensive clotting factors.  The use of a dressing in 
combination with the LFS shifts the burden of the mechanical stabilization of the wound 
surface to the mesh.  Hence, the dressing material withstands the pressure from blood 
flow while exogenous and endogenous clotting factors need only adhere the dressing to 
the wound.  Macropores, corrugations and roughing of the surface of the PDLLA 
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dressing were performed in an attempt to enlist endogenous factors in the blood as 
additional support for the LFS by allowing it to intercolate into the bandage material.   
The modifications to the PDLLA are designed to mimic the ability of surgical 
cotton gauze to intercolate endogenous blood to gain adhesion.  This was done by 
imparting a corrugated and perforated structure to the PDLLA nanofibrous mesh which 
resulted in the necessary macroporous interstitial space for sufficient blood clot 
intercolation to achieve adhesion. This was done without increasing the mass of PDLLA 
mesh.  Cotton gauze macroporosity arises from microfilamentous structure and not only 
has the deficiency of not being resorbable, but has a material mass that is not affordable 
when translated directly to a PDLLA microfibrous equivalent.   
A dressing consisting of dry, lyophilized FI and FIIa on a different backings was 
evaluated in a femoral arteriotomy (6 mg/cm
2
 pdFI, 50 U/cm
2
 pdFIIa),
22
 ballistic injury 
(10.29 mg/cm
2
 pdFI, 28.57 U/cm
2
 pdFIIa, 2.5 mg/cm
2
)
4
 and Grade V liver injury (15 
mg/cm
2
 pdFI, 37.5 U/cm
2
 pdFIIa, 117 µg/cm
2
)
21
 models.  Under normal, hypothermic 
and coagulopathic conditions, this bandage was significantly better than gauze with 
respect to minimizing blood loss and maintaining blood pressure.
4, 22
  We have 
significantly reduced the protein levels on the PDLLA making the dressing more 
economically feasible.  Compared to the grade V liver injury, our LFS contains 97% 
less FI  (0.43 mg/cm
2
) and 90% less FIIa (5.07 U/cm
2
).  Despite significantly reducing 
the protein content, our LFS successfully aided hemostasis in grade V liver injuries.   
Jackson et al. coated a silicone backing with a lyophilized FS which proved 
significantly more successful in creating hemostasis than the control dressing in a 4 mm 
femoral arteriotomy model in pigs.  Five of six wounds resulted in complete hemostasis 
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in 15 minutes compared to none of the controls after 60 minutes.
23
  Our LFS coated 
dressing failed to achieve this success.  The modified nanofiberous PDLLA succeeded 
in only 29% of the treatments; however, the microfiberous PDLLA successfully 
resulted in hemostasis in 75% of treatments.  These results were achieved after a five 
minute hold compared to the 15 minutes in the previous study.  We believe our low 
success rate is due to the limited cross-sectional area for adhesion of bandage.  This was 
supported by our success in achieving hemostasis in large liver resections.   
Our success rate significantly increased when treating larger surface areas with 
LFS coated nanofiberous PDLLA despite the existence of vessels up to 1 cm in 
diameter.  53.3% of treatments were completely hemostatic and 43.3% mostly 
hemostatic after a 3 minute hold; however, if pressure was held for 15 minutes, many of 
the mostly hemostatic results may have been upgraded.  The success appeared to be 
highly dependent on the application technique in large liver laceration.  The best results 
were achieved when a slight amount of blood was allowed to flow through the bandage 
and pressure was held over the entire length of the wound to ensure adhesion especially 
around the large blood vessels.  Practice typically resulted in better results.  When 
pressure was not held directly over the wound, pockets of blood would form under the 
bandage.  These pockets were frequently hemostatic; however, they typically resulted in 
lower adhesion of the bandage to the wound.  The treatments that continued to ooze 
were frequently linked to the lifting of the bandage by the blood flow from a major 
vessel.   
Our aim is to create a FS dressing that works under various conditions by 
untrained personnel; therefore, more work needs to be done to lessen the effect of 
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application technique.  Despite the unreliable performance, 97% of the applications 
yielded complete or mostly hemostatic results on a lethal injury.  Those rated as mostly 
hemostatic were rendered completely hemostatic by applying pressure and gauze or a 
second application of LFS coated PDLLA.  One application of LFS coated PDLLA on a 
large resection resulted in complete hemostasis without holding pressure.   
Previous research indicates that efficacy of FS depend on the surgical situation 
and the method and speed of application is critical for success.
37
  Our research supports 
these conclusions.  While our LFS alone could successfully achieve hemostasis in some 
wounds, it required a scaffold in wounds with major vasculature.  Our LFS coated 
dressings were extremely successful in treating grade V hepatic resections; however, was 
less effective when treating 4 mm femoral arteriotomies.  As previously described, the 
application technique significantly affects results and once the PDLLA is coated with the 
mixed solutions it must be applied quickly before the LFS clots.  Our future objective is 
to minimize these limitations.   
Like the LFS, the PDLLA bandage is early in its design stage.  The dressing was 
designed to provide a strong matrix so that for larger wounds the bandage provides the 
necessary strength to withstand blood pressure while the LFS stops bleeding through the 
pores of the bandage and glues the bandage to the wound.  It was also designed to 
encourage tissue regeneration with respect to cell migration and proliferation.  Details 
regarding the design of the bandage including manufacturing process, fiber features, pore 
sizes and pre-treatments of the material to make it more hydrophilic are proprietary 
knowledge of LNK Chemsolutions.  The degradation rate of the matrix after implantation 
has not yet been determined; however, it is estimated to be removed within 30 to 60 days.  
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Future studies will include detailed evaluation of (1) the interaction of the LFS and 
bandage fibers at the molecular level; (2) the degradation/dissolution rate of the bandage 
material in vivo and effects of byproducts which are anticipated as being minimal; and (3) 
the rate of remodeling of tissue on the LFS/PDLLA matrix.   
The research presented in this chapter is the first report of the use of a fully-
recombinant LFS used alone or in combination with a bioresorbable dressing.  We also 
designed and tested a prototype airbrush-based spray device for LFS application and 
compared it to a pressurized air canister and the typical dual syringe applicator.  Stelate 
liver lacerations, major lobe resections and some of the larger wedge resections included 
extensive tissue and vascular damage; however, our optimal LFS successfully achieved 
hemostasis in a significant number of the wounds.  LFS applied without the assistance of 
a dressing was able to stop bleeding of oozing wounds or those with small vessels; 
however, a scaffold was needed when wounds contained large vasculature.  Although the 
results presented in this chapter are promising, more research needs to be conducted to 
develop the best LFS application device and dressing that optimizes hemostatic results 
but is not dependent on the experience of the applicator.   
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Abstract 
Recombinant factor VIII (rFVIII) therapy for Hemophilia A has proven to be safe 
and efficacious. However, rFVIII is produced by mammalian cell culture at low levels 
similar to blood plasma which cannot satisfy the future global demand for prophylactic 
and other optimal therapies.  The milk of transgenic livestock may be the most cost 
effective and prodigious production vehicle for achieving that future goal. Prior to this 
study, FVIII expressed in mouse, rabbit, and pig milks was largely inactive.  For the first 
time, we report the expression of a bioengineered FVIII together with von Willebrand 
Factor (vWF) in milk (FVIII-tg). FVIII-tg was produced by the mammary gland at >600-
fold higher activity levels than human plasma and >450-fold higher than reported for cell 
culture.  FVIII-tg had biological activity similar to commercial rFVIII and showed 
similar binding avidity to plasma-derived vWF which is a prerequisite for stability when 
in circulation. The intravenous infusion of immunopurified FVIII-tg rendered normal 
hemostasis to hemophilia A mice in response to tail transection. Importantly, this work in 
transgenic mice serves as a basis for the translational development of rFVIII produced by 
transgenic pigs.   
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Introduction 
Hemophilia A is an X-linked, inherited disorder of blood coagulation primarily 
caused by deficiency or dysfunction of factor VIII (FVIII) that affects approximately one 
in every 5,000-10,000 males.
1-3
 Currently, hemophilic patients are treated with 
intravenous infusion of highly purified FVIII concentrates derived from donor human 
plasma or a variety of recombinantly-derived FVIII (rFVIII) produced by animal cells 
such as Chinese hamster ovary (CHO) cells in large scale bioreactors.
4-6
  Aggressive 
prophylactic FVIII replacement therapy reduces hemarthroses
7
 and this has become the 
standard of care for the management of pediatric patients with severe hemophilia and is 
now also showing benefits in adult patients.  However, to achieve this level of 
prophylactic replacement therapy requires greater than $100,000 USD per patient per 
year.
8
  Despite the clear benefits of prophylactic therapy in this population, 80% of the 
world hemophilia population does not receive adequate access to replacement therapy.  
Many factors contribute to this, but a lack of abundance and associated costs of current 
production of plasma-derived FVIII and rFVIII concentrates, preclude the application of 
universal prophylactic treatment of hemophilia A in even the most economically 
developed countries and routine access in developing countries.
1, 4, 5
  
The commercial manufacturing of FVIII from blood plasma and rFVIII from 
animal cell culture are both greatly and similarly inefficient. This is primarily due to 
limitations in the biosynthetic pathway of rFVIII which have been well detailed in 
mammalian expression systems.
9-11
  This pathway is inhibited at transcription,
12-14
 post-
translational modification and translocation from the endoplasmic reticulum to the Golgi 
apparatus.
9, 15
 While wild-type (WT)-FVIII is expressed in animal cell culture at <1 
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unit/ml, the co-expression of von Willebrand Factor (vWF) greatly stabilizes and 
increases the accumulation of secreted WT-FVIII activity and is commercially used to 
produce rFVIII.  Alternatively, we and others have previously reported on the ability of 
the mammary gland to express rFVIII in the milk of transgenic mice,
16
 rabbits,
17, 18
 
sheep
19
 and pigs
20
 (Table 7.1). Using milk avails the mammary gland’s high cell density 
of about 10
9 
epithelial cells per ml of luminal volume relative to the much lower 5 x 10
6
 
animal cells per ml of the classical bioreactor 
21
.  However, while WT-FVIII was made in 
milk at 600-fold greater concentration than blood plasma or animal cell culture, the 
specific activity of the rFVIII was very low at about 2 to 10% of expected.
16, 17, 20
 
Analysis suggests that the markedly reduced specific activity was a consequence of the 
instability of rFVIII expressed in milk, especially in the absence of vWF.  
 
Table 7.1.  A comparison of expression levels and activity of WT-FVIII made in plasma, 
cell culture and milk of transgenic animals. 
Source* 
WT-FVIII 
Concentration 
(μg/ml) 
Activity Level 
(IU/ml) 
Specific Activity 
(IU/mg) 
Human plasma
3
 0.2 1 5,000 
    
COS-1 in cell culture
10
 0.026 0.125 4,800 
Dual vWF/FVIII transfected CHO 
cell culture  
N/A 1.397
9
 >4,000
22
 
    
Milk of Transgenic Mice
16
 50.21 13.41 267 
Milk of Transgenic Rabbits
17
 117 0.521 4.5 
Milk of Transgenic Pigs
20
 2.66 0.62 233 
Milk of Transgenic Sheep
19
 0.006 N/A N/A 
* The highest expression levels of WT-FVIII reported from references provided.  N/A: not available.   
 
As a fundamental precursor to large-scale production in transgenic livestock, we 
show for the first time that fully biologically active, single chain rFVIII can be secreted 
into the milk of transgenic mice while at >450-fold activity levels than previously 
reported with WT-FVIII in animal cell culture. First, we utilized a novel bioengineered 
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form of rFVIII with demonstrated high secretion efficiency (226/N6) yielding >10-fold 
improved expression over B domain-deleted FVIII and WT-FVIII.
15
.  This particular 
form of rFVIII is expressed in mammalian cells as a single chain molecule with high 
efficiency due to improved mRNA expression, improved ER-Golgi transport, and 
reduced cellular ER stress.
23
  Secondly, we further enhanced the stability of FVIII within 
the milk environment by co-expression of vWF and alpha-1 antitrypsin (AAT).  This is 
the first report of FVIII and vWF coexpression in transgenic animals. 
 
Materials and Methods 
DNA constructs 
The WAP7FVIII 226/N6 construct was assembled by altering the Kpn I site of 
pUCWAP6
24
 by the addition of linkers that introduced a Sal I site immediately 
downstream of the 4.1 kbp WAP (whey acidic protein) promoter and in front of 1.7 kbp 
of mouse WAP 3’ UTR that contains the coding of the polyadenylation signal to produce 
pUCWAP7. The sequence for 226/N6 was removed by restriction enzyme digest using 
Sal I and Xho I from pMT2226/N6 described previously.
15
  This fragment was introduced 
into the Sal I site of pUCWAP7 and ligated.  The resulting plasmid, pUCWAP7FVIII-
226/N6, was digested with Not I to release the expression construct (WAP7FVIII-
226/N6) that was separated by agarose gel electrophoresis.  
The plasmid pUCWAP6vWF containing the WAP6vWF expression construct was 
a gift from Dr. Henryk Lubon, (American Red Cross, Rockville, MD).  This plasmid 
contained the cDNA for vWF placed between the 4.1 kbp WAP promoter and the 1.7 kbp 
3’UTR.  Removal of the WAP6vWF expression construct was achieved by digesting the 
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plasmid with Not I and Sfi I followed by agarose gel electrophoresis.  The plasmid 
designated PPL456 containing the BLG (beta lactoglobulin) driven AAT construct was a 
kind gift from Dr. David Ayares (Revivicor, Blacksburg, Virginia).  This construct has 
been previously described in detail.
25
  The expression construct (BLG-AAT) was 
removed from plasmid elements by digest with restriction enzymes Not I and Sal I 
followed by agarose gel electrophoresis.  All released fragments were purified by 
extraction prior to microinjection using a Nucleospin Extract kit (Clonetech Laboratories, 
Inc. Palo Alto, CA). 
Generation and identification of transgenic mice 
Transgenic mice were generated by pronuclear microinjection of purified DNA 
constructs through the Transgenic Core facility at the University of Michigan.  Briefly, 
purified DNA was microinjected into fertilized eggs obtained by mating (C57BL/6 x 
SJL)F1 or C57BL/6 female mice with (C57BL/6 x SJL)F1 male mice.  Pronuclear 
microinjection was performed as previously described.
26
  PCR primer pairs were:  for 
WAP7FVIII-226/N6, WAPS2 (ctgtgtggccaagaaggaagtttg)/FVIIIA2 
(ccttggcttagcgatgttga); for WAP6vWF, WAP150 (gctctctctgtgtggccaag)/vWFA1 
(ttccttctgcacaaagggtc); for AAT construct, BLG-S1 (ctggctctgacctgtccttg)/AATa1 
(atcgtgagtgtcagccttgg).   
Southern analysis was performed on select mice to confirm PCR results and 
evaluate transgene ratio and copy number.  Mouse DNA (10 μg) was digested with EcoRI 
and Hind III and subjected to agarose gel electrophoresis.  Probes were produced by 
biotin incorporation via PCR using the KPL Detector DNA biotinylation kit (KPL, Inc. 
Gaithersburg, Maryland).  PCR primers are as follows:  for WAP, WAPprobeS1 
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(gcatgctcacactcaacagg)/ WAPprobeA1 (taagagtgtggaggcgcttg);  for AAT, same primers 
as for PCR, BLG-S1/AAT-A1. Size of each probe is approximately 500 bp.  Blocking 
and detection was performed per manufacturer’s instructions using a KPL Detector AP 
chemiluminescent blotting kit followed by exposure to film.  
Mouse milk collection and preparation 
Milk collection was done as previously described
26
. Briefly, naturally lactating 
females were separated from their pups for a period of 1 to 3 hours, then anesthetized 
with 0.2 to 0.4 ml of Avertin given IP.  After becoming anesthetized, animals were then 
given 2 IU of oxytocin IM in the hind leg.  After 30 seconds each gland was massaged to 
express milk then milk was collected into a 1.5 ml microcentrifuge tube by vacuum 
aspiration through a small heat-polished glass capillary tube. Samples were stored at -
70
o
C. 
Factor VIII Biochemical Analysis 
Samples were thawed at 37 
0
C, immediately placed on ice, diluted 1:10 using PBS 
buffer and centrifuged at 10,000 rpm for 10 minutes. The upper lipid layer was removed 
and the supernatant analyzed. FVIII ELISA was purchased from Affinity Biologicals Inc. 
(Ancaster, ON, Canada). FVIII deficient plasmas and FACT (normal human pooled 
plasma) were purchased from George King Bio-Medical Inc. (Overland Park, Kansas).   
FVIII activity was measured by 1) one-stage aPTT clotting assay on an MLA Electra 750 
fibrinometer by reconstitution of human FVIII-deficient plasma or 2) by modified two-
stage assay utilizing the COAMATIC Factor VIII (Chromogenix, Milano, Italy) 
according to the manufacturer’s instructions. The ELISA activity assay standard curves 
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assumed a FVIII concentration of 200 ng/mL antigen (1 IU/mL) of activity. The ELISA 
assays on milk samples were sensitive to 0.02 μg FVIII/ml. Chromogenic FVIII activity 
measurements were sensitive to 0.05 IU/ml in milk.    
Immunoaffinity chromatography purification of FVIII from transgenic mouse milk 
Supernatant of pretreated milk samples were pooled and passed through a 0.2 um 
filter. After incubating transgenic mouse milk (diluted to 50 ml with TBS) with F8-
conjugated sepharose beads overnight, the sample and beads were packed into a 50 
ml/1.5  cm diameter column. The purification procedure was carried out according to the 
protocol described previously.
27
 226/N6-CHO protein was purified from stably-
transfected Chinese hamster ovary (CHO) cell lines as described previously.
15
 
Western Blots  
Nonreduced and reduced samples were evaluated by sodium dodecyl sulfate 
polyacrylamide (SDS-PAGE) gel electrophoresis on 4-12% NuPage
®
 Bis-Tris gels 
(Invitrogen Carlsbad, CA).  Blots were probed for FVIII with a sheep anti-human FVIII 
polyclonal antibody (USBiological, F0016-10, Swampscott, MA) primary antibody and a 
donkey anti-sheep IgG peroxidase conjugate secondary antibody (Sigma, A3415, St. 
Louis, MO).  Blots were probed for vWF with a goat anti-human vWF peroxidase 
conjugated polyclonal antibody (USBiological, V2700-04B, Swampscott, MA).  Blots 
were probed for AAT with a rabbit anti-human α1-antitrypsin polyclonal antibody 
(USBiological, A2298-27H, Swampscott, MA) primary antibody and a goat anti-rabbit 
IgG peroxidase conjugate secondary antibody (Sigma, A9169, St. Louis, MO).   
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FVIII-vWF binding ELISA 
Immulon 4HBX plates (Fisher Scientific, Pittsburgh, PA) were coated with anti-
FVIII antibody (F8C-EIA-C, Affinity Biologicals) overnight at 4
0
C diluted 1:100 in 0.05 
M sodium carbonate/bicarbonate, pH 9.6. Protein samples were diluted in TBST (50 mM 
Tris-HCl, pH 7.6, 150 mM  NaCl, 0.05% Tween 20), 3% BSA, 1% FVIII-deficient 
human plasma(George King Bio-Medical) in 1.5 mL microcentrifuge tubes, and 
incubated for 2 hours at 37
0
C.  Wells were washed with TBST containing 10mM CaCl2 
four times. Samples were loaded into wells and incubated for 2 hours. Wells were washed 
four times, and anti-vWF antibody conjugated with HRP (p0266, Dako, Carpenteria, CA) 
was diluted 1:1000 with TBST, and incubated for 2 hours at 37
0
C or overnight at 4
0
C.  
After four washes with TBST with 10mM CaCl2, O-phenylenediamine dihydrochloride 
substrate  (SIGMAFAST OPD, Sigma) was added and the reaction was stopped by 2.5 M 
H2SO4. Absorbance was read at 490 nm.  
In vivo tail clip assay in the hemophilia A mouse 
Hemophilia A mice (exon 16 knockout)
28
 were subjected to a tail clip bleeding 
assay. Mice of at least 10 weeks age were injected with purified FVIII proteins 226/N6-tg 
or 226/N6-CHO-FVIII.  C57BL/6 and hemophilia A mice littermates were used as 
controls for injection with lactated Ringer’s solution.  Mice were injected with 80IU/kg 
body weight of the FVIII proteins in 100 μl lactated Ringer’s solution via tail vein. 
Ketamine 85 mg/kg with xylazine 5 mg/kg was injected IP to induce anesthesia. After 5 
minutes, the tails of mice were cut 1.5 mm from tail tips. The tails were then immediately 
submerged into 14 ml conical tubes filled with saline at 37
0
C. Blood from the tail was 
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collected 10 minutes. Weights of the tubes at time 0 and 10 minutes were measured and 
the difference used to quantify blood lost. Mice were euthanized after the procedure. 
 
Results 
Identification and expansion of transgenic lineages    
The aim of this study was to characterize the properties of single chain rFVIII 
made in the milk of the highest expressing lineages prior to trialing in transgenic pigs.  In 
particular, we have assessed the secretion limitations, biological activity and stability of 
226/N6 in milk.  We focused our lineage expansion on a single trigenic and two bigenic 
lineages which expressed 226/N6-tg at 100-fold higher levels than other lineages: bigenic 
for 226/N6 and AAT (875 and 406) and trigenic for 226/N6, AAT and vWF (415).  
Transgenic mouse lineages were detected by Southern analysis after screening DNA 
isolated from tail biopsy using PCR.  Figure 7.1A shows the schematics for the three 
constructs used: WAP7FVIII-226/N6, WAP6vWF, and BLG-AAT. The PCR 5’ and 3’ 
oligonucleotide primer sites and restriction endonuclease cleavage sites used for Southern 
analysis are indicated.  Most mono-, bi- and trigenic lineages contained multiple copies 
of the FVIII, and/or VWF, and/or AAT transgenes, respectively.   A typical Southern 
Blot used to simultaneously detect and ascertain the copy number of the WAP7FVIII-
226/N6 and WAPvWF transgenes is shown in Figure 7.1B. The probe DNA was derived 
from the mouse WAP promoter and was designed to detect not only the FVIII and vWF 
transgenes but also the endogenous WAP gene as an internal standard present at two 
copies per mouse genome.  For example, band sizes were present in the DNA of trigenic 
415 mice (Lane 3) corresponding to 10 copies of the 2.4 kbp WAP72FVIII-226/N6, and 3 
215 
copies of the 4.5 kbp WAP6vWF relative to the 7.2 kbp endogenous WAP gene. The 
presence of the BLG-AAT transgene was confirmed by the use of the BLG-AAT cross 
junction probe (separate Southern analysis, data not shown).  All lineages studied 
contained greater than one copy of BLG-AAT transgene per genome. The estimated copy 
numbers for the highest 226/N6-tg expressers of bigenic mouse lineages were:  2 and 4 
copies of WAP7FVIII-226/N6 for Line 406 (Lane 1) and Line 875 (Lane 3), respectively 
and >1 copy for BLG-AAT.  In each lineage, the BLG-AAT transgene was likely co-
integrated into the same chromosomal loci along with WAP7FVIII-226/N6 as evidenced 
by the Mendelian co-transmission of both transgenes through F1 and F2 generations that 
were made by out breeding with wild-type mice (data not shown).  
216 
 
 
Figure 7.1.  Transgene construction schematics and Southern analysis for 226/N6, vWF, and AAT.  
(A) Schematics for transgenic constructs WAP7FVIII-226/N6, WAP6vWF and BLG-AAT are presented.  
Restriction sites (vertical arrows) used for Southern analysis and oligomeric DNA primer binding 
hybridization sites (horizontal lines and arrows) used for PCR detection of the transgenes are shown.  (B) 
Isolated genomic mouse DNA from three highest 226/N6 expressing lineages was digested with 
EcoRI/Hind III and probed with a WAP promoter probe.   Expected fragments sizes are:  WAP7FVIII-
226/N6: 2.4 kbp; WAP6vWF: 4.5 kbp; and endogenous mouse WAP gene: 7.2 kbp.  Sample loading is as 
follows:  M = molecular weight marker, lane 1-4, 406 mouse (bigenic for 226/N6 and AAT), 415 mouse  
(trigenic for 226/N6, vWF and AAT), 875 mouse  (bigenic for 226/N6 and AAT) and non-transgenic 
control. Reference DNAs: column V = 50 copies/genome WAP6vWF, column F = 50 copies of 
WAP7FVIII 226/N6 and column A = 50 copies of BLG-AAT.  Molecular weight markers are listed on the 
left and restriction digest product band designation is on the right: band eWAP = endogenous mouse WAP 
gene; vWF = WAP6vWF; FVIII = WAP7FVIII-226/N6. 
A B 
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Coexpression of 226/N6-tg, vWF-tg and AAT-tg in trigenic mouse milk 
We used comparative Western blot analysis of SDS-PAGE under non- and 
reducing conditions to determine the extent of complexation and underlying proteolysis, 
respectively. Reducing conditions disrupt both FVIII-vWF complexes and the disulfide 
bridges linking vWF subunits.  Reduced Western blots probed with anti-human FVIII 
polyclonal antibody are shown in Figure 7.2A. Commercial rFVIII (Recombinate, Baxter, 
Deerfield, IL) (Lane 2) shows typical heterogeneity due to proteolytic fragmentation of 
the B domain resulting in variably sized heavy chains of Mr 120 to 180 kDa.  In contrast, 
plasma-derived FVIII-vWF complex (CSL Behring, King of Prussia, PA) (Lane 3) shows 
less FVIII proteolysis and has a predominant species of Mr 280 kDa.  A sample pool from 
milks collected on different days from the highest expressing trigenic mouse lineage 
(415; Lane 4) shows a predominant species at Mr 190 kDa and lesser species at about Mr 
140 kDa. The theoretical molecular weight of 226/N6 is about 190 kDa. Samples from 
the highest expressing bigenic 226/N6-tg:AAT-tg mice showed a similar profile to Lane 
4 (data not shown). The non-transgenic mouse milk pool (Lane 5) shows no signal.   
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Figure 7.2.  226/N6-tg is complexed with vWF-tg in transgenic mouse milk.  Assessment of vWF 
binding by analyzing (A) reduced anti-FVIII, (B) reduced anti-vWF, (C) non-reduced anti-FVIII, 
and (D) non-reduced anti-vWF Western Blots.  All blots contain a molecular weight marker (lane 1), 
Commercial rFVIII (lane 2), commercial pd-FVIII:vWF concentrate (lane 3), 226/N6-tg mouse milk (lane 
4), non-transgenic mouse milk (lane 5). A non-reduced anti-FVIII Western Blot was performed to analyze 
nonspecific binding of mouse milk proteins to 226/N6-tg and immunopurified 226/N6-CHO (E): molecular 
weight marker (lane 1), 226/N6-CHO (lane 2), non-transgenic mouse milk (lane 3),  226/N6-CHO added to 
non-transgenic mouse milk (lane 4), and 226/N6-tg:vWF-tg trigenic mouse milk (lane 5). 
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Anti-vWF Western analysis under reducing conditions is shown in  
Figure 7.2B.  No vWF signal is observed in the rFVIII and non-transgenic mouse milk 
pool (Lanes 2 and 5, respectively). The reference plasma-derived FVIII-vWF concentrate 
shows a sharp, single band signal at about Mr  270 kDa (Lane 3) consistent with all VWF 
species existing as monomeric units that are disassociated from FVIII under reducing 
conditions.  The trigenic milk pool sample shows a similarly strong band at about Mr  270 
kDa (Lane 4). The approximate stoichiometric ratio of 226/N6-tg to vWF-tg subunits in 
the milk of trigenic lineage 415, as evidenced by Western blot, was estimated to be about 
1:1. This in turn was further corroborated by FVIII (Table 7.2) and vWF ELISA (data not 
shown) quantitation. 
 
Table 7.2.  ELISA, 2-stage activity assay, and specific activity data on mono-, bi- and trigenic mice. 
226/N6 Source Mouse ID 
226/N6 
Concentration 
(μg/ml) 
Activity 
Level 
(IU/ml) 
Specific 
Activity 
(IU/mg) 
Monogenic mice:  226/N6     
 1960-1702 0.144 0.621 4,313 
 1926-1742 0.093 0.121 1,301 
 46-1247 0.066 0.392 5,939 
Bigenic mice:  226/N6-AAT     
 875-234 34 25 735 
 875-233 6.2 44 7,097 
 516-45 7.3 13 1,781 
 406-128-10 83 122 1,470 
Trigenic mice:  226/N6-vWF-AAT     
 415-101-2 183 678 3,705 
 415-101-1-2 14.5 555 4,549 
 
Presence of FVIII-vWF complexes in trigenic mouse milk. 
This is the first report of vWF being co-expressed with FVIII in milk and also the 
first study of vWF complexation with 226/N6. Based upon the stability introduced to 
rFVIII by rvWF in cell culture,
29
 we sought a similar effect on FVIII in milk. We found 
that native, plasma-derived FVIII:VWF complexes exist within monomeric and higher 
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molecular weight vWF species under non-reducing, SDS-treatment conditions.  Similar 
to plasma-derived vWF, vWF-tg is expressed in milk as monomers and also higher 
molecular weight species that likely represent multimers consisting of monomers linked 
by disulfide bridges.  For example, Western analysis for FVIII-VWF concentrate shows 
FVIII and vWF band signals within a similar Mr range that are both >420 kDa (Figure 
7.2, lanes 3 of Panels C and D, respectively) due to co-migration caused by the 
complexes.  Conversely, the reference commercial rFVIII that is devoid of vWF has a 
similarly broad pattern as occurs under reducing conditions with an upper Mr limit less 
than 280 kDa (Figure 7.2, Panel C, Lane 2).  Congruently, rFVIII shows no signal for 
vWF (Figure 7.2, Panel D, Lane 2).  The trigenic mouse milk pool shows a predominant 
band near Mr  420 kDa and another minor band at a much higher Mr   (Figure 7.2, Panel 
D, Lane 4) that is similar to the reference plasma-derived FVIII-vWF concentrate (Figure 
7.2, Panel D, Lane 3).  This is consistent with a major population of 226/N6-tg 
complexed with monomeric vWF-tg at Mr  450 kDa and a higher band due to complexing 
with multimeric vWF-tg species. The high avidity of this complex is underscored by the 
apparent absence of free 226/N6-tg under these conditions.    
We did not observe nonspecific binding of milk proteins with 226/N6-tg in 
transgenic milk or with 226/N6-CHO added to control mouse milk by using non-reduced 
Western analysis (Figure 7.2, Panel E). Immunopurified 226/N6-CHO was made in CHO 
cells without co-expression of vWF and it migrates as a single band at Mr 190 kDa (Lane 
2). When incubated with non-transgenic mouse milk, 226/N6-CHO still consisted of a 
single band at 190 kDa (Lane 4).  This suggests that it does not form strong complexes 
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with endogenous mouse milk proteins as does 226/N6-tg with coexpressed vWF (Lane 
5).   
Coexpression of AAT 
The presence of serine proteases in milk such as plasmin and trypsin has been 
well documented 
39,40
. This BLG-AAT transgene was chosen because biologically active 
rAAT has been previously and consistently produced at greater than 1000 μg/ml in the 
milk of transgenic mice and sheep. Figure 7.3 shows the nonreduced, Western Blot 
analysis of SDS-PAGE using detection by a polyclonal anti-AAT antibody.  The AAT-tg 
was expressed at much higher levels than either 226/N6-tg or vWF-tg and estimated to be 
>1000 μg/ml.  
 
 
Figure 7.3.  AAT is coexpressed in transgenic mouse milk.  The non-reduced anti-AAT Western blot 
contains a molecular weight marker (lane 1), 2 μg (lane 2) and 5 μg (lane 3) recombinant AAT, plasma-
derived AAT (lane 4), transgenic mouse milk (lane 5), and non-transgenic mouse milk (lane 6). * - denotes 
putative AAT-serine protease inhibitor covalent complex (SERPIN). The recombinant AAT (lanes 2 and 3) 
and plasma-derived AAT references (Lane 4) as well as transgenic milk samples (Lane 5) have bands 
present at about 54 kDa and >100 kDa.  The putative AAT- SERPIN complexes indicate that the AAT was 
biologically active.  
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Quantitative analysis of rFVIII biological activity 
Biochemical analysis of FVIII within the milk of mono-, bi- and trigenic mice is 
presented in Table 7.2.  Chromogenic FVIII activity and antigen as determined by a 
FVIII-specific ELISA are shown.  Milk was collected from F1 and F2 lineages during 
three different days over a 17 day lactation. Three different F0 bigenic 226/N6-tg/vWF-tg 
founders all expressed less than 0.02 μg/ml of FVIII by ELISA and so were not chosen 
for expansion (data not shown).  
One stage FVIII (aPTT) and two stage chromogenic activities were measured in 
each of the expanded lineage specific milk pools.  For aPTT coagulation measurements, 
dilutions of milk of >1:200 were required to minimize nonlinear effects caused by milk 
calcium and lipid.  For those milks having greater than about 1 IU/ml, the aPTT and 
chromogenic activities were comparable. Table 7.2 shows the highest chromogenic 
activity and ELISA antigen values over the course of lactation within these milk samples 
and their respective specific activities. The specific activities of commercial rFVIII 
ranged from 1100 to 5000 IU/mg.  The highest FVIII antigen and FVIII activity levels 
occurred in the milk of one trigenic lineage (415), at 183 μg/ml and 678 IU/ml 
respectively, yielding a specific activity of 3,705 IU/mg. In addition, high concentration 
levels of 226/N6-tg activity and antigen were also measured in three of four 226/N6-
tg:AAT-tg bigenic lineages.   
Notably, the range of 226/N6-tg specific activities was similar for all mouse milks 
and expression levels. However, the lowest detectable levels of antigen and activities 
occurred within monogenic 226/N6-tg mice:  <0.15 μg/ml rFVIII antigen and <0.62 
IU/ml activity. The maximum and mean specific activity levels present in milk were 
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between 1,000 and 6,000 IU/mg for 226/N6-tg monogenic, 1,000 and 7,000 IU/mg for 
bigenic 226/N6-tg:AAT-tg,  3700 and 4500 IU/mg in the trigenic 226/N6-tg:AAT-
tg:vWF-tg milks. Thus, the biochemical quality of 226/N6-tg was consistent in the milk 
over a wide range of throughput by the mammary epithelia.  
Immunopurification of rFVIII from trigenic mouse milk pools using an anti-A2 
monoclonal immunosorbent (R8B12)
30
 resulted in a vWF-tg free product (data not 
shown).  The specific activity was 2838 IU/mg which compared favorably to 226/N6 that 
was immunopurifed from CHO cells at 2892 IU/mg.  Importantly, the specific activity of 
226/N6-tg immunopurified from milk was consistent with that measured directly in the 
trigenic mouse milk. ELISA detection of the binding of this vWF-free 226/N6-tg to 
plasma-derived vWF (Figure 7.4)  indicates that 226/N6-CHO, commercial rFVIII and 
226/N6-tg have similar affinity to vWF. 
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Figure 7.4. 226/N6-tg binds pd-vWF similarly to rFVIII.  The relative affinity of plasma-derived vWF 
for 226/N6-tg immunopurified from milk pools made from highest expressing trigenic mice (415), 
commercial rFVIII, and 226/N6-CHO immunoaffinity purified protein were compared. Assessment of vWF 
binding to various FVIII molecules by ELISA:  commercial rFVIII (●), 226/N6-tg (■), 226/N6-CHO (▲).  
Polynomial trend lines are shown for the reference rFVIII (solid line), 226/N6-tg (dashed line), 226/N6-
CHO (dotted line) with R
2
 values of 0.85, 0.89 and 0.97, respectively. The plasma-derived vWF was found 
to similarly bind each of the FVIII species over a concentration range that approximates the linear FVIII-
vWF binding curve.  
In vivo tail clip assay in the hemophilia A mouse 
Total blood loss in mg was observed for normal C57/BL mice and FVIII 
knockout hemophilia A (HA) mice resulting from a terminal tail transection (Figure 7.5).  
The HA mice were infused with either lactated Ringer’s, immunopurified 226/N6-CHO 
or immunopurified 226/N6-tg.  The 226/N6-CHO and 226/N6-tg proteins were each 
infused at 80 IU/kg body weight. The normal C57/BL mice typically showed a cessation 
of bleeding (4 of 4) at about 2 to 5 minutes (data not shown) with a total weight of blood 
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loss over 10 minutes ranging from 80 to 175 mg.  The HA mice infused with lactated 
Ringer’s typically did not show a cessation of bleeding (10 of 12) with a total weight of 
blood loss that ranged from 110 to 700 mg. The HA mice infused with 226/N6-CHO 
showed a cessation of bleeding (5 of 5) typically at about 2 to 5 minutes with a total 
weight of blood loss ranging from 50 to 225 mg. The HA mice infused with 226/N6-tg 
showed a cessation of bleeding (5 of 6) typically at about 2 to 5 minutes with most mice 
having a total weight of blood loss ranging from 50 to 225 mg. One HA mouse infused 
with 226/N6-tg showed a total blood loss weight of 500 mg. An analysis of variance 
indicated that the effect of treatment was significant (p < 0.001).  Post hoc analysis 
determined that only saline treated hemophilic A mice were significantly different from 
control mice treated with saline (p = 0.002).  An α of 0.05 was used as a significance 
criterion for all statistics.   
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* p = 0.002 (α0.05) 
Figure 7.5. Hemostatic efficacy in vivo of 226/N6-tg and 226/N6–CHO within the hemophilia A 
mouse model.  Total blood loss in mg was observed for normal C57/BL mice and FVIII knockout 
hemophilia A (HA) mice resulting from a terminal tail transection.  The HA mice were infused with either 
lactated Ringer’s, immunopurified 226/N6-CHO or immunopurified 226/N6-tg.  Bars represent the mean (n 
≥ 4) and the error bars the standard deviation.   
 
Discussion 
By expressing rFVIII variant with high secretion efficiency in the milk of 
transgenic mice, we have generated >450-fold higher levels of FVIII activity over that 
reported for the animal cell culture expression of WT-FVIII.  The highest reported levels 
of FVIII made in animal cell culture have been those using co-expression of vWF to 
stabilize the secreted FVIII (Table 7.1). To overcome the previously low expression of 
FVIII activity in milk, our bioengineering strategy combined the advantages of the high 
cell density of the mammary gland with high secretory efficiency, single chain stability of 
226/N6, the stabilizing complexation of co-expressed vWF, and decreased milk-borne 
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proteolysis through co-expression of AAT.  In addition, the gene design of 226/N6 not 
only imparted increased transcriptional efficiency but also benefited from decreased 
transcriptional silencing provided by the co-integration of the highly active BLG-AAT 
transgene.  This is the first proof of principle that biologically active FVIII can be made 
in milk at similarly high levels to that already demonstrated for other complex 
coagulation proteins.  While this study used mice, where typically only a few milk 
samples spanning a 17 day lactation can be collected, it was a necessary step used to 
assess the gross expression levels and general biochemical characteristics of the 
recombinant protein before attempting to translate these concepts to livestock.  Further 
optimization of mammary expression of 226/N6 such as screening for lineages having 
still higher expression levels due to more transcriptionally active chromosomal 
integration sites is best done in a livestock species that is a candidate for commercial 
production. Thus, the full delineation of our bioengineering effort to stabilize FVIII 
activity by co-expression of VWF and AAT will be best assessed and realized in the 
>100 liter per year lactations produced in animals such as pigs.  
Our studies show that the single chain structure of 226/N6-tg retains its 
procoagulant activity in milk where its specific activity is similar to commercial grade, 
plasma-derived and recombinant FVIII (Table 7.2) in contrast to the proteolytically 
fragmented, low activity WT-FVIII previously observed in the milk of mice,
16
 rabbits,
17, 
18
 sheep
19
 and pigs
20
 (Table 7.1). The robustness of 226/N6-tg activity was reflected by 
the similar specific activities of immunopurified  and milk-borne 226/N6-tg as measured 
by both one and two stage clotting assays. Importantly, the immunopurified 226/N6-tg 
rendered normal hemostasis to FVIII knockout mice in response to a post-infusion, tail 
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transection trauma challenge.  In contrast to 226/N6, heterodimeric WT-FVIII has proven 
to be unstable and therefore not suitable for production in milk. Importantly, our work 
suggests that other FVIII variants that use covalent structure similar to 226/N6 which 
stabilize the association of heavy and light chains
15, 31, 32
 may be appropriate candidates 
for abundant production in the milk of transgenic livestock.  
The co-expression of vWF in cell culture
33
 has been shown to stabilize the heavy 
and light chains of WT-FVIII. Ours is the first report of FVIII co-expressed in milk along 
with vWF.  We have shown that essentially all of 226/N6-tg was strongly associated with 
vWF-tg. The functionality of these complexes was reflected by the similarly high specific 
coagulation activity measured by one and two stage assays. This activity indicates that 
the vWF-tg is released upon thrombin cleavage of 226/N6 to form FVIIIa as occurs in 
plasma-derived FVIII that is complexed by vWF.
34, 35
 In addition, 226/N6-tg was greater 
than 90% separated from vWF-tg by immunopurification in a similar manner used to 
purify plasma-derived FVIII from vWF (data not shown). The immunopurified 226/N6-tg 
was subsequently shown to recombine in vitro with plasma-derived vWF in a similar way 
as WT-FVIII. Importantly, complexation of FVIII with vWF is a prerequisite for stability 
in circulation after infusion,
9, 29, 36
 The highest concentration of 226/N6-tg in milk 
occurred with the presence of vWF-tg at an estimated 1:1 ratio of 226/N6-tg to vWF-tg 
subunits.  The native binding behavior of the 226/N6-tg with either vWF-tg or vWF 
indirectly shows that the proper post-translational sulfation of tyrosine 1680 in the A3 
domain of 226/N6 likely occurred, as it is required for complexation.
37
  The detailed 
characterization of the post-translational modification of 226/N6-tg such as detection of 
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sulfation and also its multiple sites of glycosylation will be done on material produced 
from the milk of transgenic pigs.    
While the FVIII activity levels reported here were very high, we believe that still 
higher levels are possible in livestock.  Mammary specific expression in transgenic mice 
is typically more subject to transcriptional silencing than has been observed in transgenic 
pigs. Transgene silencing and attenuation of mammary specific expression occurs in 
>60% of mouse lineages
38
 and is thought to be primarily due to random transgene 
insertion into transcriptionally dormant chromosomal locations.
38
  Using the same WAP 
regulatory elements employed here for 226/N6-tg in mice, our past experiences with the 
expression of other complex coagulation proteins such as human protein C typically 
obtained levels of 500 to 1000 μg/ml in mice but 1000 to 5000 μg/ml in pigs.  It is 
noteworthy that the inclusion of the A1-A2 domain needed for FVIII functionality means 
that some transcriptional limitations will be also inherent as is still present in the 
bioengineered 226/N6 gene and not associated with the B domain.
12-14
 The consistently 
very low rFVIII levels in monogenic 226/N6 or bigenic vWF:226/N6 mice were likely 
due to the combination of FVIII transcriptional and chromosomal insertion transgene 
silencing.  It is also noted that co-expression of vWF and WT-FVIII in CHO cells does 
not result in higher transcriptional efficiency for either protein. In contrast, we believe 
that the high levels of FVIII and vWF expressed in bigenic 226/N6-AAT and trigenic 
226/N6-vWF-AAT mice (Table 7.2) benefited from transcriptional rescue by co-
integration of the BLG-AAT minigene. In a prior study, co-integration into the same 
chromosomal site of the BLG-AAT with a BLG-human Factor IX transgene resulted in 
increased expression in mouse milk.
39, 40
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The AAT-tg was efficiently made at >1 g/l in the majority of the mouse milks 
studied here.  This is consistent with its previously reported mammary specific 
expression behavior in mice
16
 and sheep.
41, 42
  The presence of AAT antigen reactive 
bands at about 90 to 100 kDa Mr  is consistent with the formation of stable, AAT-serine 
protease complexes reflecting the presence of serine proteases such as plasmin in milk 
and the SERPIN-biological activity of the milk borne AAT. While it is not known exactly 
how much protection from proteolysis
36
 and or metal chelation
43
 was provided to 
226/N6-tg, the highest concentration of biological activity occurred in mice having both 
by AAT-tg and/or vWF-tg. While we used co-microinjection of the three transgenes to 
make trigenic mice, we will use somatic cell cloning to make trigenic pigs with special 
attention to the preselection of cell lines having both equal stoichiometric and same site 
co-integration and therefore more predictable expression efficiency for each of the 
transgenes.  The co-expression of other protease inhibitors more specific to plasmin such 
as alpha-2 plasmin inhibitor is also another potential extension of this work.   
Pigs are the most likely choice of transgenic livestock for future production of 
FVIII because they combine the advantages of milk volume and hepatocyte-like post-
translational biochemistry such as glycosylation 
67
.  While ruminants also provide ample 
milk volume, their mammary biochemistry produces higher mannose, low sialic acid 
glycoforms which may affect circulation residence times due to interactions with asialyo 
receptors found in the human liver.
67
  Pigs have 100 days of lactation and produce 100 to 
200 liters of milk per year.
16,17,68
  Hence, the number of pigs needed to meet the current 
global FVIII demand is only about 400 if 226/N6 expression reported here in mice is 
translated into the milk of sows (Table 7.3).The advantage of pig milk over other FVIII 
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sources such as cell culture bioreactors and human plasma is evident in the greater than 
two orders of magnitude reduction in source volume estimated to meet global FVIII 
demand.
16
  In the case when infrastructure must be expanded to increase capacity, the 
capital investment costs for classical cell culture become significant.  In contrast, 
transgenic production  yields high concentration of biopharmaceutical in milk which 
reduces capital investment because adding additional pigs does not require significant 
changes in expanding infrastructure.
44
 This will become important when developing 
countries begin routine access to FVIII therapy including that needed for inhibitor 
patients to facilitate immune tolerance strategies. It is noted that perhaps 25% or more of 
FVIII used in most developed countries is consumed by inhibitor patients.
45-47
  
 
Table 7.3.  Potential volumes of source materials needed for current global 
FVIII consumption. 
Source 
Volume of Source Material 
(liters/year) 
Plasma 27,400,000 
Production Bioreactor Supernatant 13,700,000 
Milk of Transgenic Pig 40,000 
Potential volumes of source materials for Factor VIII required to meet the needs 
for current global consumption.
48
  The estimated amount of FVIII in each source:  
plasma (1 IU/ml); CHO cell bioreactor (2 IU/ml), and transgenic pig milk (678 
IU/ml).  A 20% purification yield for each source is assumed.  The milk of 400 
pigs (100 liters/year/pig) could supply the entire amount of FVIII currently needed 
for global consumption.
48
   
 
The safety and efficacy of transgenic milk derived products has crossed an 
important threshold as the US FDA and EMEA has approved recombinant anti-thrombin 
III made in goat milk (ATRYN
R
). The large scale processing renders the anti-thrombin 
product to 99.99% purity. The high levels of FVIII biological activity reported here in 
mouse milk bodes well for the development of transgenic livestock and an accompanying 
purification process that will provide an abundant, cost effective source of FVIII.  This 
source would help to enable prophylactic intravenous therapy and also the development 
232 
of alternative routes of administration including its use in longer lasting replacement 
product designs.  For example, using PEGylation
5
 to make longer lasting 226/N6-tg as 
well as application to non-intravenous methods of delivery by intratracheal
10
 or oral
5,11,12
 
administration will be facilitated by the abundance of FVIII provided by transgenic milk.   
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Citrate activation of prothrombin 
Chapter 2 was the first detailed analysis of the sequence of activation of 
prothrombin by sodium citrate.  Activation fragments were identified by N-terminal 
sequencing.  Unfortunately, this research was unable to answer several questions which 
could be elucidated by the following: 
1. FII activation in the absence of citrate:  autocatalytic or reciprocal proenzyme 
activation:  Long-term incubation of FII results in activation despite inhibition of 
FXa and FIIa.  This proteolysis could be due to either autocatalytic activation, 
reciprocal proenzyme activation (activation by FX) or by FXa which is 
autoactivated.  Purified plasma-derived material contains trace amounts of other 
proteins; therefore, it is difficult to completely isolate individual proteins to 
identify their roles in activation.
1
  Consequently, recombinant prothrombin 
preparations are needed that do not have trace amounts of plasma proteins to test 
certain hypotheses.  Once purified, recombinant FII will be incubated alone and 
with purified FX to test Teng and Seegers’2 theory that they coactivate.   
2. Separate bands from citrate activation and analyze more thoroughly:  The 
primary bands formed after citrate activation appear to be composed of thrombin, 
α-thrombin and β-thrombin.  These bands could be separated by size exclusion 
chromatography and analyzed to ensure their identities and to determine more 
accurate activity levels for each thrombin species.   
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Recombinant factor XIIIa 
Chapter 3 characterized rFXIIIa expressed in Pichia pastoris.  These results 
indicate that rFXIIIa expressed in yeast closely mimic plasma-derived FXIII and may be 
a good alternative for therapeutic uses; however, further research will further elucidate 
the efficacy of rFXIIIa as a therapeutic: 
1. Further evaluation of FXIIIa molecule:  In this chapter, I propose that the rFXIIIa 
molecule has an equivalent molecular weight as FXIII because of the addition of 
the His-tag and myc epitope which is removed by incubation with thrombin.  
These hypotheses could be confirmed by anti-His and/or anti-c-myc epitope 
immunoblot analysis.   
2. rFXIIIa as an infusion therapy:  pdFXIII is used as an infusion therapy to treat 
into individuals with FXIII deficiency.
3
  Yeast can produce ample amounts of 
rFXIIIa for use in infusion therapies; however, the feasibility, efficacy, safety and 
tolerability of rFXIIIa as an infusion therapy must be tested.  FXIII can crosslink 
substrates; however, FXIIIa crosslinks at a faster rate.
4
  Infusing the active form 
may be detrimental and therefore needs to be evaluated.   
a. rFXIIIa interaction with plasma proteins:  If used as an infusion therapy, 
rFXIIIa will need to be evaluated with regard to its interactions with the 
plasma proteins.  Deleterious effects with regard to being FXIIIa rather 
than FXIII will need to be evaluated.   
b. rFXIIIa ability to bind to fibrin’s αC-domain:  Once activated, FXIIIa 
binds to residues 241 to 476 in the αC-domain of fibrin5 which brings 
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fibrin protofibrils into close proximity.  This interaction is important for 
rapid crosslinking thereby creating a strong clot resistant to lysis.   
c. Pharmacokinetics:  The time rFXIIIa lasts in circulation and the rate at 
which it is utilized, metabolized, and removed needs to be evaluated.  
Methods used to evaluate the rFXIII expressed in Saccharomyces 
cerevisiae could be mimicked.
6
   
d. Immune response:  This yeast produced protein will need to be evaluated 
for its immunogenicity.   This will need to be tested in vivo.   
 
Optimization of a liquid fibrin sealant 
Chapter 4 identified the optimal ratio of components for a rLFS and identified 
FXIIIa as an important factor in clot strength.  The clotting kinetics and viscoelastic 
strength of our optimized LFS was equivalent to those of a commercially available LFS; 
however, it uses approximately 75% less fibrinogen and thrombin.  While these results 
are promising, more research needs to be performed to better characterize the clot that is 
formed: 
1. Examine clot structure created by optimal rLFS:  The structure of the matrix 
produced by a FS is altered by altering concentrations of any of the components 
or the pH or temperature.  Such changes can alter the function and adhesive 
nature of the FS.
7
  In addition, the fiber diameter, porosity, branching and 
permeability of a clot and fibrin(ogen)’s ability to bind platelets, endothelial cells, 
smooth muscle cells and other cells play an important role in wound healing.
8
  For 
example, high FIIa concentrations reduce “gelation time” which results in the 
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production of small fiber diameters and pores.
7
  Research also indicates that the 
rate of clot lysis is related to fiber diameter:  thinner fibers lyse at a slower rate 
than thicker fibers.
9
  Fiber diameter of clots created by rFI-based LFS should be 
compared to those produced by pdFI-based LFS in vitro.  Mullin et al. incubated 
FI with FIIa, monitored protofibril formation and fibrinolysis by turbidity, and 
evaluated fiber size by scanning electron microscopy (SEM).
9
  This research 
optimized the speed and strength of the clot formed by our rLFS; however, we 
have not yet analyzed the structure of the clot.  Microscopy and other techniques 
can be utilized to determine fibrin fiber thickness.
10
   
2. Identify rheological properties:  The rheological properties of clots created by our 
rLFS should be evaluated with and without FXIII and compared to other 
commercial FS as described previously.
11
  
3. Model diffusion effects due to increases in thrombin:  Increasing thrombin can 
result in reductions in clot strength.  This is probably due to an increase in 
viscosity created by aggregation of fibrin which minimizes the diffusion of FXIII 
need for crosslinking and creating a strong clot.  This effect should be modeled.   
4. Evaluate importance of extra FXIII activity in tissue adhesion:  Marx and Mou12 
found that the native transglutaminase activity in tissue (rat skin) is enough to 
crosslink fibrin clots created by FS.  The same methods described in this study 
can be used to determine if the significantly greater FXIII activity 
(approximately 36-fold higher) assists in adhesion to multiple tissues (not just 
rat skin).   
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5. rLFS affects on cell migration and proliferation and wound healing:  In addition 
to cessation of bleeding, the fibrin clot plays a key role in wound healing by 
serving as a scaffold for and trapping growth factors and other ingredients 
necessary for tissue regeneration.
13, 14
  The clot binds proteins and extracellular 
matrix which directly contributes to wound healing
15
 and binds fibronectin 
creating cellular adhesion.
16-18
  The fiber diameter, porosity, branching and 
permeability of a fibrin clot is important for these functions.
8
  Fibrinolysis is also 
controlled by fiber size and by binding plasminogen,
19, 20
 tissue plasminogen 
activator (tPA)
19, 20
 and α2-antiplasmin (A2AP).
19, 21
  Interactions with these 
molecules promote cell migration and encourage tissue regeneration.
13
   Several 
studies can be performed to predict rLFS’ effect on wound healing: 
a. Detailed analysis of clot porosity, fiber branching and permeability of 
clot:  Compare the porosity, branching and permeability of clots generated 
by rFI to those created by pdFI so the effect on wound healing can be 
predicted.   
b. rFI-based clot retraction:  Test the ability of a rFI-based clot to undergo 
clot retraction which is necessary for wound healing.
22
   
c. rLFS interaction with endothelial cells:  Evaluate the ability of endothelial 
cells to bind to and proliferate and migrate on rFI-based clots.  Endothelial 
cells infiltrate the clot and regenerate vascular tissue;
8
 therefore, the ability 
of these cells to thrive on the recombinant fibrin clot is critical.   
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In vivo testing of rLFS 
Chapter 6 details the efficacy of our rLFS in initial in vivo models.  Research on 
specific uses and long-term use must be completed.   
1. Long-term hemostasis, wound healing and LFS degradation:  All of our in vivo 
experiments have been nonsurvival; therefore, the ability of the rLFS with or 
without the bandage to maintain hemostasis and allow functional tissue 
regeneration without serious complications is unknown.  Kroez, Lang and 
Dickneite
23
 evaluated immune response, wound healing and degradation kinetics 
of a commercially available FS in a partial liver resection rabbit model.  These 
same methods could be used in our model.  The thickness of the FS and tissue 
regeneration is evaluated by histology.  Antibody development to human proteins 
were measured by ELISA.
23
  Survival studies on Grade V liver injuries could be 
modeled after Holcomb et al.’s methods.24, 25   
2. rLFS feasibility, tolerability, efficacy and safety for specific uses:  Commercial 
LFS’ are used in a variety of surgeries including cardiovascular,7, 26 vascular,27 
thoracic,
28, 29
 plastic,
7, 30
 reconstructive,
31
 oncologic,
32
 ophthalmologic,
32
 dental,
32
 
orthopedic,
7, 32
 hepatic
33
 and urologic surgeries,
34, 35
 microsurgical procedures
7
 
and neurosurgery.
7, 36, 37
  We need to determine whether our rLFS can be used 
successfully under the same circumstances in the pig model.   
3. rLFS as a capable delivery vehicle:  Previous research indicates that LFS’ can be 
used as a delivery vehicle for fibroblasts;
38
  however, not all sealants can be 
utilized in this manner.
39
  Determine whether our rLFS can be reliably and 
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successfully used as a delivery vehicle for fibroblasts and other possible 
drugs/factors.   
4. Perfect spray delivery device:  It is critical to develop a delivery device that is 
convenient and easy to use for medical care personnel
7
 while applying the optimal 
amount of each of the FS components.  We have had difficulties in fitting off-the-
shelf spray devices to our needs.  Our primary issue is finding a device that has 
fine control over flow rates while aerosolizing the solutions.  A device needs to be 
designed that meets all of our needs.   
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